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Abstract 
Hepatitis C virus (HCV) infection is one of the major causes of liver morbidity and 
mortality worldwide. While effective therapies are now available, if eradication of 
this virus is to be achieved globally, an effective vaccine is still necessary. During 
hepatitis C virus (HCV) infection, broadly neutralizing antibody (bNAb) responses 
targeting E1E2 envelope glycoproteins are generated in many individuals. It is 
unclear if these antibodies play a protective or a pathogenic role during chronic 
infection or if they could prevent infection or reinfection with the virus. 
 I investigated the presence and clinical associations of bNAb responses in three 
cohorts of individuals infected with or exposed to HCV infection. One with chronic 
HCV infection at differing disease states, one with chronic HCV infection at an 
early disease state and one group of individuals at high risk of HCV exposure who 
remained uninfected by conventional testing. I also studied bNAb responses in an 
individual from a HCV-HIV co-infected cohort who experienced spontaneous 
clearance of HCV after a post-therapy relapse (‘secondary spontaneous 
clearance’).  
I found a proportion of individuals when exposed to or infected with HCV produce 
a polyclonal bNAb response which may contribute to viral clearance in some 
cases. Host genetics and the ability to target multiple neutralising epitopes on the 
envelope protein are associated with such responses, although resistance 
mutations to bNAbs do exist in vivo. The presence of bNAbs is associated with 
lower levels of liver fibrosis. Using next generation sequencing technology in the 
study of B cell receptors in HCV infection revealed subtle changes in the B cell 
repertoire on HCV infection, this technology may be used in future to gain insight 
into the generation of bNAb responses. 
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One and three letter amino acid abbreviations 
Amino acid   Three letter code   One letter code 
Alanine    Ala     A 
Arginine    Arg     R 
Asparagine    Asn     N 
Aspartic acid   Asp     D 
Cysteine    Cys     C 
Glutamine    Gln               Q 
Glutamic acid   Glu     E 
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Threonine    Thr     T 
Tryptophan    Trp     W 
Tyrosine              Tyr     Y 
Valine    Val     V 
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1 Introduction 
1.1 Overview of the impact of Hepatitis C virus infection 
Hepatitis C virus (HCV) infection is one of the major causes of liver morbidity and 
mortality worldwide. It affects 2-3% of the global population(1). In up to 75% of those 
infected, the host is unable to clear the virus and develops chronic infection (2, 3). 
Once chronic infection is established, it can cause liver inflammation and fibrosis 
leading to cirrhosis, end stage liver failure and hepatocellular carcinoma, being one 
of the leading indications for liver transplant in the UK and the United States of 
America(4, 5). In addition to liver related harm, infection is also strongly associated 
with pathological B cell disorders such as cryoglobulinaemia(6) and may contribute 
to neurocognitive disturbances(7, 8). While effective directly acting antiviral (DAA) 
therapies are now available, these are unlikely to result in global eradication of the 
virus in the short to medium term without further preventative strategies. One such 
strategy is the development of a universal HCV vaccine. As vaccination candidates 
to date have not met the standards required for widespread use(9), further study of 
the interaction of HCV and the adaptive immune system is helpful to inform future 
development. 
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1.2 The structure, function and pathogenesis of HCV 
HCV, first identified in 1989(10), is a single-stranded positive-sense RNA virus 
belonging to the hepacivirus genus of the flaviviridae family (Fig. 1.1) which includes 
yellow fever, dengue and Japanese encephalitis in addition to the more recently 
identified pegiviruses.  
 
Figure 1.1 Phylogenetic tree of the Hepatitis C virus alongside related viruses in the 
Flaviviridae family.   
Phylogenetic tree (unrooted) of the family Flaviviridae and jingmenviruses based on conserved 
domains in the NS3 (right panel) and NS5 (left panel). Based on their host types, the virus names are 
shaded red (vertebrate only), yellow (vertebrate and arthropod), green (plant), blue (non-arthropod 
invertebrates), or black (arthropod only). [Figure and Legend reproduced from Shi et al J. Virol 
2016(11) Copyright American Society of Microbiology, permission granted for reuse in academic 
thesis] 
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HCV has a narrow host specificity being a predominantly human pathogen although 
other primates can sustain chronic infections(12). It primarily targets hepatocytes  
with recent reports suggesting that it may infect and replicate in other tissues 
including lymphocytes and neurons (13). 
 There are 7 accepted genotypes of HCV with at least 67 confirmed subtypes(14). 
Considerable genetic diversity exists both between and within the differing 
genotypes. The nucleotide sequence of different subtypes within a genotype differ by 
>15% whereas there can be as much as a 30-40% variation between different 
genotypes(15). This genetic diversity in part explains why HCV has been so 
successful in quickly evolving to overcome host defences.  
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Figure 1.2 Phylogenetic tree of representative sequences of genotypes and subgenotypes of 
Hepatitis C 
 Phylogenetic tree of 129 representative complete coding region sequences. Up to two 
representatives of each confirmed genotype/subtype were aligned (together with a third extreme 
variant of subtypes 4g and 6e) and a neighbor joining tree constructed using maximum composite 
likelihood nucleotide distances between coding regions using MEGA (Molecular Evolutionary 
Genetics)software(16). Sequences were chosen to illustrate the maximum diversity within a subtype. 
Tips are labeled by accession number and subtype (*unassigned subtype). For genotypes 1, 2, 3, 4, 
and 6, the lowest common branch shared by all subtypes and supported by 100% of bootstrap 
replicates (n = 1,000) is indicated by ·. [ Figure and Legend reproduced from Smith et al 2014, 
Hepatology(14) , permission granted through Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/.] 
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The geographical distribution of the different genotypes shows marked regional 
variations with genotype (gt) 1 being most common in north America, gt 3 
predominant in Asia and gt 4 most prevalent in north east Africa (Fig. 1.3). Within the 
UK, due to immigration patterns, gt 1 and gt 3 are almost equally distributed in the 
population(17).  
 
Figure 1.3 Global prevalence of HCV and distribution of genotypes. 
Map displaying overall prevalence of HCV infection (indicated by shading of country) and genotype 
distribution within those countries where information is available. 
 [Figure extracted from Negro and Alberti Liver International 2011(18) reuse authorised by John Wiley 
and Sons] 
The HCV genome has an open reading frame (ORF) of approximately 9600 base 
pairs in length which encodes for a polyprotein of around 3000 amino acids (aa), 
although this varies between genotypes and individual isolates. Before the N-
terminus of the ORF sits an uncapped 5’UTR. This combines with a portion of the 
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core coding region to form a characteristic RNA secondary structure, the internal 
ribosomal entry site (IRES), responsible for binding ribosomal subunits to enable 
subsequent translation of the ORF. 
The ORF encodes a polyprotein that is co-translationally processed by both host and 
viral encoded proteases into structural and non-structural proteins. The structural 
proteins are core and the two envelope glycoproteins named E1 and E2. The virus 
shares basic structural characteristics with other members of the Flaviviridae family, 
encompassing a nucleocapsid composed of core protein containing the RNA 
genome. This is covered in a phospholipid bilayer which incorporates the envelope 
glycoproteins E1and E2 involved in cell attachment (Figure 1.4). The non-structural 
proteins are p7, NS2, NS3, NS4 and NS5. With further understanding of the function 
of these proteins, different subunits have been identified which have distinct 
functions and act as specific targets for drug therapy.  The functions and 
characteristics of each of these proteins are addressed below. 
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Figure 1.4 Structure of the HCV genome and viral particle 
The diagram shows the accepted structure of the HCV virion with positive sense single stranded RNA 
encapsulated in a capsid constructed of core protein and also likely containing p7 ion channels. The 
outer surface of the virion incorporates a lipid membrane layer with E1E2 heterodimers protruding 
from the surface. Below is shown the relative position of the genes for these and the non-structural 
proteins in the HCV genome. 
 
1.2.1 Core and Alternative Frameshift (REF) proteins 
The core protein is usually 191 aa in length and highly basic in nature. It is one of the 
most highly conserved proteins in the HCV polyprotein(19). It consists of 3 domains, 
a hydrophilic domain, a hydrophobic domain and a final region which is important for 
correct initiation of E1 translation. Core protein is first generated in an immature form 
then cleaved from E1 by the host signal peptidase and finally cleaved again at aa 
177 by the host signal peptide peptidase to form the mature core protein (20). It is 
this mature core protein which forms the nucleocapsid. 
In addition to its structural role as part of the virus, the core protein has been 
proposed to have several pathogenic properties. It has been shown to interact with a 
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wide range of intracellular proteins including the Jak/STAT pathway and the TGF-β 
pathway (21) which may impair host immunity to the virus. 
Although the core region is one of the most conserved regions of the viral genome, 
specific mutations may produce a survival advantage. A particular strain of core 
proteins are thought to interact with the cellular protein DDX3 in replication and affect 
sensitivity to interferon (IFN) (22). Similarly, several mutations in core have been 
associated with resistance to exogenous IFN therapy (23) . 
Core protein may also be play role in the adverse liver outcomes in HCV infection. 
Transgenic mice studies have shown that those expressing core protein have a 
greater risk of insulin resistance, steatosis and possibly hepatocellular carcinoma 
(24). 
1.2.1.1 The alternative frameshift Protein (REF) 
One other incompletely understood function of the core encoding region is its 
capacity to undergo a translational frame-shift leading to the synthesis of an 
alternative frame protein (REF). This REF protein is produced when core is 
translated in the -2/+1 frame rather than from the ORF. The functions of this protein 
are less well described. It has been shown to interact with iron metabolism and may 
play a role in cellular proliferation and influence viral replication (25, 26) . 
1.2.2 Envelope proteins E1 and E2 
E1 and E2 are type I transmembrane glycoproteins. These envelope proteins form a 
highly structured noncovalent heterodimer on the surface of the virion in association 
with lipids and apolipoprotein E (Apo E). Correct folding of the protein is dependent 
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on the interaction between E1 and E2 with evidence that E1 forms trimers in the 
presence of E2 which may then organise into pentamers (27). There is evidence that 
rather than relying on conserved domains in both proteins, this interaction may be 
isolate-specific with Carlsen et al showing that generating chimeric envelope proteins 
using E1 and E2 from different isolates can disrupt this interaction(28). 
The envelope protein interacts with lipids and Apo E. Replication of the HCV virion is 
associated with lipid droplets so that in vivo the virion is coated in VLDL. This lipid 
coating is important for infectivity and may mediate resistance to neutralisation by 
antibodies. For example, an amino acid mutation at position 451 alters the density of 
lipoproteins associated with viral particles and enhances sensitivity to neutralisation 
in vitro (29). 
This lipoprotein coated envelope is responsible for attachment to hepatocytes and in 
facilitating entry into them by interacting with various cellular proteins. There is 
evidence that interaction with the LDL lipid receptor may be an initial step in 
entry(30). In addition, binding to sulphated glycosaminoglycans (GAGs) on the cell 
surface has also been shown to play a role in cell attachment (31). The best 
characterised interaction in HCV cell entry is the binding of envelope to the cell 
surface proteoglycans, CD81 and SR-BI to attach to the cell and initiate cell entry 
(32). Subsequently this appears to activate a pH dependent cellular endocytic 
pathway. This is facilitated by interaction of cellular proteins Claudin (33) and 
Occludin (34) with the envelope protein / CD81 complex (Figure 1.5). The viral 
envelope is also able to attach to the adhesion molecules DC-SIGN and LC-
SIGN(35). While these are not found on the hepatocyte cell surface, they are found 
on other hepatic cells, thus this attachment may direct circulating virus towards 
hepatocytes. 
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Legend for Figure 1.5 on following page 
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Figure 1.5 Diagram showing steps in HCV cell entry and interaction with cell surface 
molecules. 
HCV initiates its infection into hepatocytes by an attachment step at the cell surface in which virions 
interact with non-specific factors such as glycosaminoglycans (GAG). Due to the association of viral 
particles with lipoproteins, the Low Density Lipoprotein-Receptor (LDL-R) likely plays a role in this 
initial step of entry. HCV first interacts with the scavenger receptor class B type I (SR-BI), which in 
turn probably facilitates the association of viral envelope proteins with CD81. CD81 and the tight 
junction protein claudin-1 (CLDN1) naturally form a complex that is essential to HCV entry and which 
is likely regulated by the Epidermal Growth Factor-Receptor (EGFR) and the GTPase HRas. After 
interaction with the CD81/CLDN1 complex, HCV interacts with occludin (OCLN), another tight junction 
protein. Other molecules, such as the transferrin receptor (TfR), the tetraspanin CD63, and the 
Niemann-Pick C1-like1 (NPC1L1) cholesterol transporter, which is mainly localized in bile canaliculi 
(BC), have been shown to also be involved in HCV entry but for which mechanisms need to be 
elucidated. The membrane diffusion of CD81 (depicted by the red ↯) is another important element 
regulating HCV entry. The virus is next internalized by clathrin-mediated endocytosis, possibly in 
association with CD81/CLDN1 complex and EGFR. Internalization is likely favoured by the lipidic 
transfer properties of SR-BI. After fusion at low pH with the membrane of an early endosome, the viral 
genome is released into the cytosol. Next, translation and polyprotein processing take place and the 
viral RNA is replicated. In the late stages of the cycle, new virions are assembled in an ER-related 
compartment in close connection with the Very Low Density Lipoproteins (VLDL) biogenesis pathway. 
This process seems to occur in the proximity of lipid droplets (LD). Virions that are released can infect 
new cells by cell-free transmission. Particles can also be transferred directly to the neighbouring cells 
by cell-to-cell transmission for which CD81-independent and CD81-dependent routes have been 
described but are still controversial.  
 [Figure and Legend reproduced from from Feneant et al (2015) (36) under the terms and conditions 
of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)]. 
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The structure of a truncated but correctly folded E2 has recently been resolved using 
X ray crystallography (37, 38). This shows previously characterised CD81 binding 
regions identified by alanine scanning as being adjacent to one another along one 
face of the molecule (Figure 1.6).  The E2 protein consists of several relatively 
conserved regions associated with CD81 binding or structural stability and 3 variable 
regions termed HVR-1, HVR-2 and IgVR (Figure 1.7). Even within these variable 
regions some amino acids are highly conserved suggesting a role in cell entry or 
other envelope functions (39). Towards the C –terminus of the protein a hydrophobic 
‘heptad repeat’ region is located (aa 675-699). This is structural motif found in 
several viral fusion proteins and consists of a highly conserved repeating sequence 
of 7 aa. It has been shown to be important in the heterodimerisation of the envelope 
proteins and also in cell entry (40). 
The structure of the majority of E1 protein has not yet been resolved, and in general 
it has been less well characterised than E2. However a ‘fusogenic’ region (aa 274-
291) crucial for cell entry has been identified. Specific mutations may also modulate 
binding to the cell surface receptor SRB1 (41). Interactions between the two 
envelope proteins are still incompletely understood. A recent in silico study has 
proposed a structure of the whole E1/E2 protein and has suggested that E1 residues 
192-215, 258-268, 290-306 and the transmembrane domain 352-378 interact with 
the E2 protein for correct heterodimerisation (27) .  
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Figure 1.6 Diagram of the proposed structure of the E2 core structure with additional detail 
from CD81 binding regions superimposed (PDB ID 4MWF).  
This shows the E2 core in grey, with regions involved in CD81 binding highlighted pale pink and 
specific side chains associated with CD81 binding displayed as follows: carbons in pale pink, oxygens 
in red, and nitrogens in blue, with the exception of glycines, which are shown in cyan. The docked 
epitope II peptide conformer superimposed on the same sequence in E2 is shown with side chains 
displayed in stick representation, with carbons shown in purple, oxygens in red, and nitrogens in blue. 
The CD81-LEL dimer is shown the side chains of the D-helix shown in stick representation and 
positioned as a reference to how this region may interact with the E2 helix motif, W437LAGLFY443. 
[Figure and legend reproduced from Harman et al 2015 (42)Copyright American Society of 
Microbiology, permission granted for reuse in academic thesis] 
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There are several glycosylation sites throughout the envelope proteins, 4 in E1 and 
11 in E2. Of these, 5 located in E2 play an important role in infectivity forming part of 
a ‘glycan shield’. These reduce sensitivity to neutralisation and are largely 
conserved. Loss of glycosylation at these sites causes considerable deterioration in 
viral fitness(43). At the other glycosylation sites, variable glycosylation can alter viral 
infectivity and susceptibility to antibody binding. The envelope proteins also have 
conserved Cysteines (44) which are important for correct folding, and Histidines (45) 
which contribute to CD81 binding.  
While there is relatively little data on potential pathogenic effects of the envelope 
proteins on host beyond facilitating virus entry, one group has proposed that 
envelope binding to the CD81 ligand in turn activates the MAPK/ERK pathway (46) 
which may impact on cell proliferation and differentiation. This may have a 
pathological effect on hepatocytes. In addition, envelope binding to CD81 is one 
proposed mechanism of B cell dysregulation in the pathogenesis of HCV-associated 
cryoglobulinaemia (47). 
1.2.3 p7 
The p7 protein spans amino acids 751-814 of the HCV polyprotein. The function of 
p7 is incompletely understood. Recent structural analysis has shown that p7 has a 
structure consisting of two transmembrane alpha helices and a positively charged 
cytosolic loop. This is similar to transmembrane ion channels present in other 
viruses. It is mainly present on the endoplasmic reticulum, mitochondria and plasma 
membranes within infected cells.  In vitro culture studies have also shown that, 
although it is not essential for replication, it is vital for particle assembly and release, 
likely having a role in cleaving an E2/p7/NS2 intermediate protein  (48). Some work 
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has also proposed a role for p7 in cell entry but it is not essential for this process (49-
51). A recent study has also identified a region of p7 which is key for reducing the 
sensitivity of HCV to IFN (52). Whether the p7 protein has additional pathological 
effects on host cells has not been determined. 
1.2.4 Non Structural proteins 
The non-structural proteins NS2, NS3, NS4 and NS5A/B are generally concerned 
with viral reproduction and assembly. Their sequences also code for the proteases 
required to cleave each functional part of the protein from its neighbour. These 
proteases are vital for viral replication and have been successfully targeted by direct 
acting anti-viral therapies in the clinic(53). 
1.2.4.1 NS2 
NS2 forms part of the NS2/3 protease, important for cleaving NS2 from p7 and NS3. 
NS2 is also thought to play a complex role in virus assembly separate from its 
protease role, however this function is likely to involve interaction with many other 
viral proteins and has not been fully described (54). 
1.2.4.2 NS3/NS4 
In addition to forming part of the NS2/3 protease, the N-terminal third of NS3 acts as 
a serine protease in conjunction with NS4a to cleave the HCV polyprotein at 4 sites: 
NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5a/NS5B. This protease contains a  
catalytic triad essential for protein cleavage. The C-terminal 2 thirds of the NS3 
protein act as a ‘RNA helicase’. As there is no requirement for a RNA helicase in the 
HCV lifecycle it has been proposed that this may interact with HCV RNA during 
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replication to facilitate this process, or help protect viral RNA from host defences 
which use RNA binding proteins(55).  
The NS4B protein, produced by cleavage with the NS3B/4A protease, is 261 amino 
acids long. It localises to the endoplasmic reticulum. It is also thought to bind 
intracellular ‘lipid rafts’ creating an intracellular membrane which provides an anchor 
for replication complexes(56).  
Additionally, NS4B appears to be immunogenic, being commonly recognised by 
humoral and cellular immune responses in infected hosts (57). It has also been 
shown to activate the intracellular NF-kB pathway(58) which may contribute to 
intrahepatic inflammation and development of fibrosis. Of note, a particular mutation 
(Q1737H) was associated with relative IFN resistance in one study(59). NS4B has 
also been shown to have an oncogenic effect in the presence of the HRas gene (60). 
1.2.4.3 NS5A and NS5B 
Until recently, the function of the 447 amino acid NS5A protein was incompletely 
understood. It is now known to consist of 3 domains. Domains 1 and 2 are involved 
in replication and may be responsible for recruiting NS5B to the replication complex, 
whereas domain 3 associates with the core protein and is involved in viral assembly 
and intracellular transport (61). It is also thought to play a role in preventing cell 
apoptosis which in turn may have an impact on tumorigenesis within the infected 
liver(62, 63). 
NS5B consists of a 591 aa protein which acts as a RNA-dependant RNA 
polymerase, essential for viral replication (64). Because of the essential role of both 
NS5 proteins, they have been attractive target for small molecule direct acting 
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antivirals and agents targeting these regions are now the mainstay of recommended 
IFN-free treatment regimens (65).  
1.3 Virus transmission, the immune response to HCV and 
its ability to escape from host defences 
HCV is a blood borne virus and therefore is most commonly transmitted by 
inoculation of blood contaminated bodily fluids into another individual. While HCV 
has managed to infect up to 3% of the global population, it is relatively less infective 
per exposure than the other hepatotropic blood borne viruses, HBV and HIV. Its 
successful spread is partly a factor of the chronic nature of most infections, thus 
providing a long period over which to transmit the virus. It has also benefited greatly 
from human behaviours which have assisted its spread, some of which are detailed 
below. 
1.3.1 Routes of transmission 
While many bodily fluid contacts have theoretical potential for transmitting HCV, the 
most common route of transmission is subcutaneous insertion of a needle 
contaminated with blood from an infected individual. 
In developed countries, the major route of transmission remains the use of injection 
drugs and sharing of injection equipment by injection drug users (IDUs) (66). 
Symptomatic acute HCV infection is rare and HCV has the potential to spread 
undetected within these populations. Even though effective antiviral medication is 
now available(53), treatment to date has remained costly and ineffectively 
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implemented with the prevalence of HCV in IDUs rising in England in recent 
years(67).  
Other common sources of HCV transmission include tattoos or piercings using 
multiple use equipment and iatrogenic transmission. As HCV screening of blood 
products was only introduced in 1991, many individuals were infected through blood 
or blood product transfusions prior to this date. The details of these transmissions 
have recently been analysed in the Penrose enquiry (68). Groups particularly at risk 
include the haemophiliac population who received pooled clotting factors derived 
from multiple donations of blood and plasma. While screening has almost completely 
eliminated the risk to current blood product recipients, there are still occasional 
cases of transmission in the medical setting e.g. through haemodialysis equipment 
(69). 
More recently, sexual transmission has been recognised as a key component of 
acute HCV infection, particularly in men who have sex with men participating in high 
risk sexual practices. This is well documented in those co-infected with HIV(70). 
However, among heterosexual couples the risk of transmission from unprotected sex 
is low(71). Vertical transmission is recognised but infants of infected mothers are at 
relatively low risk (approximately 5% infection rate) if relevant precautions are taken 
(72). 
In the developing world, causes of transmission vary. In the Asian subcontinent and 
parts of Africa, use of inadequately sterilised needles for mass vaccination 
programmes has undoubtedly contributed to the high prevalence of HCV in these 
countries. In Egypt, which has the highest world prevalence of HCV at 14.7%, the 
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main risks for transmission have been identified as medical procedures ranging from 
injection of medications to surgery (73). 
 
1.3.2 Viral and host factors associated with spontaneous resolution 
of infection 
While most infected individuals will progress to chronic infection without therapy, 
some clear the virus spontaneously. This usually occurs in the first 6 months 
following infection. Studies of high risk individuals have identified exposed groups at 
lower risk of contracting HCV and with a higher probability of viral clearance if 
infected. 
Due to the rapid multiplication of virus and error rate of HCV RNA polymerase, even 
infection with a single strain of virus soon evolves into infection with multiple 
quasispecies. Viral factors associated with progression to chronic infection include a 
diverse range of quasispecies detected shortly after transmission(74). This either 
suggests a virus which could rapidly diversify in that particular host environment, or 
that multiple quasispecies have been transmitted initially.  
HCV proteins themselves are thought to play an important part in attenuating the 
immune response by interaction with intracellular signalling pathways essential for 
viral defence. For example, the HCV protein complex NS3/4A blocks the action of 
IFN regulatory factor-3(75) . While specific mutations in these regions associated 
with chronic infection have not been identified, it is likely some viral quasispecies are 
better able to supress the immune response than others. Indeed, small studies have 
also suggested that genotype 3 may be easier for individuals to clear during acute 
infection(76). 
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While the host immune response is key in determining whether the virus is cleared 
during the acute phase, other factors such as female sex and young age at infection 
in adults are also associated with a higher likelihood of clearance and resolution of 
reinfection(77, 78). The mechanism by which these confer an advantage is unknown 
although these effects may also be mediated through an influence on immune 
activity. 
1.3.3 Innate immunity to HCV infection 
The first immune response to viral infection is in the form of innate immunity. The 
majority of innate responses are mediated through the production of IFNs and 
downstream upregulation of IFN (IFN) stimulated genes. This occurs predominantly 
in both infected cells and the key antigen sensing cells of the immune system, 
dendritic cells and macrophages. In general the innate immune response is triggered 
by binding of viral proteins, often RNA, to host receptors. Two main pathways for this 
have been described. The cytosolic pathway is activated through RNA binding to the 
‘RNA helicases retinoic acid inducible gene-I’ (RIG-I) or Protein Kinase R receptors 
in the cytoplasm. This in turn activates the Mitochondrial Anti-Viral Signalling protein 
(MAVS). The endosomal pathway is triggered by recognition of viral proteins by one 
of the 3 antiviral Toll-Like Receptors (TLR). Binding to TLR-3 activates the ‘Toll-IL-1 
receptor domain-containing adaptor inducing IFN-β’ (TRIF) and the kinase TBK1 
(Fig. 1.8). Receptor binding in both these pathways induces a chain of interactions 
triggering the release of IFN I and IFN III. Type II IFN (IFN – γ) is produced by NK 
cells and some adaptive immune cells and potentiates the action of IFN I (79, 80). 
IFNs then bind to their specific receptors activating the Jak-STAT pathway which in 
turn upregulate an array of ‘IFN Stimulated Genes’ with anti-viral activity. 
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Figure 1.8 Outline of the endosomal and cytosolic innate antiviral pathways 
The two main pathways for cellular detection of viruses are shown. In the endosomal pathway, Toll-
like receptors results in activation of myeloid differentiation primary response 88 (MyD88) and Toll/IL-
1 receptor domain-containing adaptor inducing IFN-β (TRIF) pathways. In the cytosolic pathway 
retinoic acid-inducible gene (RIG)-like receptors (RIGI) are triggered, Protein Kinase R (PKR) is also 
phosphorylated which results in the activation on anti-transcription factors and activation of nuclear 
factor (NF)-κB. The TRIF signaling pathway can also trigger autophagy. RIGI activation triggers 
mitochondrial antiviral-signaling protein (MAVS)-dependent pathways. These pathways have common 
mediators in TANK-binding kinase-1 (TBK1) and inhibitor of nuclear factor kappa-B kinase subunit 
beta (IKK-β). These in turn activate the transcription factors IFN regulatory factor (IRF) 3, IRF7, and 
nuclear factor (NF)-κB to promote production of IFN in addition to other inflammatory molecules. 
[Figure adapted from Carty (2014) Trends in immunology (81)] 
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HCV proteins such NS3/4 are able to block IFN production to some extent in infected 
cells. Despite this, surrounding cells are stimulated to produce IFN (predominantly 
types α, β and γ) generally leading to small clusters of infected cells surrounded by 
rings of uninfected cells (82). It is interesting to note that while IFN is undoubtedly 
part of acute immune responses which promote clearance, in chronic infection, pre-
treatment high levels of IFN stimulated genes are negative predictors of response to 
dual therapy with peg-IFN-α and ribavirin (83).  
Extracellular innate antiviral defences have also recently been identified as being 
important in HCV. For example, small molecules such as complement, ficolins and 
collectins have been proposed as having importance in HCV resistance (84, 85). The 
role of lipoproteins in facilitating and inhibiting HCV infection has also been explored 
with the discovery that while ficolins can bind to E1E2 to prevent cell entry, they are 
inhibited in the presence of ApoE (86). 
Genetic factors influencing the innate immune system are associated with differential 
outcomes in acute infection and exposure. A single nucleotide polymorphism (SNP) 
at the IFN lambda 3 locus (also known as IL28B) genotype CC is associated with 
increased likelihood of clearing acute infection, in addition to its association with 
higher viral clearance rates in chronically infected individuals treated with IFN 
therapy(87-90).  
In cohorts which are at high risk of repeated exposure (i.e. injection drug users who 
share needles and injecting paraphernalia), a group of individuals have been 
identified who show no serological evidence of ever having been infected (i.e. 
standard antibody tests to non-structural proteins are negative). These uninfected 
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individuals (termed exposed uninfected or EU) have been shown to have innate 
immune system characteristics which are distinct from both healthy controls and 
spontaneous clearers (Table 1.1) (91-93). EU cohorts display raised levels of 
proinflammatory mediators IL6/IL8 and TNF-  in addition to natural killer cell activity 
compared to IDUs infected with HCV (94, 95). EU cohorts are also genetically 
distinct from spontaneous resolvers and those with chronic HCV(96) with the alleles 
for the Killer Cell Immunoglobulin Like Receptor KIR2DL3 and HLA type C1 over 
represented in both the EU and spontaneous resolver groups  whilst prevalence of  
the IL28B (IFNL3) polymorphism is similar in EU to chronically infected cohorts(93, 
95, 97, 98). 
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Table 1.1: Immunological characteristics of EU and spontaneous HCV resolvers. 
Immunological 
Compartment 
Exposed 
Uninfected 
Spontaneous 
Resolvers  
Chronically 
Infected 
Control group Ref 
Natural Killer 
Cell 
cytotoxicity  
/  (NB spontaneous 
resolvers and chronically 
infected not separated) 
Healthy controls (94) 
IL28B CC 
genotype 
   (control) Chronically 
infected 
(96) 
KIR2DL3    (control) Chronically 
Infected 
(97, 98) 
IL12 genotype 
(C allele) 
  N/A Compared to 
healthy controls 
(93) 
IL6/IL8 levels  N/A N/A 
(control) 
Healthy controls 
and chronically 
infected 
(95) 
TNF-    Healthy controls (95) 
HCV specific T 
cell 
proliferation 
 Present in 
some 
 (control) Chronically 
infected 
(92, 99) 
Summary of studies comparing immune characteristics of individuals chronically infected with HCV, 
healthy controls, individuals acutely infected with the virus who clear or spontaneously (spontaneous 
resolvers) and  those at high risk of exposure who do not show markers of infection (exposed 
uninfected). Arrows indicate level of protein expression or cellular activity (indicated by heading) 
compared to control group. The control groups used in each study are indicated in the appropriate 
column. 
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1.3.4 T cell mediated immunity and virus evasion of the T cell 
response 
T cell responses to HCV develop after 8-12 weeks of infection (100). Appearance of 
HCV specific T cells peripherally is associated with the onset of liver inflammation 
(101). In the clinic, symptomatic acute infection accompanied by evidence of liver 
inflammation is a positive predictor of viral clearance.  
Several HLA types which influence the ability of antigen presenting cells and infected 
cells to stimulate T cell activity have been associated with clearance or lower rates of 
infection. For those acutely infected with HCV genotype 1b, it has been shown that 
individuals with the HLA B27 alleles are better able to process and present key, 
conserved NS5B antigens to T cells, thus facilitating viral clearance (102).  As this 
HLA type is commonly associated with autoimmunity, it has been proposed that HCV 
may mimic some ‘self’ proteins, thus preventing a vigorous immune response 
developing in most individuals. Genome wide association studies of HCV have also 
identified other HLA loci associated with likelihood of spontaneous HCV clearance, 
namely HLA-A∗0301, B∗5701, Cw∗0102, DRB1∗0101 and the region surrounding 
DQB1*03:01 (87).  
Due to the high rate of viral turn over and rapid mutation rate, if adaptive immune 
responses targeting specific viral regions are required for clearance, the breadth of 
response is likely to be critical in determining infection outcome (74). Immune 
response ‘breadth’ has been defined in many ways but essentially relates to the 
ability of an individual’s immune system to react to or prevent infection by a wide 
range of viral genotypes, sub-genotypes or within-genotype quasispecies. A broad 
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and sustained T cell response is related to successful virus clearance in both acute 
infection and chronically infected patients undergoing treatment (103-105). 
In cohorts exposed to HCV who remain uninfected, T cell responses may also play 
an important role with evidence of adaptive HCV-specific T cell responses in up to 
60% of EU(92) (99). The presence of such responses suggests the adaptive immune 
system is exposed to the virus but that the virus is controlled before infection can 
become established enough to stimulate traditional markers of infection (i.e. 
antibodies to core and non-structural proteins).  
However, with persistent HCV antigen stimulation, T cells display an exhausted 
phenotype (106, 107). If HCV infection becomes chronic, this phenotype does not 
recover even after successful antiviral therapy(108). Experimental blockade of 
exhaustion associated molecules has been unsuccessful in promoting viral 
clearance in HCV although some boosting of adaptive responses has been seen in 
HIV (109), (110). This suggests that if the hosts T cell response is unable to clear 
virus effectively in the acute setting, it loses the ability to adequately eliminate virus. 
If this is the case, it is unlikely that T cells play a significant protective role in clinical 
outcomes once chronic infection is established. 
1.3.5 B cell mediated immunity to HCV 
1.3.5.1 Mechanism of B cell mediated immunity to virus 
The other major component of the adaptive immune response to virus is B cell 
mediated, predominantly in the form of antibodies. These are produced by a 
specialised B cell population termed plasma cells. Prior to antigen exposure, 
individuals have a diverse circulating population of B cell receptors, able to recognise 
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different antigens. These result from recombination of different V, D and J gene 
segments during lymphocyte development. There are upward of 1014 potential 
combinations and the average adult has 1010-1011 circulating B cells at any one time. 
On recognition of an antigen via the B cell receptor, B cells then internalise the 
antigen and represent it to T helper cells. On recognition of the presented antigen by 
CD4+ve T cells, co-stimulation occurs. B cells then develop into either memory B cells 
or antibody-secreting plasma cells. The initial antibody response to an antigen 
usually results in relatively non-specific binding IgM antibodies being produced. On 
chronic or repeat exposure to an antigen, more specific divalent IgG is generated. 
Over a period of chronic exposure, plasma cells divide and receptor genes undergo 
somatic hypermutation which over time increases the specificity and avidity of the 
antibodies for the antigen (Figure 1.9) 
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Figure 1.9 B cell antigen receptor diversification.  
A schematic of the BCR heavy locus is shown; with the exception of somatic hypermutation and 
class-switch recombination. Antigen receptor repertoire diversity is primarily established during 
lymphocyte development, during which V (orange), D (green), and J (yellow) gene segments are 
rearranged through the process of V(D)J recombination. Numbers of distinct V, D, and J segments 
are shown for each antigen receptor locus. During the recombination process, nucleotides may be 
added or deleted at segment junctions (magenta), contributing to additional sequence diversity. 
Complementarity determining regions are indicated. BCR-specific secondary diversification may occur 
following antigen recognition. In somatic hypermutation processes, mutations (red) are introduced 
throughout the variable region such that modified BCRs may be selected through affinity maturation. 
In class-switch recombination, gene segments encoding constant regions (blue) are rearranged 
resulting in the production of antibodies with different isotypes and corresponding effector functions. 
Abbreviations: BCR, B cell receptor; TCR, T cell receptor; V, J, and D, Variable, Joining, and Diversity 
gene segments. [Extracted from Calis 2014(111). Permission for reuse granted through RightsLink]. 
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Antibodies can inhibit viral infections in several ways. Neutralising antibodies are 
those which bind to epitopes on the virus surface which prevent interaction with host 
cell receptors, therefore preventing entry into target cells. Individuals also produce 
non-neutralising antibodies which target regions not essential for cell entry. These 
antibodies may promote clearance of functional virus from serum through 
opsonisation and subsequent phagocytosis or complement dependant lysis but 
would not directly inhibit target cell entry. Indeed, there is evidence that non-
neutralising antibodies may enhance target cell infection in other diseases(112).  
It is not known which concentration of envelope specific antibodies is required to 
prevent de novo or recurrent infection with HCV. Acutely infected individuals in the 
process of clearing the infection tend to have higher concentrations of total anti-HCV 
antibody as a whole than those who have cleared the infection some time ago(113). 
General stoichiometry studies examining antibody binding have concluded that there 
is a relationship between virion size and the number of antibody molecules needed 
to neutralise the virion, preventing it from infecting its target cell. The HCV virion has 
been shown to vary in size between 40 and 100nm in diameter (114). Papilloma 
viruses, which are a similar size to the HCV virion at 40-55nm, require 38 antibody 
particles to neutralise each virion (115, 116). Interestingly antibodies are relatively 
large in comparison to these viruses at 10nm and effective neutralisation can occur 
without saturation of binding sites with antibody particles. However, the variation in 
the size of the HCV virion suggest some incorporate more lipid than others. This 
flexibility in particle structure may contribute to masking key viral proteins from the 
immune system. 
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1.3.5.2 The anti-envelope antibody response to HCV 
In HCV, antibodies directed at different viral components appear from around 7 
weeks following infection although in some individuals this can be delayed up to 6 
months or longer in HIV co-infection (117). Phage display methods and purified 
monoclonal antibody (mAb) isolates have been used to map distinct immunogenic 
domains of E1E2 targeted by patient derived antibodies (118-123). Some of these 
are involved in cell entry and therefore elicit neutralising antibodies which prevent 
infection (NAb), others elicit non-neutralising antibodies. Perhaps the best 
characterised antibody epitope regions are the conformational immunodomains A to 
E described by Steven Foung (121, 123, 124). These are listed in Table 1.2 along 
with the names of isolated mAbs which have been shown to bind in these regions. 
Additionally, a separate research group have identified an alternative collection of 
HCV “antigenic regions” and characterised antibodies targeting these domains. 
These include antibodies directed at a region overlapping domains B and E in 
addition to domains encompassing the E1 – E2 interface (125-127). The key 
antibodies identified by this group are also shown on Table 1.2.  Recent alanine 
scanning data has located the immunodomains and their key residues on the core 
E2 structure (See Figs. 1.10 and 1.11). Note that while Domain B and D were initially 
thought to be separate (124), in fact they share common residues. In addition, 
animal immunization studies have yielded antibodies to linear epitopes that are 
essential for infection (32, 128-130). 
1.3.5.3 The antibody/B cell repertoire 
As with the T cell response, it is conceivable that an initially broader repertoire of B 
cell receptors targeting HCV may limit its ability to escape from these responses. As, 
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until recently, sequencing the B cell receptor population could only be achieved 
through a relatively laborious process, much of the work on B cell repertoire to date 
has focused on the functional breadth of antibody response. With the advent of next 
generation sequencing, there is more scope to relate this to the genetic diversity and 
evolution of B cell populations. 
1.3.5.4 Broadly neutralising antibody responses 
In acute HCV infection, there is growing evidence that a robust and ‘broad’ antibody 
response can contribute significantly to viral clearance (113, 131). Previous 
observational studies have shown rapid onset of anti-HCV antibodies to be 
associated with higher likelihood of clearance (132). More recently, it has been 
proposed that developing a broad antibody profile capable of preventing infection by 
diverse strains of HCV virus predict acute clearance in a cohort infected with 
genotype 1a HCV(113, 133).  
 
While there is no universally accepted definition of ‘breadth’ of antibody response, 
this is widely accepted as the functional ability of a mAb or the polyclonal antibodies 
derived from a single individual to bind to and prevent infection by a range of viral 
subspecies. Such antibodies are generally termed “broadly neutralising antibodies” 
(bNAbs). In the HCV field, some groups have tested against viral subspecies within 
one genotype to determine breadth(133) whereas others have used a panel of 
viruses from differing genotypes(129). As mAbs have the ability to neutralise broadly 
in such studies, this definition does not distinguish between polyclonal responses 
which target a single neutralising epitope and those which target multiple neutralising 
epitopes.  However, as the virus can evolve to escape from some of the most potent 
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bNAbs(121) , the ability to target multiple epitopes may be advantageous in 
overcoming such escape mutations to achieve  successful clearance. Little is known 
about which areas of the HCV envelope proteins are preferentially targeted by the 
humoral response in human hosts at population level as most studies analysing 
broadly neutralising activity examine only small numbers of individuals. However, a 
study screening for the prevalence of antibodies to a highly conserved linear region 
of E2, targeted by the mouse monoclonal bNAb AP33, found that only 2-15% of HCV 
infected individuals raise immunoglobulins to this region (134, 135). 
 
Why some individuals develop a broad neutralising response and others do not is 
incompletely understood. Recent work examining antibody responses to HIV have 
suggested that viral evolution is key in activating and developing B cell receptors to 
produce neutralising antibodies(136), however unlike HIV, spontaneous resolution of 
HCV infection associated with bNAbs occurs in a significant proportion of 
individuals(133) suggesting that breadth of antibody response is not solely the 
product of a rapidly evolving virus repeatedly escaping the immune response.  
 
1.3.5.5 Escape from the antibody/B cell response 
HCV has several mechanisms by which it can evade adaptive humoral responses to 
establish chronic infection.  Firstly, its error prone polymerase enables genetically 
diverse quasispecies of virus to be generated rapidly leading to the emergence of 
dominant NAb-escape mutants(15), (137).  Figure 1.11 illustrates the regions 
important for binding of known bNAbs, this can be compared with the most variable 
sites in the amino acid sequence of the genotype 1 envelope protein, shown in 
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Figure 1.12. In considering vaccine design it is important to note that variability of up 
to 30% can be observed between genotypes(15). 
Secondly, important epitopes in the virus are subject to glycan shielding. In addition, 
HVR1 and HVR2 are thought to play a role in shielding regions of the virus important 
for cell entry (138),(139). Studies of E2 structure have shown the N-terminal regions 
of E2 from HVR1 to HVR2 to be flexible suggesting they may be able to undergo 
conformational change on binding to cell surface receptors such as SRB-1 
subsequently exposing CD81 binding regions. (38) 
Furthermore, HVR1 and other regions of the virus may act as a decoy to misdirect 
the immune response. In acute infection, a predominantly HVR1 targeted response 
is associated with progression to chronic infection rather than acute resolution (140). 
Another decoy mechanism may be through secretion of  nucleic acid free, envelope 
protein coated subviral particles as described by Scholtes (2012). Such particles 
have the potential to bind antiviral antibodies reducing their impact on infectious 
virions (141). There is also evidence that some envelope molecules may mimic self-
proteins such as IgG preventing the development of a robust immune 
response(142).  
Finally, the virus is able to transmit directly from cell to cell which typically evades 
humoral responses, however one group has shown antibodies directed at SR-BI 
blockade are effective in preventing cell-cell transmission suggesting that an 
antibody based approach may not be completely ineffective in preventing this mode 
of transmission(143). 
 62 
 
1.3.5.6 Clinical relevance of antibody responses in chronic infection 
In addition to contributing to acute clearance, there is some preliminary evidence that 
antibody responses may influence chronic disease outcomes. In vitro and in vivo 
animal studies have suggested that broadly neutralising antibodies may be able to 
control levels of virus and contribute to clearance even once infection has become 
established (144) . In a case of a chronically infected patient who spontaneously 
cleared HCV,  a broad neutralising antibody response was generated with 
subsequent restoration of T cell activity(131). However, it is not yet clear whether 
neutralising antibodies have an overall protective role in chronic infection. Indeed, 
the antibody response to HCV can have pathological consequences as seen in 
cryoglobulinaemic vasculitis(6). If large scale vaccination is being considered, it is 
important to determine that stimulating such a response will not be harmful in the 
event of an infection developing. Studying clinical associations in patients with 
broadly neutralising antibodies can reveal associations with any adverse outcomes 
and can yield insights into patient factors associated with neutralising antibody 
production. 
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Table 1.2 Key HCV envelope epitopes targeted by monoclonal antibodies derived from 
patients. 
 
Immunodomain  Key Antibodies Key binding residues in 
E1E2 glycoproteins 
Reference 
A CBH-4B, CBH-
4D, CBH-4G 
540, 542, 556,627 (120) 
B HC-1, HC-11, 
CBH-5, AR1B 
425, 427,438, 530, 535 (120) 
(125) 
C CBH-7 544, 547, 549, 550 (145) 
D HC-84 (including 
HC-84.26, HC-
84.20 and HC-
84.24) 
441,442,443,616 (NB also 
overlaps with some 
domain B residues) 
(145) 
E AP33 
AR1A 
413,415,418,420 (146)  
(125) 
B and E 
overlap 
AR3B,  
 
412,416,418,423,424,523, 
525,530,535,540 
(125) 
E1 /E2 
interface 
AR4A 201,204,205,206, 487, 
657,658,692,698 
(127) 
AR5A 201,204,205,206,639,657, 
658,665,692 
(127) 
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Figure 1.10 Immunodomains of the E2 protein on the core E2 structure  
Binding regions of antibodies confirmed as belonging to separate immunodomains from alanine 
scanning experiments. These are displayed on a model of the E2 core structure as generated by 
Kong et al (2013) (37). Different colours notify regions which cluster together according to patterns of 
monoclonal antibody binding when analysed in a heatmap. Note, while Domain B and Domain D have 
some separate residues, there are also regions which overlap. Domain C is relatively poorly 
characterised compared to the other domains. Domain A represents the AP33 antibody binding region 
which is not included in the core E2 structure but is shown in a region where it would most likely 
appear on the complete E2 structure. Individual amino acid residues thought to be important in CD81 
binding are shown alongside the core structure with Domain B clustering residues coloured pink and 
Domain D clustering residues coloured bright green. [Figure and legend adapted from Pierce et al, 
2016(145) as permitted by the National Academy of Sciences].  
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1.4 Methods of studying humoral responses to HCV 
Following the discovery of HCV, initial research was limited due to a lack of in vitro 
and in vivo models replicating the process of infection and cell entry. 
Few animals are naturally susceptible to HCV infection, despite a number of species 
recently discovered as carrying the related Pegivirus species. Primates can be 
infected, although experimentation on these animals is often not practical. Several 
studies inoculating primates with live virus and assessing responses to basic 
vaccines have been conducted (147, 148). More recently chimeric mammal models, 
in particular mouse models with human hepatocytes grafted onto their liver, have 
been generated to study effects of HCV infection in vivo(149). However, the immune 
responses identified in mice are not directly comparable to those in humans. 
In vitro, the main challenge was identifying a liver cell line which was permissible to 
viral infection. Initially, this was overcome by creation of a sub-genomic replicon 
which mimics viral replication in Huh7 hepatoma cells(150). However, replicons do 
not contain envelope genes and do not undergo cell entry. Subsequently, the 
isolation of the JFH-1 strain of HCV, which can infect Huh7 cells and undergo a 
complete viral lifecycle, allowed further investigation of the effects of HCV including 
the cell entry step (151). Additional aids to studying replication and infection were the 
introduction of reporter genes into the virus such as luciferase(152). Other groups 
have identified different cell lines which are permissive to infection by different 
genotypes (153) and the JFH-1 virus can be modified to contain sequences from 
other genotypes(154). Another challenge with the hepatoma cell model is such cells 
do not secrete VLDL when grown in standard tissue culture media. As HCV virions 
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are typically coated in VLDL, this limits the conclusions which can be drawn from 
work with this cell line. Interestingly, the addition of human serum to the culture 
medium has been shown to restore the VLDL content of virions(155). Alternative cell 
models, such as the use of human liver progenitor cells (the HepaRG cell line) are 
also able to produce virions incorporating VLDL and can be used in studies of cell 
entry inhibition(156). Recently, an infection model using hepatocyte stem cells has 
been described which allows infection by wild type HCV from patient serum (157, 
158). 
For the study of cell entry alone however, a fully infective virus was not necessary. 
Therefore, the pseudoparticle system (HCVpp) was developed (159-161) which used 
transfection of HEK-293T cells with plasmids constructed from a phCMV-7a 
expression vector. These three plasmids contained 1) a whole E1E2 sequence 
derived from patient samples, with flanking regions containing start and stop codons, 
2) a non-HCV polymerase and structural protein (e.g. retroviral or lentiviral gag-pol, 
initially Murine Leukaemia Virus was used) and 3) a reporter gene such as green 
fluorescent protein or luciferase. Following transfection, the HEK-293T cells produce 
particles coated in envelope protein containing a reporter gene (HCVpp), which are 
released into the media following transfection and can be harvested to ‘infect’ naive 
Huh7 cells. HCVpp have been widely used as a model for virus entry as they use a 
similar cell entry processes to live virus, largely being dependant on the CD81 
protein. The level of HCVpp entry can be quantitated by looking for the strength of 
the reporter signal and inhibition of entry can also be inferred by measuring reduction 
in this signal. In addition, the lysate from the HEK-293T cells producing HCVpps 
contains E1E2 protein which can be used downstream in ELISA assays. 
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However, as with HCVcc produced in HUH7 cells, lipids are not incorporated into 
pseudoparticles as they would be with live virus. This is important as predominantly 
lipid mediated entry pathways have been identified, such as using Syndecan 4 which 
interacts with apolipoprotein E  to mediate cell entry(162). Changes in ApoE 
availability are likely to influence infectivity and susceptibility to antibody mediated 
neutralisation(163). The VLDL receptor has also been shown to act as an HCV 
receptor independent of CD81(164, 165). Therefore while the HCVpp model is more 
practical to use than live virus by not requiring containment in a category 3 
laboratory, and offers the potential to explore the behaviour of a wide range of 
envelope sequences, it is not an entirely faithful model of cell entry of live virus 
studied in vivo. 
1.5 Clinical Impact of HCV 
Within the UK, HCV contributes to a significant proportion of morbidity and mortality. 
While death rates from other major causes show a downward trend, those from end 
stage liver disease due to HCV have doubled in the past decade(166). While much 
of the measurable burden of HCV is on liver health, individuals chronically infected 
with HCV can report a multitude of symptoms which can be attributed to the virus 
and it can significantly reduce quality of life even in the absence of end stage 
cirrhosis(8).  
1.5.1 Liver morbidity 
1.5.1.1 HCV induced cirrhosis 
HCV infection is not hepatocytolytic and therefore much of its pathogenic effects on 
the liver are secondary to activation of the host’s inflammatory responses within the 
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liver. Over years to decades, these processes lead to liver cell death, deposition of 
scar tissue and disorganised regeneration of liver. Once there is irreversible scarring 
and alteration of liver microarchitecture this is termed liver cirrhosis (167). HCV has 
several molecular mechanisms thought to contribute to liver fibrosis and ultimately 
cirrhosis. In particular infection has been shown to increase levels of fibrogenic TGF-
β(168), HCV core and non-structural proteins can also directly interact with fibrin 
producing stellate cells within the liver(169). 
In the modern era, diagnosis of liver fibrosis and cirrhosis in HCV can now be 
achieved using a non-invasive technique called transient elastography which uses 
shear waves to measure liver stiffness. Correlation of transient elastography values 
in patients with HCV liver disease with histological diagnosis of cirrhosis has been 
extensively validated (170).  . 
In the presence of ongoing liver inflammation or additional liver insults, such as 
alcohol use, decompensated cirrhosis can result. As the liver’s vascular architecture 
is disrupted, the venous pressure in the portal vein can increase, leading to opening 
of small vessels which bypass the liver and directly connect the portal system to the 
systemic venous system. This has several consequences including an increase in 
the renin and aldosterone hormones which promote retention of salt and water 
ultimately leading to oedema and ascites (low protein fluid collecting in the 
abdomen). This can lead to infection, or kidney failure which both carry a high 
mortality rate (171).  
Porto-systemic collaterals bypassing the liver can cause ammonia based waste 
products from the gut to enter the systemic circulation, rather than being metabolised 
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by the liver. This can cause cerebral dysfunction known as encephalopathy which 
can significantly impair the individual’s ability to care for themselves as well as being 
associated with increased mortality(172). 
Increased portal pressure can also result in bleeding from dilated porto-systemic 
collaterals termed ‘varices’, most commonly gastric or oesophageal. Bleeding from 
these vessels is associated with a 14% in-hospital mortality (173). 
While cirrhosis is generally thought to be irreversible in HCV, following successful 
viral treatment, improvement in histological and non-invasive measurements of liver 
fibrosis have been observed, suggesting that reversal of cirrhosis may be possible in 
some individuals (174, 175). However, the majority of those who have developed 
cirrhosis remain at risk of these complications for life. There is also some evidence 
that those who clear HCV without developing cirrhosis may still be at higher risk of 
developing significant liver disease in the future (176).  
 Therefore, the ability to prevent infection altogether through public health measures 
or vaccination, or treatment strategies to target those in the early stages of infection 
are the only clear ways to prevent the large burden of liver disease caused by this 
condition. While several therapies to slow or reverse progression of liver fibrosis 
have been trialled, these have not yet shown a significant impact in human 
subjects(177). 
1.5.1.2 Hepatocellular carcinoma 
There is also evidence that both the metabolic liver effects induced by HCV and 
proto-oncogenic effects of some HCV proteins may have an additional role to play in 
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progression to hepatocellular carcinoma (178). This condition creates a significant 
morbidity and mortality burden on affected populations.  
Compared to other malignancies, hepatocellular carcinoma (HCC) has one of the 
largest recent increases in incidence in the UK(179). Chronic HCV infection is 
thought to have had a significant impact on this with AASLD guidelines suggesting 
that HCV-infected patients with cirrhosis develop HCC at a rate of 2.5%/year. This 
risk is increased by additional liver comorbidities such as alcohol excess and HBV 
coinfection(180). 
HCC predominantly develops in individuals who have already progressed to liver 
cirrhosis. This is thought to be due to the cumulative effect of DNA damage as a 
consequence of the chronic liver inflammation, cell damage and regeneration which 
occurs as cirrhosis develops (178). However, non-cirrhotic HCC has been reported 
in individuals mono-infected with HCV and some HCV proteins are thought to have 
direct carcinogenic effects.  
Transgenic mouse models have identified a link between core protein and possibly 
NS5A with generation of HCC. Other molecular studies have found NS5B mediated 
inhibition of the “Retinoblastoma” tumour suppressor gene and core protein 
mediated dysregulation of the p53 pathway (181).  
1.5.2 Cryoglobulinaemia and B cell lymphoma 
HCV is the most common cause of the benign B cell disorder, mixed 
cryoglobulinaemia (MC), and is linked to the development of B cell lymphoma. MC is 
a clonal B cell disorder characterised by precipitation of antibody aggregates on 
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serum cooling which can be re-dissolved at 37oC. These precipitates consist of auto-
reactive antibodies targeting the fixed (Fc) region of host IgG (also known as 
Rheumatoid factor-like activity)(6).  
1.5.2.1 Clinical syndrome 
While patients can have positive autoantibodies in the absence of any 
symptoms(182), the cryoglobulinaemia syndrome is typically associated with 
vasculitic symptoms and complications including skin rashes, joint pains, renal 
failure, pulmonary haemorrhage and peripheral neuropathies. The condition may be 
a precursor to B cell lymphoma although only a minority of cryoglobulin-positive 
patients progress to this.  
1.5.2.2 Possible pathogenesis 
The exact pathogenesis of cryoglobulinaemia in HCV is incompletely understood. 
The disorder has been associated with expansion of a naïve subtype of B cells(183). 
The B cell activating factor molecules have also been implicated (184). The 
presence of HCV is generally required for persistence of cryoglobulinaemia and it 
generally resolves on successful treatment of the virus. This has led some to 
speculate that HCV proteins may induce cryoglobulinaemia, either through directly 
activating B cells or by acting as a molecular mimic of the IgG Fc portion. One study 
reported a HCV-related B cell lymphoma which had gene usage similar to B cells 
bearing receptors targeting the E2 envelope protein which further supports this 
theory(185). 
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1.5.3 Cardiovascular morbidity 
As seen in some other chronic inflammatory conditions, increased rates of 
cardiovascular disease have been reported in those chronically infected with HCV 
(186). This is of particular interest as the HCV lifecycle is so closely associated with 
lipid metabolism and dyslipidaemia is a well-documented risk factor for vascular 
disease. In one study HCV infection was associated with lower lipid levels but higher 
vascular mortality(187). Additionally, analysis of the Scottish Clinical HCV database 
revealed reduced cardiovascular mortality following SVR(188). However, at a 
population level, it is difficult to separate the effects of the HCV virus on vascular 
health with the impact of adverse lifestyle risk factors associated with HCV infection. 
1.5.4 Neuropsychiatric effects 
The presence of HCV infection with or without cirrhosis can itself be associated with 
fatigue and reduced quality of life (189). HCV has also been demonstrated to infect 
brain tissue (190) and subtle impairments in cognition, along with structural changes 
visible on MRI scanning, can be detected in individuals with minimal liver 
fibrosis(191). 
1.5.5 Metabolic effects of HCV 
HCV infection has been linked with an increased risk of developing features of the 
‘metabolic syndrome’ (dyslipidaemia, hypertension and insulin resistance) with 
hepatic steatosis in up to 85% of infected individuals. Systemic metabolic 
disturbance , in particular insulin resistance progressing to Type II Diabetes 
Mellitus(192) is thought to be more common in gt 1 infection than with gt 3 infection, 
whereas hepatic steatosis alone is more likely to occur in gt 3. This highlights the 
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distinct pathophysiological pathways of the different genotypes (193). The presence 
of steatosis had been linked to adverse treatment outcomes using IFN based 
regimens (194). 
There are multiple mechanisms by which the virus is thought to exert these effects. 
Hepatocytes infected with gt 3a upregulate synthesis of fatty acids with impaired β–
oxidation(195), potentially through mitochondrial damage, and altered triglyceride 
export. HCV proteins have been shown to interfere with insulin signaling pathways, 
in particular core protein activates peroxisome proliferator-activated receptor gamma 
(PPARγ) which is a target for anti-diabetic therapies (196). 
1.6 Strategies to control HCV infection and its impact 
1.6.1 Medical therapy 
Following the characterisation of HCV in 1989, IFN alpha 2b was the first effective 
therapy to be identified against the virus (197). However, this only resulted in 
normalisation of liver biochemistry in around 50% of individuals and infection tended 
to relapse on cessation of treatment. 
In 1999, PEGylated IFN alpha was introduced along with the combination therapy 
with the antiviral agent ribavirin. This longer acting preparation of IFN led to better 
outcomes although the rate of Sustained Viral Response (SVR – defined as 
undetectable viral load 6 months after cessation of therapy) was still low (40%) (198) 
with significant problems with tolerability due to haematological and neuropsychiatric 
effects(199). 
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Since then, the development of several new direct acting antiviral agents (DAAs) in 
addition to a genotype tailored approach has transformed the face of therapy to the 
extent that the most recent EASL recommended regimens do not include IFN (Figure 
1.13). The various agents used in this guideline are described in more detail below. 
 
Figure 1.13 European Association for the Study of the Liver treatment recommendations on 
treatment of Hepatitis C 2016. 
 [Extracted from EASL Recommendations on Treatment of Hepatitis C, Journal of Hepatology with 
permission granted through  RightsLink] 
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1.6.1.1 Ribavirin 
Ribavirin is a guanosine analogue which prevents RNA synthesis, therefore has 
been used as an anti-viral agent against several viruses including HCV. While its 
effects on RNA synthesis explain some of its antiviral activity, it is also thought to 
have wider anti-viral actions and is effective against some DNA viruses. Despite the 
fact that it is a non-specific antiviral agent, it still improves SVR rates in combination 
with some of the most recent DAA regimens in difficult to treat patients (200).  
1.6.1.2 Protease inhibitors 
Protease inhibitors (PI) were the first licenced DAA agents designed to target the 
HCV polyprotein specifically. Initially only two such agents, Boceprevir and 
Telaprevir were licenced, although several other agents are now available for use. 
These small molecules bind directly to the NS3 protein site responsible for cleaving 
the junctions between NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B(201). 
This prevents efficient formation of the replication complex therefore limiting HCV 
production. 
First generation molecules were very genotype specific being active against gt 1, 
and more effective against gt 1b than gt 1a due to the higher natural occurrence of 
resistance mutations in the gt 1a sequence(202). This led to the introduction of 
routine testing for specific resistance mutations prior to therapy in the clinic. In those 
with a favourable HCV profile, SVR rates of up to 70% were reported in treatment 
naïve individuals without cirrhosis. However, these combinations still required 
prolonged treatment with IFN and ribavirin alongside PI therapy. In addition to the 
common side effects with IFN/ribavirin, there was a significantly increased risk of 
rash in triple therapy. In one report, patient withdrawal rates due to tolerability were 
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26% with an on-treatment mortality rate of 2%(203). These agents have largely been 
superseded by newer DAAs, however a newer PI Simeprevir is still recommended 
for use in the EASL guidelines. 
  
 
1.6.1.3 NS5B inhibitors 
The NS5B inhibitors are also small molecules specifically designed to target the 
replication complex, in this case the NS5B RNA polymerase. 
Some of these have activity against gt 1, 2, 3 and 4 although they are considerably 
less effective against gt 3 when used as monotherapy (204). 
Initial studies using the NS5B inhibitor Sofosbuvir reported SVR rates upward of 90% 
in IFN-free regimes for gt 1 infected patients (205). These medications are much 
better tolerated than IFN-based therapies with fewer drug interactions making them 
more practical to use. The cost of regimes containing these inhibitors has prevented 
them being universally used for all genotypes of infection, however the most recent 
NICE guidance has approved NS5B containing regimes for all individuals infected 
with gt 1 in the UK(206). The financial burden of increased levels of screening and 
treating HCV-infected patients with DAA containing regimes has been estimated to 
increase costs 5-fold in the short term, although longer term savings from prevention 
of complications could be expected(207). 
1.6.1.4 NS5A inhibitors 
The NS5A inhibitors impact on replication, assembly, and secretion. Some NS5A 
inhibitory molecules have pan-genotypic activity(53). Daclatasvir, the first of these 
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agents to be licenced, targets Domain I of the NS5A molecule involved in replication. 
While NS5A inhibitors have not been tested as monotherapy in large clinical trials, 
they enhance the efficacy of NS5B inhibitors when used in combination. For 
example, Ledipasvir is now marketed as a single tablet in combination with the NS5B 
inhibitor Sofosbuvir. This combination is reported to produce SVR rates of 95% after 
8 weeks of therapy in gt 1 virus-infected patients without cirrhosis who had not 
previously received treatment (208, 209).  Daclatasvir combined with Sofosbuvir is 
one of the few IFN-free combinations proven to be effective against gt 3 in patients 
with cirrhosis (210). Velpatasvir is the newest of these agents to be licensed which 
also has pan-genotypic activity (211). Therefore, with the addition of NS5A inhibitors 
to existing DAAs, effective IFN-free regimens are possible for the vast majority of 
patients with HCV, although their use is currently limited by cost.  
1.6.1.5 Tailored therapy 
Due to the cost and side effects involved in PI therapy, testing for the host IL28B CC 
mutation also became common in the clinic as individuals carrying this genotype 
were more likely to achieve SVR with IFN/RBV alone(88). Therefore, the introduction 
of these drugs not only heralded a new era in the types of treatments used for HCV 
but began a trend for tailored therapy based on both host and viral characteristics, 
highlighting the ability for different strains of the HCV virus to behave very differently 
and the influence of the host immune system on the virus’ ability to sustain infection. 
Due to the widespread efficacy of some of the newer DAAs, such highly tailored 
therapy is no longer necessary for most. In the UK, due to cost reasons, IFN 
containing regimes may still be used as a first line approach where patients are able 
to tolerate these. However, the most recent international treatment guidelines 
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suggest that the choice of antiviral treatment is based on HCV genotype, presence of 
cirrhosis and exposure to previous therapy, with testing for resistance mutations in 
the NS5A gene where this is available(65). In addition, interactions with several 
common medications have been noted which will also influence drug choice. While 
resistance to the newer DAAs is rare, it is likely that viral sequencing, in addition to 
host characteristics, will be useful in predicting the most successful second line 
regimes for those not achieving SVR with standard DAA treatment. 
1.6.2 Risk factors for poorer outcome in HCV infection and 
treatment 
1.6.2.1 HCV Genotype 
As noted above, genotype has a significant impact on both the development of 
cirrhosis and the efficacy of different treatments. While gt 3 infection was associated 
with higher rates of cirrhosis in untreated infection, in the IFN/RBV era, genotypes 2 
and 3 were easier to treat than gt 1 and 4 with SVR rates of 70% compared to 40%. 
With the advent of DAAs, gt 1 now has a larger selection of effective therapeutic 
agents, perhaps because the research effort has been concentrated on this 
genotype. It is therefore now easier to treat than gt 3, with SVR rates of >90% 
achievable for all clinical groups except those with decompensated cirrhosis. 
1.6.2.2 Age 
In HCV, as liver cirrhosis develops over a period of decades, typically 20% 
developing cirrhosis after 20 years of infection, adverse liver outcomes increase with 
age (212). There are few longer term follow up studies on the prevalence of cirrhosis 
beyond 20 years post-infection, however one long term study revealed that although 
Caucasian populations had relatively low rates of cirrhosis at age 61-80, 78% of the 
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Asian population studied had cirrhosis. As other factors were comparable between 
the groups this was felt to reflect longer duration of infection in Asian populations 
who were generally infected in childhood (i.e.  20 years earlier than the Caucasian 
population) (213). This suggests that as the HCV-infected population ages, 
prevalence of cirrhosis will increase dramatically unless effective treatment is 
implemented. 
There is also evidence to suggest that those infected at an older age develop more 
rapidly progressive liver disease (214). Finally, in the IFN era of treatment, advanced 
age was associated with a higher risk of treatment failure. Whether this remains true 
in the DAA era is yet to be seen (215). 
1.6.2.3 Alcohol use  
In the western world, perhaps the biggest predictor of adverse liver outcomes is 
concomitant alcoholic liver disease. Innes et al. used the Scottish national HCV 
database to determine the impact of alcohol excess on liver cirrhosis in HCV and 
found that consuming more than 50 units of alcohol per week was the most 
influential of all risk factors, accounting for up to 50 % of cirrhosis in HCV infected 
individuals (216). 
Alcohol use is also associated with a higher rate of decompensated liver disease and 
HCC (217). In addition to being a potent hepatotoxin in excess, alcohol may affect 
the HCV life cycle, promoting viral replication and having a synergistic effect in 
promoting liver damage in the context of HCV (218).  
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1.6.2.4 Coinfection 
HIV coinfection is generally thought to lead to more rapid progression of liver 
disease. Indeed, as mortality rates from HIV infection itself have improved, liver 
disease from HCV / HBV and other causes is becoming one of the leading causes of 
death in the HIV infected population (219). HIV co-infection traditionally made 
successful treatment of HCV more difficult, although the DAA therapies now appear 
to be equally effective in patients with HIV coinfection (220). 
HBV coinfection is also associated with poorer liver outcomes and HBV reactivation 
a recognised risk with DAA treatment in individuals previously infected with 
HBV(221). 
1.6.2.5 Obesity 
Increasing obesity levels have led to an epidemic of non-alcoholic steatohepatitis 
and associated liver morbidity in the developed world. Given that HCV infection can 
induce a metabolic syndrome, obese HCV-infected individuals are at even higher 
risk of developing this(222). Those who suffer from both HCV infection and the 
metabolic syndrome are at greater risk of adverse liver outcomes and weight loss is 
recommended in those with a high BMI. 
1.6.3 Population level prevention strategies 
The importance of reducing new HCV infections and treating existing ones has been 
recognised internationally by WHO and by individual countries. Within the UK, both 
Public Health England and Health Protection Scotland have been proactive in 
introducing measures to prevent new infections and accurately document the burden 
of disease (223, 224).  
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Before specific strategies to tackle HCV were developed, the HIV epidemic prompted 
the development of needle exchange and public education programmes to reduce 
transmission of blood borne viruses in general. These have undoubtedly had a 
beneficial effect in reducing HCV transmission within IDU populations. 
In 2014 the WHO published specific guidance on reducing transmission of HCV in 
people who inject drugs (225). However, in Scotland a public health strategy for 
preventing infection has been in place since 2008 (224) which involved creating a 
database of HCV-infected patients to monitor outcomes and inform strategies to 
improve these and a number of outreach programmes for screening and treating 
high risk populations linked to addiction and prison services. Further initiatives such 
as dried blood spot screening of age targeted populations and opt-out testing in 
emergency departments have detected new cases and are being more widely 
adopted (226). 
With the advent of the newer DAA therapies, several economic models have 
suggested that treating HCV infected individuals at high risk of transmission, for 
example PWIDs, would be cost effective in preventing further HCV infection in the 
IDU population(227, 228). Others have suggested that at present the costs involved 
would be prohibitive(207).  
While these strategies work well for first world countries with a well-resourced and 
nationally funded health service, they would be more difficult to implement in 
countries with poorer healthcare infrastructure or a largely private provider model of 
healthcare, as those in need of such interventions are usually least able to pay. 
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1.6.4 Vaccine development 
1.6.4.1 Types of vaccines 
The principle of vaccination is to prime the immune system with exposure to an 
antigen so the next time this antigen is encountered (on a live pathogen) a rapid and 
robust immune response is produced, preventing or limiting the consequences of 
infection.  The very earliest trials of HCV vaccines involved injecting live virus, or 
virus like particles into primate test subjects who generally cleared the infection. 
These trials revealed more rapid clearance of infection in “vaccinated” subjects on 
rechallenge (229).  Analysis of the immune response generated by inoculation 
showed both cellular and humoral adaptive responses. Passive immunisation 
through exposure to serum from infected individuals, infusion of pooled 
immunoglobulins or monoclonal, anti-HCV antibody has also been shown to reduce 
the risk of infection in primates and humans (12, 130, 230). Further studies using 
modified whole virus produced in cultured cells (HCVcc) demonstrated induction of 
broadly neutralising antibodies in mice (231).  
Attempts to identify specific HCV proteins which would give the broadest and most 
potent protection have involved trials of numerous combinations of structural and 
non-structural proteins. One barrier to a specific protein based approach is difficulty 
in generating an immune response which is broad enough to prevent infection by the 
various strains of virus present. In HCV, this is particularly relevant given the huge 
diversity of sequence seen both within and between genotypes. One approach to 
combat this is to identify proteins which are relatively conserved across strains which 
should elicit a ‘broad’ immune response, effective against different genotypes and 
subgenotypes. In vaccines for other viruses various strategies are used to achieve 
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this. One method is to use envelope or surface antigens which induce a ‘sterilising’ 
humoral response i.e. preventing cellular infection, such as the recombinant surface 
antigen used in Hepatitis B vaccination(232) . In others, for example the recently 
designed Multimeric-001 influenza vaccine (233), a number of conserved proteins 
are included which induce both antibody and cellular responses. The choice of 
proteins included in vaccines depend on specific characteristics of the virus, 
immunogenicity of the proteins and whether the aim is to prevent infection altogether 
or simply ensure that infection follows a more benign course. One potential target in 
HCV is the conserved E2 epitope corresponding to the broadly neutralising antibody 
AP33, however this appears to be poorly immunogenic in humans (134). 
To combat lack of immunogenicity, a protein of interest is often expressed on the 
backbone of an immunogenic protein or whole virus and an immunostimulant 
adjuvant may be used (234). In initial chimpanzee trials of using whole envelope 
protein as an immunogen, the addition of the oil emulsion agent MF59 improved 
clearance of subsequent infections suggesting that a more vigorous immune 
response was generated(235). This agent has also been used in human trials of 
HCV vaccination(236). Other work exploring use of organic compounds such as 
archaeosomes or m-ADP have also shown increased immunogenicity in animal 
studies(237). Using an immunogenic viral vector to deliver the vaccine has also been 
explored, one anti-HCV vaccine using this strategy is based on an Adenovirus 
vaccine and has been trialled in primates and healthy subjects (238).  
Additional considerations in vaccine development are the mode and timing of 
vaccines delivery. Some, such as polio, can be delivered orally or intranasally, but 
traditionally, the majority of human vaccines have been delivered intramuscularly. 
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Recently it has been shown that influenza vaccines delivered more superficially into 
the skin using a microneedle patches may be more effective that using the 
intramuscular route (239). While novel delivery systems may have cost implications, 
if they improve uptake and effectiveness this may justify such cost(240). 
As the immune response to an antigen tends to wane over time, some vaccines 
require a ‘booster’ vaccination to be given after a period of years has elapsed, for 
example that against tetanus toxoid. For other viruses, rapid evolution requires more 
frequent vaccination such as in influenza. In addition, some vaccines are more 
effective following a course of multiple exposures rather than a single immunisation 
such as the Hepatitis B vaccine. Finally, from a practical perspective, storage 
conditions of vaccine preparations differ; with some requiring cold storage wheras 
others remain stable at room temperature for prolonged periods of time. The ideal 
vaccination for the populations who would most benefit from HCV immunisation 
would be a single or compressed course of vaccinations with a preparation not 
requiring continuous cold storage. This would enable delivery of the vaccine to areas 
with less developed healthcare systems and to more transient populations such as 
people who inject drugs (PWIDs) as has been demonstrated for other viral vaccines 
(241). 
 
While B and T cell responses to many HCV viral proteins have been recognised, T 
cell targeted vaccination strategies have tended to use non-structural protein 
antigens whereas B cell targeted strategies often concentrate on responses to the 
envelope proteins. It is unfortunate that the vaccines at the later stages of 
development have not aimed to elicit a strong B cell and T cell response in 
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combination as experts in the field have suggested this strategy is likely to be 
necessary for a broadly effective vaccine (242). 
 
1.6.4.2 T cell targeting vaccines 
 
The most promising T-cell focused vaccine to enter clinical trials has involved the 
HCV non-structural proteins expressed on an adenoviral backbone. This has been 
trialled on 30 healthy subjects eliciting robust T cell responses, however efficacy of 
preventing infection in individuals at high risk of HCV transmission has yet to be 
seen (238). Another study of a non-structural peptide vaccine elicited a 60% CD4 
response rate in healthy subjects (243). While this is encouraging, this is a much 
lower response rate than found in most anti-viral vaccines which have been adopted 
in clinical practice.  
A novel approach to T cell stimulation in harnessing and modifying host antigen 
presenting cells has also been trialled (244). While this has proved effective in 
eliciting a strong T cell response, it is difficult to see such an approach being a 
practical and cost effective solution for the populations who would most benefit from 
an effective vaccine.  
1.6.4.3 B cell targeting vaccines  
 
Several researchers have sought to induce bNAbs through vaccination, 
predominantly by using part or all of the E1E2 molecules. Stamataki et al (2007) 
showed that immunisation of rodents with E1E2 had the ability to induce strain 
specific NAbs with some cross-strain neutralising activity (245).  
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The pharmaceutical company Chiron have been developing a commercial vaccine 
based on recombinant gt1a E1E2 proteins which, when administered with an 
oil:water adjuvant, produced sterilizing immunity in some chimpanzees against gt 1a 
and 1b viruses and shorter duration of infection in others. This vaccine has also 
undergone Phase 1 trials in human subjects where pan-genotypic neutralising 
antibodies were observed in one subject(246). Interestingly this vaccine has also 
been shown to induce significant CD4 T cell responses suggesting that any 
protection conferred by envelope protein based vaccines may be due to a 
combination of adaptive responses(236). However, in one trial, only 5/16 vaccinated 
subjects’ serum were able to reduce infectivity of gt 1a virus by 50%, while some 
individuals produced non-neutralising antibodies which interfered with the 
neutralising response (247), this suggests that a vaccine based on specific epitopes 
rather than the whole E1E2 protein may produce more effective protection. 
It is interesting to note that reinfection in individuals possessing neutralising 
antibodies has been described suggesting that protection is incomplete or that, in 
these cases, it may have been too ‘strain specific’ as evidenced by the fact that few 
of those who progressed to chronic infection possessed ‘cross-reactive’ antibodies 
(113). Therefore, the ultimate aim for those producing an envelope protein based 
vaccine is to produce one that generates an antibody response effective against a 
broad range of HCV strains. 
    
1.7 Hypotheses and scope of thesis 
I aimed to explore the following hypotheses in the work described in this thesis: 
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 There are a wide range of B cell responses to HCV infection with some 
individuals better able to produce neutralising antibodies which prevent 
infection by diverse strains of the virus. This is influenced by host 
characteristics. 
 In those who are exposed to HCV but do not develop or resolve infection, 
anti-envelope antibody responses play a significant role. 
 In chronic HCV infection, the anti-envelope B cell response plays an important 
role in HCV pathogenesis or prevention of this. 
 Further characterising the host and antibody characteristics of HCV infected 
individuals displaying a broadly neutralising response and viral mechanisms 
of  bNAb evasion may reveal important targets for vaccine design. 
 In those who develop chronic HCV infection, HCV has a detrimental effect on 
the B cell population as another mechanism for resisting viral clearance by the 
immune system. 
I addressed these hypotheses through laboratory based work using blood samples 
from cohorts of clinically characterised individuals infected with or exposed to HCV. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals/Reagents  
1 kb DNA Ladder (Invitrogen) 
100 bp DNA Ladder (Invitrogen) 
2-Amino-2-(hydroxymethyl)-1,3-propanediol (TRIS) (BDH) 
3,3’5,5’-tetramethylbenzidine (TMB) substrate (Sigma) 
Absolute ethanol (Bamford Laboratories) 
Agarose (Melford) 
Ampicillin (Melford) 
β-mercaptoethanol (Sigma) 
Bromophenol Blue (BDH) 
Ethanol (ThermoFisher Scientific) 
Glutathione –S – Transferase (GST) (produced in house) 
Hanks Balanced Salt Solution (HBSS) (Sigma) 
Histopaque (Sigma) 
IgG (human) (Sigma) 
IgM (human) (Sigma) 
Isopropanol (ThermoFisher Scientific) 
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Kanamycin (ThermoFisher Scientific) 
Methanol (ThermoFisher Scientific) 
NEBNext® Multiplex Oligos for Illumina® (New England Biolabs) 
Phosphate Buffered Saline (Tissue Culture grade) (Sigma) 
Proteinase K (ThermoFisher Scientific) 
Random Hexamers (Roche) 
RLT buffer (Qiagen) 
RNAse free DNAse (Qiagen) 
Sodium Chloride (NaCl) (BDH) 
Streptavidin (Sigma) 
Sucrose (BDH) 
Triton X-100 (Sigma) 
Tween-20 (Bio-Rad Laboratories) 
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2.1.2 Kits  
300 cycle MiSeq version 2 reagent kit (Illumina) 
Agencourt® Ampure® XP beads (Beckman Coulter) 
Bright-Glo Luciferase Assay System (Promega) 
CloneJet PCR cloning kit (ThermoFisher Scientific) 
Gateway® Vector Conversion System (ThermoFisher Scientific) 
HotStarTaq DNA Polymerase Kit, (Qiagen) 
Hydragel 4IF dynamic protein electrophoresis kit (Sebia) 
 KAPA HiFi Real-Time PCR Library Amplification kit for Illumina libraries (KAPA 
Biosystems) 
KAPA SYBR® FAST ABI Prism qPCR library quantification kit (KAPA Biosystems) 
LR Clonase II Enzyme Mix (ThermoFisher Scientific) 
NAbTM Protein G Spin Kit 0.2mL (ThermoFisher Scientific) 
pENTR/D-TOPO directional cloning kit (ThermoFisher Scientific) 
Phusion HighFidelity DNA Polymerase Kit (New England Biolabs) 
QIAamp Viral RNA Kit (Qiagen) 
QiAMP DNA Mini Kit (Qiagen) 
Qiagen Plasmid Maxi Kit (Qiagen) 
QIAprep Spin Miniprep Kit (Qiagen) 
QIAquick Gel Extraction Kit (Qiagen) 
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Qubit® dsDNA High Sensitivity kit (Invitrogen) 
Restriction enzymes and buffers (assorted) (New England Biolabs) 
RhF latex agglutination assay (Siemens) 
RNAse H (ThermoFisher Scientific) 
RNeasy Plus Mini Kit (Qiagen) 
Superscript III Reverse Transcriptase Kit (ThermoFisher Scientific) 
TaqMan ® SNP Genotyping Assay (Life Technologies) 
Vilo Reverse Transcriptase Kit (Invitrogen) 
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2.1.3 Equipment 
2200 TapeStation (Agilent Technologies) 
7500HT Fast Real-Time PCR system (Applied Biosystems) 
Chameleon II plate reader (Hidex) 
GeneAmp PCR Machine (Applied Biosystems).  
MiSeq System Desktop Sequencer (Illumina)  
Nanodrop 1000 spectrophotometer (Thermo Scientific, UK) 
Qubit® 2.0 Fluorometer  (Thermo Fisher Scientific) 
Varioskan microplate reader (Thermo Fisher Scientific) 
 
2.1.4 Cell lines 
 
Cells   Description    Source 
Huh7 Human Hepatoma cell 
line 
Jean Dubuisson (CNRS, 
Institut de Biologie de 
Lille, Lille, France) 
 
HEK-293T Human Embryonic Kidney 
cell line 
American Type Culture 
Collection 
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2.1.5 Antibodies 
2.1.5.1 Primary Antibodies 
Table 2.1 List of primary antibodies used 
Antibody Name Description Type Reference 
Anti-E2 AP33 Monoclonal (biotinylated 
and non-biotinylated) 
Mouse (129, 248) 
Humanised AP33 
(hAP33) 
Monoclonal 
Also known as MRCT10 
Humanised mouse  (249) 
Anti-E2 CBH-4B* Monoclonal Biotinylated Human (120) 
Anti-E2 CBH-5* Monoclonal Biotinylated  Human (119) 
Anti-E2 CBH-7* Monoclonal Biotinylated  Human (119) 
Anti-E2 HC-1* Monoclonal Biotinylated Human (250) 
Anti-E2 HC-11* Monoclonal Biotinylated Human (121) 
Anti-E2 HC-84.1* Monoclonal  Mouse human 
chimeric 
(124) 
Purified IgG from 
patient samples 
Polyclonal IgG  Human (purified 
using NAbTM Protein 
G Spin Kit 
ThermoFisher 
Scientific) 
(251) / this 
project  
Anti-SRB1 
mAb151-NP1 
Monoclonal Human-mouse 
chimera 
(252) 
Anti-mu(human 
IgM) 
Polyclonal (Sigma) Goat  
Anti-CD81 (clone 
JS-81)  
Monoclonal. (BD 
Biosciences) 
Mouse  
*Kindly provided by Professor Steven Foung 
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2.1.5.2  Secondary Antibodies 
Anti-streptavidin-HRP conjugate (Sigma) 
Anti-mouse-HRP conjugate (Sigma) 
Anti-human IgG-HRP conjugate (Sigma) 
Anti-mu (human IgM)-HRP conjugate (Abcam) 
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2.1.6  Solutions 
2.1.6.1  Bacterial propagation 
Luria Broth (LB)  
170 mM NaCl, 10 g/l Bactopeptone, 5 g/l 
yeast extract 
LB-agar 
LB plus 1.5 % (w/v) agar 
 
2.1.6.2  DNA Manipulation 
DNA loading dye  
30 % glycerol, 0.25 % bromophenol blue, 
0.25 % xylene blue 
 
TBE (10x)  
8.9 M Tris-borate, 8.9 M boric acid,  
0.02 M EDTA (pH 8.0) 
 
TE buffer (supplied by Qiagen) 
0.01M Tris-HCl (pH 8.0), 0.001M  EDTA  
ddH2O water  
pH adjusted to 8.0 
 
2.1.6.3 Cell Lysis 
Cell Lysis Buffer (LB2) 
 20 mM Tris-HCl pH 7.4, 20 mM 
iodoacetamide, 150 mM NaCl, 1 mM 
EDTA, 0.5 % Triton X-100 
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2.1.6.4 Tissue Culture 
Trypsin solution 
 0.25 % (w/v) Trypsin dissolved in phosphate buffered saline (PBS) 
 
Versene 
 0.6 mM EDTA in PBS, 0.002 % (w/v) phenol red 
 
DMEM complete 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % foetal calf 
serum (FCS) (heat inactivated at 56oC for 30 min), 100 U/ml penicillin, 100 μg/ml 
streptomycin, 0.1 mM non-essential amino acids and 2 mM glutamine. 
 
2.1.7 Oligonucleotide Synthesis 
Oligonucleotides were purchased from Sigma unless otherwise stated in the text. 
2.1.8 Patient-derived E1E2 mammalian expression plasmids 
Table 2.2 shows all patient-derived E1E2 sequence clones discussed in this 
thesis, some of which were expressed in the HCVpp system and used for 
downstream assays. Where the sequence has been used as one of the panels of 
HCVpp developed to test for breadth of neutralisation (cross-genotype or 
intragenotype 1) this is indicated under neutralisation panel.  
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Table 2.2 Table of patient derived E1E2 sequences inserted in phCMV plasmids and used in 
the HCVpp system in this thesis. 
Name of 
clone 
Locat
ion  
Infects 
as 
HCVpp 
Panel Accession 
number  
Additional description Ref 
H77c (1a) USA Y IG1 
XG 
AF011751 gt 1a also referred to as gt 1a 
control or wt gt 1a 
(253) 
UKN1B5.23 
(1b) 
Nott, 
UK 
Y IG1 
XG 
AY734976 gt 1b also referred to as gt 1b 
control or wt 1b 
(254) 
JFH-1   (2a) Japa
n 
Y XG AB047639 gt 2a referred to as gt 2a in 
methods 
(151) 
UKN 2B1.1 
(2b) 
Nott, 
UK 
Y XG AY734982 gt 2b referred to as gt 2b in 
methods 
(254) 
UKN3A13.6 
(3) 
Nott, 
UK 
Y XG AY894683 gt 3a referred to as gt 3a or gt 
3 in methods 
(254) 
UKN4.11.1 
(4) 
Nott, 
UK 
Y XG AY734986 gt 4a referred to as gt 4 in 
methods 
(254) 
UKN1a14.38 
(1av93) 
Nott, 
UK 
Y IG1 AY734971.1 gt 1a (254) 
UKN1a14.43 
(UKN96) 
Nott, 
UK 
Y IG1 AY734968.1 gt 1a (254) 
UKN1A20.8 
(1av220) 
Nott, 
UK 
Y IG1 EU155192.1 gt 1a (254) 
UKN1B14.81
8 (UKN181) 
Nott, 
UK 
Y IG1 - gt 1b (254) 
1012-01 Gla,
UK 
Y - - gt 1a from CHCV patient 1012  
1012-02  Gla,
UK 
Y IG1 KU645403 
 
gt 1a from CHCV patient 1012 (251) 
1012-03 Gla,
UK 
Y - - gt 1a from CHCV patient 1012 
(similar to 12-02) 
 
1012-04 Gla,
UK 
Y - - gt 1a from CHCV patient 1012 
(similar to 12-02) 
 
1012-06 Gla,
UK 
Y - - gt 1a from CHCV patient 1012  
1012-08 Gla,
UK 
N - - gt 1a from CHCV patient 1012  
1012-10 Gla,
UK 
Y - - gt 1a from CHCV patient 1012  
1012-11 Gla,
UK 
N - - gt 1a from CHCV patient 1012  
1012-20 Gla,
UK 
Y/N - - gt 1a from CHCV patient 1012  
1012-22 Gla,
UK 
Y - - gt 1a from CHCV patient 1012  
1047-10 Gla,
UK 
Y   gt 1 from CHCV patient 1047  
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1047-16 Gla,
UK 
Y   gt 1 from CHCV patient 1047  
1013-01 Gla,
UK 
Y IG1 KU645404 gt 1a from CHCV patient 1013 (251) 
1013-04 Gla,
UK 
N - - gt 1a from CHCV patient 1013  
1013-04 Gla,
UK 
Y - - gt 1a from CHCV patient 1013  
1013-07 Gla,
UK 
N - - gt 1a from CHCV patient 1013  
1034-11 Gla,
UK 
Y IG1 KU645405 gt 1a from CHCV patient 1034 (251) 
1034-12 Gla,
UK 
N   gt 1a from CHCV patient 1034  
1034-14 Gla,
UK 
Y/N   gt 1a from CHCV patient 1034  
1034-15 Gla,
UK 
N   gt 1a from CHCV patient 1034  
1037-02 Gla,
UK 
Y/N   gt 1a from CHCV patient 1037  
1037-04 Gla,
UK 
Y IG1 KU645406 gt 1a from CHCV patient 1037 (251) 
1037-12 Gla,
UK 
Y/N   gt 1a from CHCV patient 1037  
1112-01 Gla,
UK 
N   gt 1a from CHCV patient 1112  
1112-02 Gla,
UK 
N   gt 1a from CHCV patient 1112  
1112-03 Gla,
UK 
N   gt 1a from CHCV patient 1112  
1112-04 Gla,
UK 
N   gt 1a from CHCV patient 1112  
1112-05 Gla,
UK 
N   gt 1a from CHCV patient 1112  
ET10 (TPC 
in Chapter 6) 
Lon,
UK 
Y IG1 KU645407 gt 1a sample taken from 
patient ET in 2010 
 
ET08 (TPA 
in Chapter 6) 
Lon,
UK 
Y   gt 1a sample taken from 
patient ET in 2008.  
 
Abbreviations used in the table:  Nott (Nottingham), Gla (Glasgow), Lon (London). Infectivity was 
tested as described in Methods and recorded as Y if the luciferase signal given using the plasmid 
was 10 times higher than background. Y/N indicates a reading twice background levels but not 10 
times higher, N indicates a reading lower than 2x background (i.e. luciferase signal from HCVpp 
not containing envelope sequences). Where a term other than the standard name is used to refer 
to the sequences in the text (e.g. gt 2a for JFH-1) this is indicated in additional information. Where 
HCVpps bearing the sequence have been used in neutralisation panels described in Methods, this 
is indicated with IG1 for intragenotype 1 panel and XG for cross-genotype panel. 
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2.2 Clinical cohorts 
2.2.1 Cohort of individuals chronically infected with HCV (CHCV) 
Individuals with either gt 1 or gt 3a chronic HCV infection were prospectively 
recruited from three HCV clinic sites in Glasgow. Patients were excluded if they 
were on treatment at the time of enrolment, had a history of other liver 
comorbidities or hepatocellular carcinoma or had a BMI >31. These exclusions 
were included to ensure that any liver pathology detected in the individuals was 
likely to be secondary to their HCV. In addition, no patients had a prior history of 
clinical cryoglobulinaemia. A cohort of 24 healthy controls (HC) with no history of 
liver disease, IVDU or other systemic pathologies was also recruited from adjacent 
clinics and staff volunteers. Recruitment of these cohorts and subsequent 
experiments using their samples and analysis using anonymised clinical data were 
approved by the West of Scotland Research Ethics committee. Informed consent 
was obtained according to the declaration of Helsinki.  
All individuals completed a clinical questionnaire and additional clinical details 
were obtained from patient notes. All individuals had blood tests for routine clinical 
parameters including liver function tests (LFTs) and viral load in addition to IL28B 
status. They also had experimental whole blood and serum samples taken. For all 
patients recruited at one site, facilities were available to test for cryoglobulinaemia, 
therefore these individuals gave an additional serum sample collected in a serum 
tube pre-warmed to 37°C. Transient elastography measurement of liver stiffness 
was performed in all HCV positive individuals using a Fibroscan® (Echosens). 
Recruitment of patients and collecting clinical samples and patient data for this 
cohort was conducted by the research nurse team from the Glasgow Research 
Centre. Further processing of patient samples and analysis of these and 
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anonymised patient data was performed jointly by me and my colleague, Dr Mark 
Robinson (MRC University of Glasgow Centre for Virus Research). 
2.2.2 Historical cohort 
This cohort consisted of individuals recruited from 1999-2005 by Professor Peter 
Mills, Consultant Gastroenterologist, Gartnavel General Hospital, Glasgow. They 
were originally recruited as part of a study of liver biopsies in HCV. Liver 
biopsies were taken at the point of recruitment which were analysed by local 
pathologists with liver disease stage and key features recorded. A snap frozen 
liver biopsy and serum samples were also taken at the point of recruitment 
which were stored at -70°C.  Clinical information for the majority of the 
patients was recorded at baseline and maintained in a database with clinical 
outcome data (progression of liver disease / date of death/date of last follow 
up) being available for 98 patients within the database. Recent clinical data had 
been entered by medical students Jeeva John and Mark White and Harriet Tan. 
Informed consent was obtained from subjects at the time of recruitment 
according to the declaration of Helsinki. Local ethical approval was granted for 
recruitment to the original study and an amendment granted to me by the West 
of Scotland Regional Ethics Service (trial registration number 12/WS/0231) to 
enable use of the serum samples from these patients taken at the time of 
recruitment and linked, anonymised clinical data in my research project. 
 
2.2.3 Exposed uninfected (EU) cohort 
A cohort of current IDU who were not known to have ever been infected with HCV 
infection or other blood borne viruses was recruited between 2003 and 2014 by 
Professor Matthew Cramp and his research team at the University of Plymouth 
from a variety of locations in Plymouth, UK as previously described (92, 93). 
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These individuals were screened for evidence of current or previous HCV infection 
using diagnostic tests for antibodies to core and non-structural proteins (third 
generation ELISA by Abbot IMx) and HCV RNA by qualitative PCR (Amplicor, 
Roche Diagnostics). A confidential interview using a structured questionnaire was 
conducted to collect demographic data and a detailed injecting history. This 
included age at first injection, duration of injecting behaviour, frequency of injecting 
episodes, current injecting behaviour, frequency of sharing intravenous 
paraphernalia (needles, syringes, filters, spoons and water), frequency of sharing 
with a contact known to have HCV infection, and risk of non-IDU HCV exposure. 
The EU cohort was derived from a subgroup of this group of IDUs who were 
negative for both tests for HCV infection and included those judged to be at 
substantial risk of HCV exposure based on a >1 year history of injecting drug use 
and regular sharing of needles and related paraphernalia. All individuals had 
serum and whole blood samples drawn for laboratory analysis and clinical details 
entered in respective databases. Where possible, follow up clinical information and 
clinical samples from recruited individuals were obtained. Two individuals who 
were found to have developed HCV infection on further testing were excluded from 
the cohort.  Dr Matthew Cramp kindly provided the samples from this cohort for 
testing. Drs Paraskevi Mandalou and Megghie Ow in his group provided the 
clinical data and assisted me with some of the laboratory assays on these 
samples.  
2.2.4 The St Mary’s Acute Hepatitis C Cohort 
The St Mary’s Acute Hepatitis C Study (104), is a well-characterised cohort of HIV-
infected individuals with acute HCV infection recruited by Dr Emma Thomson. On 
recruitment to the study following acute HCV infection, clinical information, viral 
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and biochemical parameters and residual serum and whole blood samples were 
taken at serial time points (TP) during the course of infection.  
Informed consent in writing was obtained and the study protocol conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki with ethical approval granted 
by the Riverside Research Ethics Committee. I was given permission by Dr 
Thomson (MRC University of Glasgow Centre for Virus Research) to use selected 
samples from this cohort in my research.  
 
2.3 Cell Culture 
All components of cell culture media were supplied by Invitrogen. Huh7 and HEK-
293Tcells were grown in DMEMcomplete and maintained at 37oC in an 
atmosphere of 5 % CO2.  
Cell lines were typically grown in 80 cm2 or 175 cm2 tissue culture flasks (Nunc). 
Cells were passaged at 90 % confluency by washing gently with PBS followed by 
their removal with trypsin (Sigma) diluted 1:100 in versene (TV). Cells were then 
resuspended in 10 ml of DMEMcomplete before re-seeding or use in experiments. 
2.4 Generation of HCV Pseudoparticles and lysate of 
cells expressing E1E2 glycoproteins 
2.4.1 Amplification of patient-derived viral sequences 
2.4.1.1 Viral RNA extraction and cDNA synthesis 
Viral RNA was extracted from 140 µl of patient serum using the QuiAMP Viral RNA 
mini kit (Qiagen) as per protocol and eluted in 60 μl of buffer AVE (Qiagen). This 
was converted to cDNA using the Superscript III First Strand cDNA synthesis kit 
(ThermoFisher Scientific) using random hexamers (Roche), with an RNA digestion 
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step. 8 μl of eluted RNA was mixed with 1 μl of random hexamers (Roche) 1μl 
dNTPs (0.25mM), and RNase free water added to make a total volume of 11μl. 
This was incubated for 5 mins at 65oC before cooling on ice. Subsequently, 4μl 
First strand buffer, 1μl DTT (0.1M), 1μl RNaseOUT™ Recombinant Ribonuclease 
Inhibitor and 1μl SuperScript™ III reverse transcriptase (200units/μl) were added. 
RT was performed at 50oC for 60 minutes before heat-inactivation at 70oC for 15 
mins. Following cooling, 2 U of RNAse H (ThermoFisher Scientific) was added and 
the mixture incubated at 37 oC for 20 mins before storing at -20 oC.   
2.4.1.2 Design of primers for cloning patient derived E1E2 sequences 
Degenerate nested primers were designed to flank E1E2 (Table 2.3). These were 
adapted from primers previously described (160)  with degenerate positions based 
on the most common variable nucleotides from an alignment of all gt 1a and gt 1b 
sequences stored on the Los Alamos database (www.hcv.lanl.gov accessed 
24/11/2012). This alignment was generated using CLC Genomics Workbench 7 
(see Fig. 1.12). As with the original primers, stop and start codons were added 
along with a tag to allow directional cloning. The length of the primers was also 
adjusted to optimise PCR. As a positive control to confirm the presence of HCV-
specific cDNA, primers for NS5B were also used (a gift from Dr Carol Leitch within 
the MRC University of Glasgow Centre for Virus Research).   
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Table 2.3 Primers used in PCR amplification of genotype 1 E1E2  
Genotype 1 E1E2 degenerate primers 
Primer Sequence 5’ – 3’ GC 
content 
(%) 
Tm 
(OC) 
Gt 1a/b 
outer 
sense 
GTG AAY TAY GCR ACA GGG AA 40-55 49-
53 
Gt 1a outer 
antisense 
GCA AAG CAG AAR AAC ACG AG 45-50 52-
53 
Gt 1 a/b 
inner 
sense 
CACC ATG GGT TGC TCY TTY TCT ATC TTC 
 
38-48 47-
49 
Gt 1a inner 
antisense 
AAAGTTTCTAGATTA CYG CCT CYG CYT 
GGG AKA  
56-78 49-
56 
Gt 1b Outer 
Antisense 
AGGCRGCRCARAAGAACACRA 52 63-
70 
Gt 1b Inner 
Antisense 
AAAGTTTCTAGATTARGCCTCRGCYTGRGCTA 44 67-
72 
 
 
Control NS5B gt 1primers*  
HCV1/3_OS  CRT ATG AYA CCC GCT GYT TTG AC 50 64.8 
HCV 1 IS CTCCACAGTCACTGAGAGCGAYAT 52 67.6 
HCV 1 IAS AATGCGCTRAGRCCATGGAGTC 54 70.1 
HCV 1 OAS CCT GGA GAG TAA CTR TGG AGT G 50 53.3 
*Kindly supplied by Dr Carol Leitch. Start codon is underlined, stop codons are highlighted in bold 
and directional tag is indicated in italics. Regions indicated in red text are additional nucleotides 
added to optimise the PCR reaction 
2.4.1.3 PCR amplification of E1E2-encoding sequences and gel purification 
cDNA was amplified using a nested PCR with the degenerate primer pools 
described above and HotStarTaq polymerase enzyme kit (Invitrogen) according to 
protocols for a 20 µl reaction using 2 µl of cDNA. 1 µl from the outer primer PCR 
was used as DNA template for the reaction using the inner primers. PCR was 
performed in a GeneAmp PCR Machine (Applied Biosystems). Cycling conditions 
for PCR were as shown in Table 2.4. 
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Table 2.4 PCR cycling conditions for amplification of E1E2-encoding sequences 
Step 
E1E2 Outer 
Primers 
E1E2 Inner 
Primers 
NS5B Outer 
Primers 
NS5B Inner 
Primers 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Temp 
(°C) 
Time 
(sec) 
Initial denaturation / 
activation 
95 300 95 300 95 300 95 300 
Denaturation 
X 35 
cycles 
94 15 94 15 94 15 94 15 
Annealing 50 60 67 60 53 30 55 30 
Extension 72 90 72 90 72 90 72 90 
Final extension 72 600 72 600 72 600 72 600 
Hold 4 ∞ 4 ∞ 4 ∞ 4 ∞ 
 
 
PCR products were purified by running on a 0.8% agarose gel in 0.5% TBE using 
DNA loading gel alongside a 1 kb DNA ladder (Invitrogen). These were visualised 
using a UV lamp and bands at an appropriate size (1.8 kb) were excised. DNA 
was then extracted using  the Qiagen Gel Extraction kit (Qiagen). DNA was eluted 
using TE buffer (Qiagen).  NS5B primers to conserved regions within this 
sequence were used as a positive control in optimising the PCR protocol, 
subsequently samples known to have E1E2 amenable to amplification by the 
primers were used as positive controls. The inner gt 1a primers were also used to 
amplify the HCV gt 1a H77 sequence using the existing functional E1E2 
expression vector as a template. This was used as a positive control in the 
downstream cloning and expression experiments. 
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2.4.2 Cloning into directional TOPO GatewayTM entry vector 
Purified products arising from successful PCR reactions were subcloned into the 
pENTR D-TOPO directional cloning vector (ThermoFisher Scientific) according to 
the product protocol. Briefly 4 µl of purified DNA was added to 1 µl of kit salt 
solution and 1 µl of linearised pENTR D-TOPO vector (Fig. 2.1). After incubating at 
room temperature for 30 mins, the solution was chilled on ice and 2 µl was added 
to competent OneShot ®E.coli cells (ThermoFisher Scientific) and incubated for 30 
mins. These were then subjected to heat shock at 42°C for 30 seconds, chilled on 
ice for 5 mins, and incubated in 250µl of S.O.C. Medium at 37°C for 1 hour with 
shaking. Subsequently, 50 µl of bacterial culture was spread on selective LB Agar 
plates containing 50 µg/ml Kanamycin. Following incubation overnight at 37oC, 20 
(or maximum number of discrete colonies where less than 20 had formed) were 
selected and cultured in 5 ml LB Broth containing 50 µg/ml Kanamycin. Vector 
DNA was then extracted from the cultures using the QIAprep Spin Miniprep Kit 
(Qiagen) according to protocol. 
 The presence of inserts was screened for by performing a digestion reaction. Due 
to internal digestion sites in the E1E2 protein, digestion using the AscI and NotI  
restriction site flanking the insert did not enable easy differentiation between 
plasmids with inserts and those without. Therefore PvuII was used which gave 3 
bands at 2.5kb, 1.5kb and 1.1kb and smaller fragments <400bp with no insert and 
4 bands at 2.5kb 1.8kb 1.3kb and 1.0kb insert alongside smaller fragments 
<400bp when insert was present. 1 µl eluted plasmid DNA was digested using the 
PvuII enzyme (NEB) incubated at 37°C for 1h (Fig. 2.2).  Samples containing 
inserts were submitted to GATC Biotech AG (Germany) for Sanger sequencing to 
confirm that they carried the desired E1E2-encoding sequences. Sequences which 
were complete without internal stop codons were selected for insertion into the 
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mammalian expression vector phCMV(161)  that had been specifically adapted to 
act as a Gateway®-compatible destination vector (phCMVGateway®) by Dr 
Vanessa Cowton in our lab (see section 2.4.4 for details).  
 
 
Figure 2.1 pENTR D –TOPO directional cloning vector  
This diagram shows the layout of the vector with directional insertion sites, kanamycin resistance 
enzyme and digestion restriction sites for digestion enzymes NotI and AscI. Image obtained from 
thermofisher website.[ https://tools.thermofisher.com/content/sfs/manuals/pentr_dtopo_man.pdf 
accessed 16/11/2016] 
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Figure 2.2 PuvII digestion of pENTR-D TOPO vectors to determine presence of an E1E2 
insert. 
Vector DNA was obtained using the QIAprep Spin Miniprep Kit and eluted in water. 1µl of the 
elutate was added to a PuvII enzyme solution (NEB)in appropriate NEB buffer and incubated at 
37°C for 60 mins. The resulting digestion mix was run on an 0.8% Agarose gel for 1 hour at 70V. 
The presence of a single band at the leftmost well is undigested DNA from a phCMV plasmid not 
containing E1E2. Presence of a single band at 1.6kb and at 600kb suggested no insert. Presence 
of multiple smaller bands suggested an insert. Due to the presence of internal restriction sites in 
some E1E2 sequences the pattern of smaller bands was not the same for all inserts. Those 
samples with evidence of an insert were sent for confirmatory Sanger sequencing. 
  
2.4.3 Calculating dN/dS ratios for E1E2 sequences from single 
patients 
For individual patients where more than 3 unique sequences were identified 
through amplification and subcloning as above, the dN/dS ratio was calculated. 
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This can reveal regions under positive and negative selection due to host and viral 
fitness pressures.  
Sequences from each patient were aligned initially in CLC Genomics Workbench 
v. 7.0.3. and these alignments transferred to the MEGA 6.0 program for further 
analysis (16). Nucleotide substitutions resulting in an amino acid change 
compared to conservation of an amino acid were identified by HyPhy diversity 
analysis and dN/dS ratios were generated. The HyPhy software also generated 
probability values for conservation or non-conservation of each amino acid 
position.  
2.4.4 Transferring E1E2-encoding sequences into the 
phCMVGateway® expression vector 
pENTR vectors containing envelope sequences of interest were used to transfer 
the E1E2 sequence to a phCMVGateway® expression vector. This vector had 
been generated using the Gateway ® Vector Conversion System (ThermoFisher 
Scientific) by Dr Vanessa Cowton. To perform the reaction, 150 ng of entry clone 
DNA was mixed with 300 ng of phCMVGateway® expression vector and TE buffer 
added to give a final volume of 8 µl. Subsequently 2 µl of LR Clonase II enzyme 
mix (ThermoFisher Scientific) was added to the solution, mixed by pipetting and 
incubated at 25°C for 1 hour. Next, 1 µl of Proteinase K was added and incubated 
for 10 mins at 37°C. 2 µl of the reaction mix was used to transform chemically 
competent E. coli by heat shocking at 42°C for 30 seconds then returning to ice for 
2 mins followed by incubating at 37°C in 250 µl of LB for 1 hour.  50 µl of this 
mixture was plated onto LB agar plates containing 10 µg/ml ampicillin overnight. 
Colonies which grew were then incubated in 5 ml of LB containing 10 µg/ml 
ampicillin for 16 hours and plasmids extracted from the resulting bacterial culture 
using the Qiagen Miniprep Kit as per protocol. Quantity of the plasmid DNA 
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obtained was measured using a Nanodrop spectrophotometer (ThermoFisher 
Scientific). Functionality of the sequences in the expression vector was tested by 
generating HCVpps.  
2.4.5    Generating HCVpps by HEK-293T cell transfection 
 HEK-293T cells in subconfluent 10 cm tissue culture dishes were co-transfected 
with the retrovirus packaging vector pMLV gag – pol, the transfer vector pMLV-Luc 
and a HCV E1E2-expressing vector phCMVcE1E2 using a Calcium chloride 
precipitation method as described by Tarr et al (160).  Some of the phCMV vectors 
had been created as part of a previous project, others were generated during the 
course of this work using methods described above. 24 hours after co-transfection, 
medium was replaced with 6 mls of fresh DMEM containing 10% FCS and 10 mM 
HEPES, pH7.0.  After 72 hours, the supernatant medium was harvested and 
passed through a 0.45 µM filter and used as a source of HCVpp. 
2.4.6 Infectivity testing of HCVpps  
HCVpps were tested for their ability to infect Huh7 cells as follows: Huh7 cells 
were seeded at 4 x 103 in a 96 well Immulon-II plate (Nunc)  and incubated for 24 
hrs. HCVpps from individual patient sequences were generated and 40 µl of 
HCVpp containing supernatant added to Huh7 cells, after 3 hrs the medium was 
changed and the cells incubated for a further 72 hrs before lysing and testing for 
infectivity using the Light Glo Luciferase assay (Sigma).  
 Infectivity was confirmed in HCVpp generating a light unit signal 10x the 
background signal from uninfected Huh7 cells (approximately 1000 RLU in most 
assays). Indeterminate infectivity was defined as a RLU signal between 2 and 10 
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times background levels. For use in downstream neutralisation assays, only 
HCVpps with a signal 10 times above background were selected.   
2.4.7 HEK-293T cell lysis and extraction of lysate 
Media was removed from 10 cm tissue culture dishes containing previously 
transfected HEK-293T cells. 1ml of Lysis Buffer 2 (LB2) was added and incubated 
while rocking for 10 mins. Following lysis, the lysate was clarified by spinning at 
13,000 revolutions per minute for 1 min. The supernatant was removed and either 
used directly or stored at -20°C for future use.  
2.4.8 Testing HEK-293T cell lysate for E1E2 production 
 
For some HCV E1E2-expressing vectors not producing infective pseudoparticles, 
transfected HEK-293T cells were lysed in Lysis Buffer 2 using 1ml per plate. 
Lysates were centrifuged for 5 min to pellet cell debris and the supernatant lysate 
was tested for the presence of E2 protein in a capture ELISA. This used 
apreviously described method whereby ELISA plates coated with Galanthus 
nivalis agglutinin (GNA) lectin were used to capture E1E2 glycoproteins from HEK-
293T cell lysates which were then probed using anti E1E2 antibodies(123). Lysate 
from HEK-293T cells transfected with a non-E1E2 containing plasmid were used 
as a negative control. Test lysates were diluted 1:3 in PBS with 0.05%Tween and 
2%Milk added (PBSTM) and 100 µl/well added in triplicate to 2 separate GNA 
plates. Following incubation and wash steps, one plate was probed with the 
antibody AP33 at (at 0.1 µg/ml in PBST) the other with CBH-4B (at 2 µg/ml) (255). 
These recognise a linear and a conformational epitope on HCV E2 glycoprotein 
respectively. Following incubation and washing, HRP-conjugated anti-mouse or 
anti-human IgG (Sigma, cat no A4416 or A0170, respectively) was added at a 
concentration of 1:1000 (A4416, approximately 1 µg/ml) or 1:5000 (A0170, 
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approximately 2 µg/ml) in PBST. Following incubation for 1 hr, the plates were 
washed with PBST and then the bound antibodies detected using TMB (3,3’, 5, 5’-
tetramethylbenzidine, Sigma) substrate. Presence of E2 was confirmed by an 
absorbance level higher than the mean negative control plus 2 standard deviations 
in the AP33 assay. Correct folding of E2 was confirmed by an absorbance level 
higher than the mean negative control plus 2 standard deviations in the CBH-4B 
assay as this antibody is conformation sensitive. For individuals where  several 
E1E2 sequences had been isolated, some producing infective  HCVpp and others 
resulting in E1E2 expression but non-infective HCVpps, sequences were aligned 
using Mega 6.0 molecular genetics software (16) to identify the variable regions 
between functional and non-functional sequences. 
The majority of the experiments in this section (2.4.8) were performed under my 
supervision by medical students Ruairi Wilson and Jane Hamilton. I designed the 
experiments and analysed and interpreted the results in conjunction with the 
students. 
2.5 Generating panels of HCVpps bearing a diverse range 
of E1E2 sequences for testing breadth of antibody 
binding and virus neutralisation 
2.5.1 The Cross Genotype (XG) panel 
To determine reactivity and neutralisation of patient-derived IgG across different 
genotypes, a panel of HCV pseudoparticles bearing test envelope proteins from 
the main infecting genotypes in the UK was used. This was termed the Cross 
Genotype (XG) panel and comprised E1E2 from 6 HCV sub-genotypes which had 
been generated prior to this project and are described elsewhere (129). The 
sequences incorporated into this panel were: gt1a H77c (Accession number: 
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AF011751), gt1b UKN1B5.23 (AY734976); gt2a JFH-1 (AB047639); gt2b, UKN 
2B1.1 (AY734982); gt3a UKN3A13.6 (AY894683); gt4 UKN4.11.1 (AY734986). 
While it would have been useful to test against gt 5 and gt 6, the E1E2 sequences 
which were available in the HCVpp system for these genotypes proved to have 
low infectivity (<1000 RLUs) and therefore could not be used reliably in 
neutralisation assays.  
2.5.2 The intragenotype 1 (IG1) panel 
To allow investigation of antibody reactivity against a diverse range of envelope 
variations within a single genotype, as might arise during a natural infection, I 
developed the intragenotype 1 (IG1) panel. 
All gt 1 phCMVcE1E2 vectors held in the lab were tested for functionality in the 
HCVpp system as described previously. This included phCMVcE1E2 vectors 
bearing E1E2 sequences derived from gt1 HCV-infected patients from the CHCV 
cohort and the St Mary’s acute HCV cohort (256) generated as detailed above. In 
addition, it included a bank of phCMVcE1E2 vectors generated as part of a 
previous project using patients from the Trent Cohort (17).  
 An alignment of all sequences was generated in CLC Genomics Workbench 7. Gt 
1a sequence H77 was included as a standard reference sequence and ten 
additional sequences were selected by phylogenetic analysis (Fig. 2.3) on the 
basis of overall genetic difference (p distance) and representation of amino acid 
variability found in all available gt1 E1E2 sequences registered with the Los 
Alamos HCV sequence database (see Fig. 1.12).  
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Legend for Figure 2.3 on following page 
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Figure 2.3 Molecular phylogenetic analysis of HCV gt1 E1E2 amino acid sequences to 
determine the IG1 panel. 
A phylogenetic tree was generated from protein alignments of all gt 1 E1E2 sequences inserted 
into phCMV vectors held in the lab. This was generated by the maximum likelihood method using 
the JTT matrix-based model(257). A discrete gamma distribution was used to model differences in 
the evolutionary rates among sites (5 categories [gamma distribution parameter = 0.3680]). The 
tree with the highest log likelihood (−7,055.2655) is shown. The tree is drawn to scale, and the 
genetic distance for each branch length is indicated by the scale bar. Bootstrap analysis with 1,000 
replicates was performed. The percent support for branches with >70% bootstrap support is 
indicated. Sequences are indicated by coloured symbols as follows: blue, sequences classified to 
be functional in the HCVpp system; red, non-functional sequences; green, functional sequences 
included in the gt1 panel. Evolutionary analyses were conducted with the MEGA (v.6) program(16) 
Molecular Phylogenetic analysis by Maximum Likelihood method. [Figure and Legend reproduced 
from Swann et al, J. Virol, 2016 (251) as permitted by the American Society for Microbiology for 
authors of papers published in their journals]. 
2.6 ELISA Assays 
2.6.1 Serum IgG Purification 
Serum was incubated with Triton X-100 (Sigma, UK) at a final concentration of 
0.05% to deactivate any virus particles present. Disinfected serum in 250 µl 
aliquots was then added to a Protein G IgG purification spin column (Thermo 
Scientific, UK), washed to remove all detergent and IgG eluted, as per 
manufacturer’s protocol, in 1.2 ml of elution buffer and the eluate neutralised. The 
final concentration of IgG was determined using a Nanodrop 1000 
spectrophotometer (Thermo Scientific, UK). 
2.6.2 GNA ELISA to detect human IgG binding to E1E2 proteins 
Briefly, Immulon II ELISA plates (Dynal) coated with Galanthus nivalis agglutinin 
(GNA) were used to capture E1E2 glycoproteins from lysates of HEK-293T cells 
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transfected with plasmids expressing E1E2 glycoproteins. In general these were 
diluted 1:3 in PBST prior to use. IgG for each test subject was subsequently added 
at a concentration of 200 µg/ml in PBS containing 0.05% Tween-20 and 2% 
Skimmed Milk Powder (PBSTM). Plates were incubated for 1 hour and washed 6 
times in PBST. The bound human IgGs were detected using an HRP conjugated 
anti-human IgG antibody (Sigma A0170) diluted 1:5000 (2µg/ml), incubated for 1 
hour and washed as previously. Presence of secondary antibody was determined 
using TMB (3,3’, 5, 5’-tetramethylbenzidine, Sigma) substrate incubated for a 
maximum of 10 mins or until a clear colour reaction was visible in the positive 
control. The reaction was stopped with 0.5 M sulphuric acid. Absorbance values 
were measured at 450 nm using a Varioskan microplate reader (Thermo Fisher 
Scientific). Occasionally variations in secondary antibody were used – where 
applicable this has been stated clearly in the text. 
2.6.3 Purified sE2 ELISAs 
2.6.3.1 Detection of Human IgG binding to sE2 
A soluble form of gt 1a E2 (H77) protein (sE2) was generated following expression 
in High Five insect cells (Life Technologies Ltd) and subsequently purified by Dr 
Ania Owsianka in our lab. Immulon II ELISA plates were coated with 100 µl per 
well of sE2 at concentration of 1 µg/mL. Plates were washed and 50 µl of serum 
diluted 1:50 in PBSTM was added to each well in duplicate. After washing, binding 
of human IgG was detected as described for the GNA ELISAs.  
2.6.3.2 Detection of Human IgM binding to sE2 
To detect IgM, Immulon II ELISA plates (Dynal) were coated with sE2 as 
described above. Subject serum was diluted 1:50 with PBSTM and pre-incubated 
three times on a glutathione-S-transferase coated plate to remove non-specific 
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antibodies, then added to the E2-coated plate. After incubation and wash steps 
using high tween PBSTM (0.5% Tween-20), IgM binding was detected using HRP-
conjugated anti-Mu antibody (Abcam) at a 1:500 dilution(2µg/ml). The remainder 
of the ELISA protocol was as for the E1E2 ELISA described above. 
2.6.3.3 E2 epitope competition ELISA 
Competition ELISAs were conducted using purified patient IgG samples to 
determine if IgG targeted specific CD81-binding sites where a characterized set of 
antibodies are known to bind (see Table 2.5).  
Immulon II plates were coated with sE2 as above and incubated with purified 
patient IgG at 200 µg/ml in PBSTM for 1h. Subsequently, monoclonal antibodies 
(mAbs) (listed in Table 2.5) to discrete E2 immunodomains (119, 120, 145) were 
added at a concentration close to their EC50 (determined by producing dilution 
curves of these antibodies on sE2 coated plates Fig. 2.4). All antibodies were 
biotinylated except HC-84.1 which was a mouse-human chimera. Streptavidin-
HRP was added to detect biotinylated antibodies and anti-mouse IgG (Sigma 
A4416) to detect HC-84.1 (1:10000 dilution, approximately 0.1µg/ml for both 
reagents) and binding measured as above. The reduction in relative binding of 
each mAb (calculated as percentage reduction in absorbance) on addition of 
patient IgG compared to PBSTM control was determined.  
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Table 2.5 Antibodies used in E2 epitope competition ELISA  
Immuno
domain  
Antibody EC50 
(µg/ml) 
Key binding residues in 
E1E2 glycoproteins 
Reference 
A CBH-4B 
(non-
neutralisi
ng)  
0.004 540, 542, 556,627 (120) 
B HC-1 0.05 529, 530, 535 (120) (125) 
B HC-11  0.003 425, 427,436, 437,438, 
442,443, 529,530, 535 
(120)  
C CBH-7 0.01 544, 547, 549, 550 (145) 
D HC-84.1  9.6 441,442,443,616 (NB also 
overlaps with some domain B 
residues) 
(145) 
E AP33 
 
0.01 413,415,418,420 (146) (129) 
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Figure 2.4 Concentration curves of ELISA absorbance values for antibodies to known 
epitopes on sE2 
Antibodies as listed above were diluted from a stock concentration, which was 1 µg/ml in PBST for 
all except HC-84 where the stock concentration was 250 µg/ml. 50 µl/well of stock solution and 
serial 1:3 dilutions in PBST were added to wells on a sE2 coated Immulon plate and binding 
detected using either streptavidin-HRP conjugate or anti-mouse monoclonal antibody A4416 
(Sigma)  as described in the text. Absorbance values were plotted and EC50 values calculated 
using GraphPad Prism 6.0 software and are  listed  in Table 2.5. Mean and SEM values are shown. 
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2.7 Assays to determine HCVpp infectivity in the 
presence of antibodies and cell entry protein 
blockade 
2.7.1 HCVpp neutralisation assay  
Neutralisation assays were conducted to determine the ability of test IgG to 
prevent infection of Huh7 cells by HCVpps bearing various envelope sequences. 
The IgG and HCVpps used for each experiment are described fully in the relevant 
chapters. These assays were performed as previously described (119). Briefly, 
Huh7 cells were seeded at 4x103 cells per ml in DMEMcomplete with 200 µl added 
to each well in a 96-well flat bottomed plate (Nunc) and incubated overnight. The 
following day, test subject IgG was added to 40 µl of HCVpp-containing medium 
prepared from transfection of HEK-293T cells as described above. In general IgG 
was added at a concentration of 100 µg/ml, which represents an approximate 
serum dilution of 1:50-1:100. For some samples where IgG could not be purified, a 
dilution of heat-treated serum was used. In addition, in some cases a 
dose/response curve was generated by testing at serial dilutions of IgG. This is 
described fully in the relevant sections.  The mouse monoclonal anti-E2 antibody 
MAb AP33 (258), (259) and healthy control IgG were included as positive and 
negative controls, respectively. After incubation for 1 h the IgG-HCVpp mixture 
was added to the Huh-7 cells (following removal of medium). After incubation for 3 
h, the inoculum was replaced with fresh medium and following a further 72 h 
incubation luciferase activity in infected cells was detected as a marker of HCVpp 
infectivity using the Bright-Glo Luciferase kit (Promega, UK) and relative luminosity 
measured in relative light units (RLU) using a Chameleon II plate reader. Virus 
neutralisation was defined as 50% reduction in luminosity compared to wells 
where HCVpps were added without IgG.  
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2.7.2 HCVpp Susceptibility to SR-BI and CD81 blockade 
To determine if differential use of entry proteins was a factor in susceptibility to 
neutralisation, selected HCVpp were tested for sensitivity to blockade of the cell 
surface receptors SR-BI and CD81. 
HCVpp were generated as described previously. Prior to adding these to Huh7 
cells, the cells were incubated with 40 µl modified DMEM containing anti-CD81 
antibody (clone JS-81, Sigma) at 1 µg/ml or anti-SR-BI MAb151-NP1(252, 260) at 
decreasing concentrations from 10 µg/ml to 0.03 µg/ml. After 1 h the DMEM was 
removed and 40 µl of test HCVpp were added or DMEM added to control wells. 
These were incubated for 4 h and then medium changed. Infectivity of HCVpp in 
the presence of cell receptor blockade was determined using a Glo Luciferase 
Assay as described above at 72 h post-infection.  
 
2.8 Testing for the ability of purified IgG to neutralise cell 
culture infectious HCV (HCVcc) 
These experiments were conducted by Dr Vanessa Cowton and Mrs Sarah Cole 
with purified IgG from the CHCV cohort after discussion with me. 
Infectious virus was produced in Huh7 cells by electroporation of RNA encoding 
full-length JFH-1 or chimeric JFH-1. The chimeric strains 2B.1.1/JFH1 and gt1a 
H77/JFH1 (HQL) have been described previously (123, 261). The neutralization of 
cell culture infectious HCV (HCVcc) infection was tested in Huh7-J20 cells, a 
stable cell line expressing green fluorescent protein fused in-frame to alkaline 
phosphatase with a cleavage site containing the recognition site for the HCV 
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NS3/NS4 protease. Infection and replication of virus results in secretion of alkaline 
phosphatase into the extracellular culture medium(261).  
Huh7-J20 cells were seeded at 1 × 104 cells/well in a 48-well tissue culture dish 
and incubated at 37 °C. Supernatant media from electroporated cells containing 
secreted virus was incubated with test IgG at a concentration of 100µg/ml for 1 h 
at 37 °C before adding to Huh-J20 cells for 3 hours. This was then replaced with 
400 μl of fresh medium and the cells incubated at 37 °C for 72 hours. 
To measure the extracellular SEAP activity (therefore relative infectivity), 90 μl of 
culture medium was collected and mixed with 10 μl of 10-times concentrated LB2 
to inactivate the virus. The SEAP assay was performed using the Phospha-Light 
assay system (Thermo Fisher) to measure secretory alkaline phosphatase (SEAP) 
levels. 
2.9 Cryoglobulin detection and analyses 
2.9.1 Cryoglobulin detection 
Only one of the two hospital sites used to recruit the CHCV cohort and 
corresponding HCs had facilities available for testing for cryoglobulins according to 
accepted standards (262). Therefore, all CHCV cohort patients and HC recruited 
at this site had an additional sample of serum taken for cryoglobulin testing. A 
small number of individuals at the second site also had samples taken and 
transferred in a pre-warmed container for testing.  For each individual, a 9 ml 
whole blood sample was collected in pre-warmed serum tubes and maintained at 
37°C until the sample had been spun in a centrifuge and the supernatant serum 
transferred to a universal container. This serum was stored at 4oC for 7 days and 
observed for precipitate development. A patient was recorded as cryoglobulin-
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positive if a precipitate formed, disappeared on re-warming to 37°C and 
reappeared on further cooling for 7 days (Fig. 2.5). The presence of 
immunoglobulin was subsequently confirmed by cryoglobulin typing where the 
volume of precipitate allowed. Preparing samples and testing for the presence of a 
cryoglobulin precipitate was performed by me and Dr Mark Robinson. 
 
 
Figure 2.5 Image of cryoglobulin precipitate  
Image of 2 samples after chilling at 4oC for 7 days showing no precipitate on left hand sample while 
clear precipitate is visible on the right. While a small amount of red cell contamination is visible in 
the right hand sample, the precipitate disappeared on warming to 37°C for 30 min and reappeared 
on re-cooling for 7 days. 
 
 
2.9.2 Cryoglobulin isolation and typing 
Following re-precipitation, cryoglobulins were washed 3 times in ice cold PBS and, 
if sufficient sample remained, were re-suspended for typing using 250 μl PBS by 
warming to 37°C. 10 µl of cryoprecipitate solution was added to 6 wells of a 
Hydragel 4IF dynamic protein electrophoresis kit (Sebia). Following 
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electrophoresis, the gel was stained using the secondary antibodies provided for 
IgG, IgM, IgA, Igk, Ig followed by a destaining step. Presence of a polyclonal 
band in one lane and a mono- or oligo-clonal band in another indicated a Type 2 
MC (Fig. 2.6). Presence of 2 polyclonal bands indicated Type 3 MC. Typing was 
performed by the Immunology Laboratory, Gartnavel Hospital, Glasgow. 
 
 
Figure 2.6 Protein electrophoresis of a cryoglobulin with monoclonal IgM bands.  
[Image reproduced from https://www.studyblue.com (accessed 10/10/16)] Example of an 
electrophoresis gel of a cryoglobulin precipitate prepared as described above with staining 
indicating binding of secondary antibodies to the antibody classes indicated below each lane. This 
particular example shows monoclonal bands in IgM and polyclonal IgG / light chains indicating a 
Type 2 MC. NB this image is shown to illustrate a positive result and is not an image from samples 
collected during this study. 
 
2.9.3 Rheumatoid factor testing 
Where sufficient sample remained following cryoglobulin testing, 10 µl of the 
remaining resuspended cryoprecipitate was tested for Rheumatoid factor (RhF) 
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activity using the Siemens RhF latex agglutination assay. This was performed by 
staff at the Immunology Laboratory, Gartnavel Hospital, Glasgow.  
2.9.4 Testing cryoglobulins for binding to sE2 
2.9.4.1 IgM concentration ELISA 
IgM from the resuspended cryoglobulin precipitate was tested for its ability to bind 
to sE2 compared to IgM from serum samples taken from the same individual. 
Cryoglobulins from 4 patients with G1 HCV were heated to 37°C and re-
suspended in saline as above. Serum from the same patients, cryoprecipitate 
solution and serum from HC were diluted to 1:50 in PBST and tested for 
concentration of IgM using a standard IgM ELISA – all steps prior to addition of the 
secondary antibody were conducted at 37°C to prevent precipitation of the 
cryoglobulin. Briefly, Immulon plates were coated with a goat anti-human IgM 
(Sigma) at a 1:10000 dilution then blocked with PBSTM. Test serum and 
cryoprecipitate were diluted 1:100 and 1:1000 in PBSTM and 100 µl added in 
duplicate alongside serial dilutions of human IgM of known concentration (Sigma). 
Purified IgG was used as a negative control. IgM binding was detected using HRP-
conjugated anti-Mu antibody (Abcam) at a 1:500 dilution. After a further incubation 
and wash step, TMB substrate was then added and the reaction allowed to 
continue for 7 mins before stopping with 50 µl of 0.5 M H2SO4. The strength of the 
colour signal was read using a Varioskan plate reader to determine the A450. 
Absorbance readings for the standard curve of IgM were used to calculate the 
concentration of IgM in cryoprecipitates and serum. 
2.9.4.2 Testing cryoglobulins for binding to sE2 
Immulon 96-well plates were coated with sE2 in PBS (1 µg/ml, 100 µl/well) as 
previously described. Reprecipitated cryoglobulin samples, corresponding serum 
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samples and HC serum samples were diluted in high tween (0.5%) PBSTM (PBS 
with 0.5% Tween-20 and 2% skimmed milk powder) and heated to 37 °C. Sample 
concentrations were adjusted to ensure equal concentrations of IgM. 100 µl of 
each sample were pre-incubated with GST coated plates for 20 min to pre-adsorb 
non-specific antibodies, this was repeated a total of 3 times. The pre-adsorbed 
samples were subsequently added in duplicate to the gt1a sE2-coated plate. 
These initial steps were conducted at 37°C to prevent precipitation. Subsequently, 
the plates were washed in high Tween PBSTM and HRP-conjugated anti-Mu was 
added (Abcam). After a further incubation and wash step, TMB substrate was then 
added and the reaction allowed to continue for 7 mins before stopping with 50 µl of 
0.5 M H2SO4. The strength of the colour signal was read using a Varioskan plate 
reader to determine the A450.  
2.10 B cell receptor (BCR) gene amplification 
2.10.1 PBMC separation and RNA extraction 
An 18 ml whole blood sample was obtained from each patient in the CHCV cohort 
and associated HCs. Peripheral blood mononuclear cells (PBMCs) were isolated 
from this by centrifugation over a Histopaque gradient and washing with Hanks 
Balanced Salt solution (HBSS). Two aliquots of PBMCs suspended in HBSS were 
removed and the PBMCs pelleted by further centrifugation. To obtain RNA, the 
supernatant was removed with a pipette and the PBMC pellet lysed using 1 ml 
buffer RLT containing ß- mercaptoethanol. Subsequently total RNA was isolated 
using the RNA-Easy kit (Qiagen) following an on-column DNase-digestion 
(Qiagen) step according to manufacturer’s protocol. RNA quality and quantity were 
assessed on a 2200 TapeStation (Agilent Technologies). 
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2.10.2 cDNA synthesis and PCR for BCR gene sequencing 
Sequencing of the BCR of selected patients was conducted in collaboration with 
Dr Mark Robinson and Dr Rachael Bashford Rogers (RBR) from the Sanger 
Centre, Cambridge. PBMCs from 6 HCV positive, cryoglobulinaemia positive 
patients, 6 HCV positive, cryoglobulin negative patients and 4 healthy controls 
(from the CHCV cohort) were prepared for BCR diversity analysis.  Total RNA was 
extracted as described above. cDNA libraries were prepared using an Ig heavy 
chain specific antisense primer and selected samples also had libraries prepared 
using IgG and IgM specific primers as published by RBR and reused with her 
permission (Table 2.6) (263).  
Reverse transcription was performed using the VILO kit (Invitrogen). Briefly, for 
each reaction 500 ng total RNA was mixed with 4 µl 5x VILO Reaction Mix, 2 µl 
10x Superscript ® Enzyme Mix and DEPC-treated water up to a total reaction 
volume of 20 µl. Tube contents were incubated at 25°C for 10 mins then at 42°C 
for 60 mins. The reaction was terminated by heating to 85°C for 5 mins.  
 
2.10.3 BCR gene amplification and analysis. 
Subsequently the BCR cDNA libraries were amplified using a pool of B cell 
receptor primers as published by RBR (Table 2.6) (263). Each reaction contained 
0.5 μl each of sense and antisense primers of a 5 μM working stock, 0.5 μl 
HotStarHiFi® High-Fidelity DNA Polymerase (Qiagen),  4 μl 5x HotStarHiFi PCR 
buffer  and 2 μl cDNA per 20 μl reaction. The following PCR program was used: 5 
mins at 95oC, 40 cycles of 30 seconds at 94oC, 30 seconds at 65oC and 1 min at 
72 oC, with a final extension cycle of 7 mins at 72 oC on a GeneAmp 
(ThermoScientific) thermocycler.  
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Table 2.6 Primers used for amplification of BCR genes 
Pimer (5’ to 3’) Region Sense/Antisense 
CTTACCTGAGGAGACGGTGACC 
JH 
consensus 
Antisense 
GGCCTCAGTGAAGGTCTCCGCAAG VH1-FR1 Sense 
GTCTGGTCCTACGCTGGTGAAACCC VH2-FR1 Sense 
CTGGGGGGTCCCTGAGACTCTCCTG VH3-FR1 Sense 
CTTCGGAGACCCTGTCCCTCACCTG VH4-FR1 Sense 
CGGGGAGTCTCTGAACATCTCCTGT VH5-FR1 Sense 
TCGCAGACCCTCTCACTCACCTGTG VH6-FR1 Sense 
CAGGAGACGAGGGGGAA BCR IgM Antisense 
CACCGTCACCGGTTCGG BCR IgG Antisense 
 
These primers are as designed and published by RBR (263) and reused with her permission. 
 
2.10.4 NGS library preparation and sequencing 
 
PCR products were purified using Agencourt® Ampure® XP beads (Beckman 
Coulter) and checked for purity using the TapeStation; for all heavy chain samples, 
clear bands were seen at approximately 315 bp in length and quantified using a 
Qubit® 2.0 Fluorometer with the Qubit® dsDNA High Sensitivity kit (Invitrogen) 
using the Qubit High Sensitivity dsDNA assay.  16 µl of PCR product was end-
repaired, A-tailed and adaptor-ligated using the Kappa Real-Time Library 
Amplification kit and NEBNext® Multiplex Oligos primers for Illumina (NEB) as per 
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protocol. All amplified libraries were checked on a 2200 TapeStation (Agilent 
Technologies) to ensure specific products and were quantified using the Kappa 
SYBR FAST Illumina library quantification kit. Purification and library preparation 
was performed predominantly by Mark Robinson with some assistance from me. 
The prepared library samples were sequenced using a MiSeq System Desktop 
Sequencer (Illumina) with a 300 cycle MiSeq version 2 reagent kit (Illumina) and 
sequences sent to RBR for further analysis using an in-house phylogenetics 
programme. Further details of the analyses performed using this programme are 
given in Chapter 8. 
2.11 Host DNA isolation and single nucleotide 
polymorphism (SNP) analysis for HLA genes 
rs9275224 and rs2395522 
In the CHCV cohort DNA was extracted from 200 µl of whole blood using the 
QIAmp DNA Mini Kit (Qiagen) as per protocol. As no whole blood sample was 
available for the Historical cohort individuals, the QIAmp Viral RNA kit was used 
without a DNAase step to extract both RNA and DNA simultaneously from 140 µl 
of serum stored at -70°C. Custom primers for SNPs rs9275224 and rs2395522 
were obtained from ThermoFisher Scientific. 1 µl of DNA from CHCV samples or 5 
µl of RNA/DNA mix from historical samples were included in a qPCR reaction 
using a TaqMan® Assay kit to test each sample for the presence of SNPs in both 
genes. The qPCR reaction was performed on a 7500HT Fast Real-Time PCR 
system (Applied Biosystems).  Samples were assigned as A/G heterozygotes or 
AA or GG homozygotes according to the colour signal generated. 
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2.12 Statistical analysis and bioinformatics software 
Statistical analysis was conducted using GraphPad Prism 6 Software (GraphPad 
Software, California) and SPSS v. 19.09 (IBM, New York) for the most part of this 
project. Where other programmes were used, this has been stated in the individual 
chapters.  
Molecular genomics analysis was conducted using CLC Genomics Workbench 7 
(Qiagen Bioinformatics) and MEGA 6.0 (MEGA Software (16)) software unless 
stated otherwise in the text. 
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3 Broad anti-HCV antibody responses and their 
association with improved clinical disease 
parameters in chronic HCV infection 
[The work described in this chapter has been published in Swann et al., J. Virol, 2016 
(251)  - the American Society of Microbiology copyright licence allows authors to 
reproduce their work as part of academic theses] 
3.1 Introduction 
 
Antibodies targeting the HCV envelope glycoproteins E1 and E2 can contribute 
significantly to viral clearance in acute HCV infection (113, 131). A recent study on 
individuals acutely infected with gt 1 HCV found that those developing a broad 
neutralising antibody (bNAb) response, able to prevent infection by a diverse range 
of HCV envelope strains in vitro, were more likely to clear infection(133).There is 
evidence that bNAbs may contribute to viral suppression and even clearance once 
infection has become established in some cases (144) (131).  
It is likely that host genetics play a significant part in the ability to mount a bNAb 
response as genetic polymorphisms have been associated with a bNAb profile in 
acute clearance (133). Similarly, host HLA type is known to be important in T cell 
mediated clearance of some HCV genotypes(264). In HIV it has also been 
postulated that it is viral evolution which drives a bNAb response (136)  with the 
development of matured affinity responses. However, it is difficult to prove whether 
co-evolution of broadly neutralising antibodies is predominantly dependent on viral 
characteristics, host physiology and genetics or an equal contribution from both. 
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Although there is evidence that bNAbs have clinical relevance in acute infection, 
during chronic HCV infection neutralising antibody (NAb) responses, targeting E1E2 
envelope glycoproteins and capable of preventing infection by some strains of HCV, 
are generated in many individuals. It is unclear if these antibodies play a protective 
role.  Indeed, humoral  immune responses induced by HCV can have pathological 
consequences as seen in cryoglobulinaemic vasculitis (6).  Therefore I aimed to 
investigate the presence of polyclonal broadly neutralising antibody (bNAb) 
responses in chronically infected HCV (CHCV) patients in order to determine any 
association with clinical outcomes and host factors. I also aimed to explore the 
relationship between overall anti-E1E2 antibody binding and functional neutralising 
ability of the polyclonal responses. 
3.2 The CHCV and healthy control cohorts 
 
Subjects with either gt1 or gt3 CHCV were prospectively recruited from 3 local liver 
clinics as described in Materials and Methods. Individuals with co-existing liver 
pathologies or with BMI >31 were excluded. Healthy controls with no liver 
pathologies or significant co-morbidities were also recruited and their samples used 
as negative controls in subsequent experiments.  All subjects completed a symptom 
questionnaire, clinical details were recorded and baseline biochemistry, virology and 
host IL28B genotype profiles were determined. Liver stiffness of CHCV individuals 
was measured by transient elastography using a Fibroscan ® (Echosens). Serum 
and whole blood samples were obtained from all participants. Samples from 8 of the 
recruited healthy controls and 51 of the chronically infected cohort were available at 
the time this part of my research was conducted and therefore were used in the 
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following experiments. Their demographics are summarised below (Table 3.1 and 
3.2). Comparisons of categorical variables were made using Chi Squared tests, 
ordinal variables were compared using Wilcoxon Rank Sum tests. Gt 3 individuals 
were more likely to be non-Caucasian (P=0.04)  as would be expected given that gt 
3 is most prevalent in Asia. 
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 Table 3.1: Demographics of CHCV and Healthy Control cohorts 
Demographics 
 
CHCV  
(n=51) 
 
Healthy Controls (n=8) 
Number 
Percentage 
/Range Number 
Percentage 
/Range 
Age 
Median (range) 46 (28-68) 
 
50 
 
(30-69) 
Gender (M/F) 
No. male (%) 35 (68.6) 
 
4 
 
(50) 
Ethnicity 
Caucasian (%) 47 (92.2) 
 
8 
 
(100) 
Source of infection 
No. IVDU (%) 32 (62.7) 
  
Estimated duration of infection 
(years) 25 (2-58) 
  
IL28B CC genotype 
(%) 17 (35.4)* 
  
Anti-HBc positive 
(%) 11 (24.4)** 
  
BMI (kg/m2) 
Mean (range) 26 (19-31.5) 
  
Diabetes 
Present (%) 2 (3.92) 
 
0 
 
(0) 
Previously treated$ 
(%) 21 (46.7)** 
  
HCV RNA load pre-treatment  IU/ml  
Median (range) 6.8x105 
(2272 - 
1.1x107) 
  
Cirrhosis 
Present (%) 18 (36) 
  
Transient elastography (kPa) 
Median (range) 9 (4-75) 
  
*3 subjects not tested **no information available for 6 subjects. $All individuals had HCV infection at 
the time of testing; those previously exposed to interferon were either relapsers or null responders. No 
individuals were on therapy at the time of sampling. There were no significant differences between 
healthy controls and CHCV in the parameters measured using Chi squared test for categorical data 
and Wilcoxon rank sum test for ordinal data. 
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Table 3.2 : Comparison of demographics and clinical parameters between CHCV gt 1 and gt 3 
infected patients. 
Demographics 
Gt 1 (n=27) Gt 3 (n=24) 
P 
value 
Number Percentage /Range Number 
Percentage 
/Range 
Age 
Median (Range) 47 (35-66) 45.5 (28-68) 0.49 
Gender (M/F) 
No. male (%) 18 (67) 17 (71) 0.77 
Ethnicity 
Caucasian (%) 27 (100) 20 (83) 0.04 
Source of infection 
No. IVDU (%) 19 (70) 13 (54) 0.26 
Estimated duration of 
infection (years) 
Median (range) 
20 (5-40) 26 (2-58) 0.50 
IL28B CC genotype 
(%) 8 (30) 9 (38) 0.56 
Anti-HBc positive 
(%) 3 (11) 8 (33) 0.09 
BMI kg/m2 
Mean (Range) 24.9 (19.8-29.7) 25.6 (19.4-31.5) 0.94 
Diabetes 
Present (%) 1 (4) 1 (4) 1.00 
Previously treated 
(%) 14 (52) 7 (29) 0.15 
HCV RNA load pre-
treatment  IU/ml 
Median (Range) 
498520 (2272-11300000) 788327 
(7687-
7030000) 0.59 
Cirrhosis 
Present (%) 9 (33) 10 (42) 0.57 
Transient elastography 
(kPa) 
Median (Range) 
8.3 (3.5-69.1) 9.25 (4-75) 0.60 
 
P values were calculated using Chi squared test for categorical data and Wilcoxon rank sum test for 
ordinal data. 
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3.3  The cross genotype (XG) and Intragenotype 1 (IG1) 
panels 
To determine reactivity and neutralisation of patient-derived IgG across a diverse 
range of envelope sequences, two panels of HCV pseudoparticles bearing test 
envelope proteins were used. The first, the XG panel, enabled analysis of antibody 
reactivity with E1E2 proteins of different viral genotypes. It is based on a previously 
described panel (see Materials and Methods).  
The second, termed the IG1 panel was designed as part of my project to allow 
investigation of antibody reactivity within a single genotype as might arise during a 
natural infection. The E1E2 sequences from gt1 infected patients from the CHCV 
cohort were PCR-amplified and cloned into the mammalian expression vector 
phCMV. This process is described briefly below with further detail in Materials and 
Methods.  
3.3.1 Generating HCVpps for use in the IG1 panel 
Gt 1 infected samples in the CHCV cohort with higher viral loads were selected for 
amplification. Viral RNA was extracted from CHCV patient serum using the QIAamp 
Viral RNA mini kit (Qiagen) and converted to cDNA using the Superscript III First 
Strand cDNA synthesis kit (ThermoFisher Scientific).  
3.3.1.1 Amplifying E1E2 from patient serum 
Initially previously published primers (160) were used to attempt to amplify the whole 
of E1E2 from cDNA. NS5B primers donated by Dr Carol Leitch were used as a 
positive control to confirm presence of virus (see Materials and Methods for 
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sequences). A product would be expected at 1.8kb for the E1E2 primers and a 
600bp for the NS5B primers. Unfortunately, the original E1E2 primers failed to yield 
any PCR product despite confirmation of the presence of virus using the NS5B 
primers (Fig. 3.1). The only product shown in the E1E2 primer group is likely to 
represent a primer dimer complex. While there is evidence of possible contamination 
in the negative control for the NS5B primers in this PCR there may be non-specific 
binding of primer to human genetic material creating some faint non-specific bands. 
This band is different to the clear single positive band shown in those patients with gt 
1 HCV infection. 
 As several attempts at amplification of E1E2 with the previously published primer 
set did not produce a product of the correct size, a modified set of degenerate 
nested primers flanking E1E2 were designed as described in Materials and Methods 
with a directional cloning tag added to the inner sense primer. Cycling conditions 
were as described in Materials and Methods. 
PCR products of the correct size were obtained for 10/15 samples tested with an 
example of positive products shown in Fig. 3.2. In this figure products of the correct 
size (1.8kb) are clearly demonstrated for pts 1013, 1032 and 1034 with a smaller 
(incomplete E1E2) product for 1021 and primer dimers only for the remainder of 
samples tested. Further PCR reactions generated for sample 1012,1018,1029,1047 
and 1112. Altering the annealing temperature was required to obtain PCR products 
for some of the samples (1010 and 1037), however full length E1E2 could not be 
amplified from others (1002,1003,1021,1031 and1046) despite prior confirmation of 
presence of HCV cDNA using NS5B primers to conserved regions. As the product 
generated from these primers had to produce a functional, correctly folded protein in 
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frame while including minimal extra genetic material from core protein and p7 there 
were limited options to alter the sequence of these primers to optimise PCR 
conditions.  
For those samples where PCR products of the correct molecular weight were 
generated, these were purified by running on a 0.8% Agarose gel, excising bands of 
an appropriate size (1.8kb) and extracting DNA using the Qiagen Gel Extraction kit. 
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Figure 3.1 PCR of cDNA from patient serum samples with published E1E2 primers and 
validated NS5B primers for HCV gt1. 
Three gt 1 infected samples from the CHCV cohort with higher viral load were selected for 
amplification of E1E2 sequences (1012, 1037 and 1047 labelled 12,37 and 47 respectively)  
alongside a healthy control sample (labelled –ve). A cDNA library was created from HCV RNA 
isolated from patient serum using the QiaAMP Viral RNA mini kit (Qiagen). The complete E1E2-
encoding region was amplified using previously described nested primers(160) using a HotStarTaq 
PCR kit. In addition, a separate PCR was performed on the same samples using previously validated 
NS5B region primers as described in Materials and Methods. The PCR product was run on a 0.8% 
agarose gel alongside an Invitrogen 1kb DNA ladder. The expected product size for E1E2 is 1.8kb 
and 600bp for NS5B. 
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Figure 3.2 Two gels displaying products from PCR of cDNA from patient serum samples with 
modified E1E2 primers.  
Gt 1 infected samples from the CHCV cohort with higher viral load were selected for amplification of 
E1E2 sequences. A cDNA library was created from HCV RNA isolated from patient serum using the 
QiaAMP Viral RNA mini kit (Qiagen). The complete E1E2-encoding region was amplified using 
degenerate nested primers as described in Materials and Methods using HotStarTaq PCR kit. The 
positive control is from including the standard gt 1a H77 E1E2 expression vector as a template in the 
second step of the nested PCR.  The PCR product was run on a 0.8% agarose gel alongside an 
Invitrogen 1kb DNA ladder. The expected product size for E1E2 is 1.8kb. 
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3.3.1.2  Identifying E1E2 sequences of interest to test in the HCVpp system 
The purified PCR products were sub-cloned using the pENTR D-TOPO directional 
cloning kit (ThermoFisher Scientific, see Materials and Methods). Colonies from 
each subcloning reaction were cultured in selective media and plasmid DNA 
extracted and screened for vector inserts by digesting with PVUII. Those plasmids 
shown to have inserts were then sequenced by GATC-Biotech to confirm the 
presence of E1E2-encoding sequences.  
At least one E1E2 sequence was obtained from each of these 10 individuals. For 
some, over 20 sequences were obtained, in others, fewer than 5 successful sub-
cloning reactions were generated despite repeated attempts.  A selection of E1E2 
sequences were chosen for insertion into phCMV expression vectors (as described 
in materials and Methods) from each of the patients with multiple sequences. For 
those 5 individuals with 5 or more unique sequences cloned a phylogenetic tree was 
constructed and sequences selected on the basis of overall genetic distance from 
other sequences and variability at key amino acid residues at known neutralising 
epitopes. For the remaining 5 individuals where fewer than 5 sequences, an attempt 
to transfer all unique sequences to an expression vector was made. Overall a total of 
39 sequences were transferred into vectors for testing in the HCVpp system. 
These expression vectors were used to generate HCVpp which were then tested for 
their ability to infect Huh7 cells as described in Materials and Methods. Infectivity 
was determined by assessing the luciferase signal 72 hours post-infection. Those 
HCVpp generating a signal of > 1000 RLU (approximately 10x the background level 
from uninfected Huh7 cells) were deemed functional, those with signals below this 
level were deemed non-functional as they were inappropriate for use in downstream 
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neutralisation assays because natural variability of the assay would make IC50s 
difficult to interpret at a signal value so close to background. However,Some of 
theseHCVpps had evidence of  weak infective activity displaying a signal between 2 
and 10 times background level. The process of generationg a phylogenetic tree and 
determining HCVpp infectivity data for sequences from patient 1012 is shown in Fig. 
3.3.  
3.3.1.3 Selecting E1E2 sequences to use in the Intragenotype 1 (IG1) panel 
All sequences functional in the HCVpp system from the CHCV cohort (generated as 
above), and others historically generated functional sequences were aligned and a 
phylogenetic tree generated as described in Materials and Methods section 2.5. 
From these analyses, 11 sequences giving the greatest level of diversity were 
selected to form the IG1 panel. The selected panel provided variability at 146 of the 
156 amino acid residues identified as variable in >10% of gt1 E1E2 sequences from 
the Los Alamos database and an additional eleven sites that represent more minor 
variations (see Figure 1.12).  
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Legend for Figure 3.3 on following page 
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Figure 3.3 A) Phylogenetic tree of sequences derived from pt 1012 and B) Infectivity of HCVpps 
bearing those sequences. 
A) Sequences were obtained from subcloning the E1E2 PCR product from patient 1012 generated as 
described in materials and methods were aligned using MEGA 6 software and a Maximum Likelihood 
phylogenetic tree constructed with bootstrap values based on 1000 replicates. The pink boxes 
represent sequences chosen to transfer to the expression vector based on genetic distance from 
other sequences and variation at key aa residues. B) Huh7 cells were infected with HCVpp bearing 
E1E2 sequences from different patients. At 72 h post infection, cells were lysed and luciferase activity 
determined. The bars show mean RLU with error bars representing the SEM.  Functionality was 
determined by a RLU value >10x background (i.e. uninfected Huh7 cells). The positive control was 
HCVpps generated using the standard gt 1a expression vector bearing the H77 sequence.  HCVpps 
were tested in quadruplicate over 2 separate experiments.Mean and SEM are shown. 
 
3.4 Cross-genotypic antibody reactivity is associated with 
lower viral load. 
Patient IgG reactivity to HEK-293T-cell expressed Panel XG E1E2 was tested by 
GNA-capture ELISA as described in Materials and Methods. IgGs from healthy 
control (HC) samples were included as a negative control and a standard curve of 
the broadly binding linear anti-E2 antibody AP33 was included as a positive control 
and to allow comparison of results across ELISA plates. 
 In order to compare clinical parameters between those patient IgGs with broader 
binding characteristics and those who were poor binders or only bound to one or two 
genotypes, it was necessary to determine which patients to include in broad and 
narrow binding categories. Unlike neutralisation assays, there is no accepted level of 
absorbance indicating positive binding in this assay; indeed across genotypes the 
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absorbance levels given by AP33 was extremely variable at the same concentration 
of antibody.  Moreover, while the lysates were all prepared in the same way, it is 
likely that levels of expression varied between the constructs.  As all of these 
individuals have been exposed to HCV it was difficult to validate an appropriate ‘cut 
off’ for a positive ELISA result, with the majority of individuals showing absorbance 
levels >2x  the HC samples used over several genotypes. At the time of optimising 
this assay, recruitment of healthy control samples had not completed, however if a 
larger pool of these samples had been available an alternative method would have 
been to set an arbitrary cut off based on HC values. 
Despite these limitations there were individuals who clearly had stronger and 
broader antibody binding than others displaying absorbance levels of over 10-fold 
that of HCs (Table 3.3). Therefore, to allow comparison of binding strength and 
breadth within the cohort, I chose to rank each sample according to its relative 
binding strength based on absorbance readings for each genotype. Samples were 
ranked from 1 (highest) to 51 (lowest) for each gt. I then added all gt ranks for each 
individual. From this sum of ranks, a final rank position was assigned, which gave an 
overall indication of the relative binding strength and breadth for each patient.  
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Table 3.3: Relative absorbance of samples (compared to 1µg/ml AP33) against E1E2 in the XG 
panel and ranking of samples according to overall binding. 
Sam
ple 
Gt 
1a 
Gt 
1b 
Gt 
2a 
Gt 
2b 
Gt   
3 
Gt   
4 
Ran
k 1a 
Ran
k 1b 
Ran
k 2a 
Ran
k 2b 
Ran
k 3 
Ran
k 4 
Sum 
of 
rank
s 
Overa
ll 
Rank 
1001/
00 6.7 33.1 1.4 2.3 7.7 5.9 19 2 11 8 19 19 78 6 
1002/
00 0.4 0.4 0.1 0.0 3.6 0.0 51 51 51 42 33 48 276 50 
1003/
00 13.4 18.7 2.8 0.6 61.9 67.6 12 9 6 15 1 2 45 1 
1006/
00 4.9 6.0 0.3 0.1 4.9 1.8 24 31 31 29 29 37 181 34 
1008/
00 1.5 10.8 0.4 0.2 57.2 0.6 39 21 27 21 2 46 156 28 
1009/
00 1.5 7.4 0.4 0.1 27.3 0.6 41 27 25 36 4 47 180 33 
1010/
00 86.8 5.2 0.4 0.1 2.1 4.2 1 34 22 25 41 24 147 27 
1012/
00 31.4 13.8 0.5 0.4 23.1 50.3 7 15 17 17 6 3 65 4 
1013/
00 3.6 6.0 0.2 0 3.2 2.7 28 32 45 49 35 34 223 42 
1015/
00 0.9 9.2 0.4 0.2 34.6 4.0 47 25 21 23 3 27 146 26 
1016/
00 7.9 13.1 0.7 0.2 19.6 17.7 17 19 15 18 9 7 85 9 
1018/
00 8.2 14.5 0.4 0.2 7.1 6.6 16 13 28 19 22 17 115 15 
1020/
00 2.4 3.0 0.3 0.1 22.1 0.7 33 43 33 35 8 45 197 36 
1021/
00 26.6 13.2 1.2 3.1 3.4 27.5 8 18 12 5 34 4 81 7 
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1022/
00 39.1 4.5 0.3 0.1 2.4 9.8 4 37 40 39 40 11 171 29 
1023/
00 14.3 13.5 0.1 0.1 16.8 11.2 10 16 49 28 10 9 122 19 
1024/
00 3.0 2.9 0.3 0.1 3.8 1.1 29 45 32 32 31 41 210 40 
1029/
00 6.4 12.8 0.4 0.1 22.7 9.3 21 20 20 37 7 13 118 18 
1030/
00 6.7 4.9 0.3 0.1 0.8 1.6 20 35 29 31 50 38 203 38 
1031/
00 34.5 7.0 0.8 0.1 2.5 10.7 5 29 14 27 38 10 123 20 
1032/
00 8.4 10.1 0.4 0.1 6.0 22.9 15 23 19 38 26 5 126 21 
1033/
00 0.7 3.7 0.2 0 2.4 0 48 40 44 47 39 49 267 49 
1034/
00 6.4 13.4 0.4 0.1 25.7 18.9 22 17 26 26 5 6 102 11 
1035/
00 76.2 8.2 0.3 0.1 2.1 13.3 2 26 35 30 42 8 143 24 
1036/
00 1.7 20.8 1.5 2.3 3.8 5.6 36 6 9 9 32 20 112 14 
1037/
00 2.7 7.1 0.1 0.2 1.5 3.6 31 28 50 22 44 28 203 38 
1038/
00 1.9 9.7 0.3 0.0 1.3 2.9 35 24 39 44 47 33 222 41 
1040/
00 12.3 28.0 4.5 4.3 3.0 9.8 14 3 3 4 36 12 72 5 
1041/
00 1.0 5.5 0.2 0 8.5 0.8 45 33 43 46 16 44 227 43 
1042/
00 41.3 6.0 0.3 0.2 7.4 9.1 3 30 30 20 20 14 117 17 
1043/
00 1.1 20.6 1.9 3.0 7.1 4.5 44 7 7 6 23 23 110 12 
1045/
1.6 3.3 0.3 0.0 0.3 1.5 38 42 37 45 51 39 252 47 
 150 
 
00 
1046/
00 14.0 23.8 1.5 1.7 5.7 6.9 11 5 10 12 27 16 81 7 
1047/
00 32.2 3.5 0.3 0.1 1.5 1.9 6 41 38 34 45 36 200 37 
1049/
00 2.7 1.5 0.3 0.1 10.3 2.9 32 49 36 24 13 32 186 35 
1050/
00 18.8 4.3 0.2 0.1 10.5 95.3 9 38 41 33 12 1 134 23 
1052/
00 0.7 1.6 0.2 0 7.2 0 49 48 48 48 21 50 264 48 
1054/
00 5.8 2.9 0.3 0.1 15.6 4.6 23 44 34 40 11 22 174 30 
1055/
00 2.7 2.6 0.2 0.1 2.9 1.0 30 46 42 41 37 42 238 46 
1056/
00 3.9 2.2 0.2 0.0 4.8 1.4 27 47 46 43 30 40 233 45 
1057/
00 1.1 1.5 4.0 16.4 1.4 2.5 43 50 4 1 46 35 179 32 
1060/
00 1.5 4.8 21.8 0 0.2 0 40 36 1 51 52 51 231 44 
1061/
00 7.0 34.0 3.9 6.4 9.9 8.1 18 1 5 2 14 15 55 2 
1062/
00 4.7 19.2 1.8 2.5 9.1 3.1 26 8 8 7 15 31 95 10 
1063/
00 0.5 13.8 0.6 1.1 6.3 4.1 50 14 16 13 25 26 144 25 
1064/
00 0.1 4.2 0.2 -0.7 1.2 1.0 52 39 47 50 48 43 279 51 
1072/
00 1.2 10.1 0.4 0.7 2.0 3.2 42 22 24 14 43 29 174 30 
1074/
00 1.6 16.4 0.9 2.0 7.9 5.5 37 10 13 11 18 21 110 12 
1089/
00 2.0 16.2 0.4 2.1 8.0 4.1 34 12 18 10 17 25 116 16 
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1112/
00 13.3 25.4 5.2 5.5 6.3 6.0 13 4 2 3 24 18 64 3 
1128/
00 4.8 16.3 0.4 0.5 5.6 3.1 25 11 23 16 28 30 133 22 
HC 
1025 0.9 0 0.03 0 1.0 0 - - - - - - - - 
HC 
1027 0.4 0.8 0.02 0.00 0.1 0.04 - - - - - - - - 
The table shows adjusted absorbance values compared to Healthy Control samples for E1E2 GNA 
ELISAs using purified IgG from CHCV patients at 200µg/ml. To allow comparison between separate 
ELISA plates, absorbance readings were standardised according to absorbance values on a standard 
concentration curve of AP33, a linear antibody known to bind to most genotypes of HCV E2. The 
values shown in the table is the concentration of AP33 (in µg/ml) giving an equivalent Absorbance 
value to the sample.  For healthy control samples (denoted by HC) and some CHCV samples, 0 has 
been used where the ratio was lower than 0.01. Values are the average obtained  over 3 experiments 
with samples tested  in duplicate Samples were ranked from strongest binding (1) to weakest binding 
(51) for each subgenotype tested against. These ranks were totalled for each individual and this total 
was used to give an overall rank. .  
 
The simplest way to compare those with broader and narrower binding 
characteristics was to divide the cohort in half based on binding rank and to compare 
the top ranked half with the lower half to determine any clinical associations with 
breadth of antibody binding. Those in the top ranked half (i.e. with broader ELISA 
reactivity profiles) had a significantly lower viral load (P=0.03, Fig. 3.4). Individuals 
with a broader breadth of binding were more often infected with gt 1 HCV and 
conversely individuals with a narrower breadth of binding were more often infected 
with gt 3 HCV (P=0.04, Table 3.4). These associations appear to be independent as 
there was no relationship between gt of infection and viral load (P=0.59, Table 3.2). 
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The association of cross-genotype breadth and infection with gt 1 may simply reflect 
a closer sequence homology between gt 1 and the other genotypes tested i.e. gt 1a 
is more closely related to gt 2 and gt 1b is closely related to gt 4a(14). Another 
explanation is that gt 3 envelope sequences may be less variable, therefore 
generating a less diverse pool of antibodies. However, if this was the case gt 3 virus-
infected individuals would be expected to have a higher rate of reactivity against the 
standard laboratory gt 3 sequence. In fact the number of individuals with a low level 
of reactivity to their own genotype was similar between gt 1 and gt 3 infected 
individuals.  9 gt 3-infected individuals had an adjusted absorbance <5 x mean HC 
absorbance to gt 3 lysate, compared with 8 gt 1 infected individuals with an adjusted 
absorbance <5 x HC mean absorbance when tested on the gt 1a lysate. It is also 
possible that gt 3 infection fails to induce bNAb through other, unknown 
mechanisms. 
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Figure 3.4 Association of viral load with cross-genotypic E1E2 binding.  
The relative binding of CHCV cohort IgG to E1E2 from 6 subgenotypes of HCV was determined by 
ELISA. The IgG samples were ranked from 1 to 51 according to their binding signal for each 
subgenotype. The sum of these ranks was used to order the samples from highest cross-genotypic 
binding to lowest.  The binding of the highest ranked of the cohort was regarded as “Broad” and that 
of the lower half as “Narrow”. The viral loads of the two groups were compared using the Mann 
Whitney U test. Mean and SD are shown. 
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 Table 3.4 Associations of IgG binding of panel XG by E1E2 ELISA with clinical features.  
 
Statistical comparisons were made using non parametric tests (Fisher’s exact test for categorical 
data, Wilcoxon Rank Sum for ordinal or numeric data). Significant P values are shown in bold. 
 
XG ELISA broad  (n=25) XG ELISA narrow (n=26) P value 
Age Median (range) 46 (29-66) 46 (28-68) 0.63 
Gender (M/F)       
No. male (%) 
19 (76) 16 (62) 0.26 
Ethnicity              
No. Caucasian (%) 
1  (4) 3  (12) 0.32 
Source of infection 
No. IVDU (%) 
17  (68) 14  (54) 0.39 
Estimated duration 
of infection (years) 
Median (range) 
19  (2-40) 31  (5-58) 0.29 
IL28B CC genotype 
(%) 
9  (36) 8  (31) 0.77 
Anti-HBc positive 
(%) 
6  (24) 5  (19) 0.74 
BMI kg/m2   Mean 
(range) 
25.9  (21-31.5) 25  (19.8-30) 0.69 
Diabetes Present 
(%) 
1 (4) 1 (4) 1.00 
Previously treated 
(%) 
9 (36) 12 (46) 0.57 
HCV RNA load pre-
treatment  IU/ml 
Median (Range) 
265234                      
(7687- 3010000) 
1054634                      
(2272-7140000) 
0.03 
Cirrhosis Present 
(%) 
9   (36) 10  (38) 0.57 
Transient 
elastography (kPa) 
Median (Range) 
8.85 (3.5 - 45) 9 (4 -75) 0.99 
Genotype 1 (%) 17 (68) 10 (38) 0.04 
Genotype 3 (%) 7 (28) 16 (64) 0.04 
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3.5  XG neutralisation does not have an association with 
clinical factors 
Purified IgGs derived from the CHCV cohort were tested for their ability to neutralise 
(reduce infectivity by 50% or more) HCVpp bearing envelope proteins from Panel XG 
(Table 3.5). Breadth of neutralisation, defined as broad (neutralisation of >3/6 
genotypes) or narrow (<4/6 genotypes), was analysed for association with clinical 
factors (Table 3.6). Twenty (39%) of the 51 individuals tested had broad cross-
genotypic neutralising IgGs.  
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Table 3.5 Percentage reduction in infectivity (neutralisation) of HCVpp in the XG panel by 
CHCV patient purified IgG 
Sample 
ID 
Gt 1a Gt1b Gt 2a Gt 2b Gt 3 Gt 4 Number of gt 
neutralised (/6) 
1001/00 73.9 48.2 45.8 5.1 47.8 67.3 2 
1002/00 -6.7 -51.7 20.9 -4.2 34.2 15.9 0 
1003/00 76.7 71.9 84.4 30.2 66.3 89.6 5 
1006/00 61.2 16.1 54.0 18.3 36.2 77.4 3 
1008/00 54.6 42.5 65.0 23.7 77.5 73.5 4 
1009/00 50.8 39.3 67.3 20.9 48.4 71.4 3 
1010/00 73.6 60.5 73.1 37.0 45.7 86.1 4 
1012/00 74.6 56.1 84.9 45.4 76.2 86.7 5 
1013/00 84.8 11.1 39.4 30.8 48.9 70.0 2 
1015/00 68.0 37.3 66.7 26.8 48.7 82.9 3 
1016/00 75.7 79.8 88.9 7.4 74.9 89.1 5 
1018/00 76.8 50.8 40.4 -6.2 49.6 79.6 3 
1020/00 56.1 44.7 38.8 5.0 53.0 83.3 3 
1021/00 62.7 34.7 55.4 25.7 46.2 88.1 3 
1022/00 73.1 55.1 63.3 32.5 51.6 81.3 5 
1023/00 58.7 54.4 67.1 -6.8 73.5 90.1 5 
1024/00 55.4 65.6 72.5 29.0 40.2 76.8 4 
1029/00 46.4 30.9 83.2 13.4 67.1 87.8 3 
1030/00 18.4 13.7 54.9 26.4 27.9 79.6 2 
1031/00 41.0 1.2 11.0 38.2 31.6 75.3 1 
1032/00 64.5 -8.8 81.0 40.3 79.1 86.0 4 
1033/00 23.5 68.3 34.4 13.7 27.8 61.9 2 
1034/00 47.7 42.7 47.3 16.6 26.4 59.1 1 
1035/00 82.4 65.7 66.7 45.1 48.3 87.5 4 
1036/00 65.3 46.5 52.2 23.7 22.5 65.1 3 
1037/00 74.6 54.5 65.5 16.1 61.6 90.9 5 
1038/00 38.6 40.6 77.1 29.4 51.7 79.0 3 
1040/00 75.3 53.4 34.4 29.6 29.4 63.6 3 
1041/00 66.6 -29.2 43.7 25.8 71.5 71.9 3 
1042/00 67.9 57.0 57.4 39.6 80.2 89.9 5 
1043/00 44.4 45.5 31.7 -4.1 32.9 60.7 1 
1045/00 61.0 22.5 37.2 36.3 -22.6 65.0 2 
1046/00 79.4 60.0 62.5 50.2 64.0 82.9 6 
1047/00 52.5 5.4 40.3 45.6 62.9 71.4 3 
1049/00 58.1 24.0 66.8 45.0 50.3 82.0 4 
1050/00 84.4 49.5 51.5 45.5 54.3 76.2 4 
1052/00 62.0 -29.6 34.5 14.3 19.7 54.2 2 
1054/00 13.6 -5.0 39.1 5.5 37.1 82.7 1 
1055/00 61.5 0.2 32.1 1.7 53.7 79.2 3 
1056/00 73.8 0.3 53.1 21.4 50.1 73.3 4 
1057/00 41.3 49.1 60.4 29.4 56.8 70.0 3 
1060/00 41.9 45.1 49.7 31.2 45.9 65.8 1 
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1061/00 65.2 55.5 46.0 31.9 52.8 75.8 4 
1062/00 46.3 60.5 10.2 0.3 41.2 60.2 2 
1063/00 27.8 32.4 39.1 15.2 43.5 72.2 1 
1064/00 24.6 37.9 31.8 12.6 34.1 48.2 0 
1072/00 61.9 36.3 39.2 21.8 28.8 60.2 2 
1074/00 61.3 37.4 41.0 34.1 37.2 76.0 2 
1089/00 28.4 23.9 23.6 26.4 44.9 60.5 1 
1112/00 70.9 35.9 63.5 38.9 50.3 69.8 4 
1128/00 81.7 70.3 48.1 39.0 65.9 81.9 4 
This table shows mean percentage reduction in infectivity (or percentage neutralisation) of HCVpp of 
the relevant genotype on Huh7 cells  in the presence of 100µg/ml of purified IgG as described in 
Materials and Methods. Values are averaged over 3 experiments with samples tested in duplicate. 
Infectivity was determined using the signal from a BrightGlo Luciferase assay of infected Huh7 cell 
lysate.  The percentage reduction in infectivity is taken as the percentage reduction in RLU signal in 
test wells compared to control wells where no IgG was added. Individuals were classed as 
‘neutralising’ an HCVpp genotype if the reduction in infectivity was 50% or greater. Negative values 
indicate infectivity was enhanced by the test IgG. 
 
Association of clinical parameters with neutralisation group was determined using 
Fisher’s exact test for categorical variables and Wilcoxon Rank Sum testing for 
ordinal data. There were no significant associations of breadth of cross-genotypic 
neutralisation with viral load or other clinical factors (Table 3.6). However, a trend to 
association of broader inter-genotypic neutralisation with anti-hepatitis B virus (HBV) 
core (anti-HBc) antibody status was seen (P=0.07). This may reflect a cohort who 
participated in higher risk injecting behaviour experiencing both exposure to HBV 
and also a wider range of HCV viral strains. It is also interesting to note that 
clearance of HCV in chronically infected patients has been reported in those 
exposed to HBV suggesting this may stimulate an immune response against 
HCV(265, 266) .  
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Table 3.6 Associations of cross-genotypic neutralisation breadth with demographics and 
clinical parameters. 
 
XG panel 
Broad  (n=20) Narrow  (n=31) P value 
Age  Median  (Range) 47  (35-66) 45 (28-68) 0.51 
Gender (M/F)  No. male (%) 13 (65) 22  (71) 1.00 
Ethnicity Caucasian (%) 18  (90) 29 (93) 1.00 
IVDU  (%) 14 (70) 18 (58) 0.55 
Duration of infection Median 
years (range) 
27.5 
(12-55) 
18 
(2-58) 
0.38 
IL28B CC genotype (%) 6 (30) 11 (35) 0.77 
anti-HBc positive (%) 7 (35) 4 (13) 0.07 
BMI mean kg/m2 25.5 (19.8-31.5) 25.6 (19.4 -30.3) 0.47 
Diabetes (%) 0 (0) 2 (6) 0.51 
Previously treated (%) 6 (30) 15 (48) 0.39 
HCV RNA pre-treatment  IU/ml 
Median (Range) 
966647 
(7687-5000000) 
615833 
(2272 -11300000) 
 
0.76 
Cirrhosis Present (%) 7  (35) 12 (39) 1.00 
Fibroscan kPa Median (Range) 9.0 (3.5-45) 7.3 (4-75) 0.72 
Genotype 1 (%) 12 (60) 15 (48) 0.26 
Statistical comparisons were made using non parametric tests (Fisher’s exact test for categorical 
data, Wilcoxon Rank Sum for ordinal or numeric data). 
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3.6 Intra- genotype 1 (IG1) panel neutralisation breadth is 
associated with degree of liver fibrosis, age and body 
mass index (BMI) but not with viral load. 
Similarly, IgG from 20 CHCV individuals with gt 1 infection were tested for 
neutralising activity against the intragenotype panel (IG1) and the number of 
pseudoparticles neutralised to the 50% level by 100µg/ml purified IgG from each 
individual calculated (Table 3.7). Neutralisation of >7/11 strains was defined as 
‘broad’ while ‘narrow’ neutralisation was defined as <8/11 strains.  
Analysis of the demographics of broad and narrow neutralising individuals in this 
subgroup was conducted as above (Table 3.8). Interestingly, this revealed an 
association between breadth of neutralisation and age, with the broadly neutralising 
group being significantly younger (P=0.024; Table 3.8). In addition, for this subgroup 
of gt 1-infected individuals there was a striking association between breadth of 
neutralisation activity and liver fibrosis. The broadly neutralising group had lower 
levels of liver fibrosis as determined by transient elastography (P=0.009; Table 3.8, 
Fig. 3.5a) and significantly fewer cirrhotic individuals (P=0.02; Fig. 3.5b) than the 
narrowly neutralising group. To determine if age was a confounding factor in the link 
between neutralisation breadth and fibrosis I analysed the impact of both variables 
together using the Generalised Linear Model (SPSS V.19.0). This showed the 
association between neutralisation breadth and Fibroscan readings remained 
significant when corrected for age (P=0.025, Generalised Linear Model, SPSS V. 
19.0).  
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There is also an association of broader neutralisation and lower BMI which just 
reaches statistical significance (Table 3.8, Fig. 3.6a P=0.048). This may simply 
reflect the effect of confounding , although there was no correlation between BMI 
and Fibroscan readings in this cohort (Fig. 3.6b Pearson’s r=0.07, P=0.77) an 
association between obesity and cirrhosis in larger populations is well documented 
(222). There is some evidence that obesity can impact on the humoral response in 
influenza, therefore it is an intriguing possibility that obesity may also play a role in 
breadth of antibody mediated neutralisation in HCV (267). As with Panel XG, there 
was no association between breadth of neutralisation of Panel IG1 and viral load. 
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Table 3.8 Associations of inter-genotypic neutralisation breadth with demographics and 
clinical parameters. 
 Intra-genotypic panel (IG1) 
Broad   (n=10) Narrow    (n=10) P value   
BvN 
Age  Median (Range) 41.5 (38-66) 51.1(44-65) 0.024 
Gender (M/F)  No. male (%) 6 (60) 6 (60)0) 1.0 
Ethnicity Caucasian (%) 10 (100) 10 (100) 1.0 
IVDU  (%) 8 (80) 6 (60) 0.63 
Duration of infection             
Median years (range) 
15.5 (12-37) 24 (5-37) 0.70 
Estimated Age at infection 23.5 (4-45) 24.5 (11-50) 0.89 
IL28B CC genotype (%) 3 (30) 2 (20) 1.0 
anti-HBc positive (%) 2 (20) 1 (10) 1.0 
BMI mean kg/m2 24.2 (21.0-28.5) 26.6 (21.2-29.7) 0.048 
Diabetes (%) 0 (0) 1 (10) 1.0 
Previously treated (%) 3 (30) 6 (60) 0.20 
HCV RNA pre-treatment  IU/ml 
Median (Range) 
218838                     
(2272-2359543) 
498520          
(88676-11300000) 
0.13 
Cirrhosis Present (%) 1 (9) 7(70) 0.02 
Transient elastography kPa 
Median (Range) 
5.4 (4.1-14) 21.1 (3.5-70) 0.009 
Genotype 1 (%) 10 (100) 10 (100) 1.0 
Statistical comparisons were made using non parametric tests (Fisher’s exact test for categorical 
data, Wilcoxon Rank Sum for ordinal or numeric data). Significant P values are shown in bold. 
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Figure 3.5 Association of intra-genotype 1 neutralisation breadth and liver fibrosis. 
A) Fibrosis as quantified by  Transient Elastography using Fibroscan ® was measured for each 
individual at the time of sampling. Individuals were divided into broad and narrow neutralising groups 
according to their ability to neutralise the IG1 panel as described above and Fibroscan values for 
individuals in each group compared using the Wilcoxon Rank Sum test. B) Those individuals tested in 
the IG1 panels were categorised as having cirrhosis or no cirrhosis on the basis of Fibroscan, clinical 
and biopsy data. The number of HCVpp neutralised to 50% in the IG1 panel by the individuals in each 
of these groups were compared using the Wilcoxon Rank Sum test. Mean and SD are shown. 
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Figure 3.6 Association of BMI with A) IG1 breadth of binding and B) Fibroscan ® measurement 
of liver fibrosis 
A) The BMI of CHCV cohort individuals was assessed in clinic at the time of sampling. This 
information was compared for individuals with IG1 broad and narrow neutralising profiles and 
compared using a Wilcoxon Rank Sum test. Mean and SD are shown. B) The Fibroscan readings for 
individuals used in the IG1 cohort was plotted against their BMI and Pearson’s r coefficient of 
correlation calculated where a value of 1 indicates a perfect correlation. 
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3.7  Neutralisation of HCVcc and clinical parameters 
While HCVpps are a good model for viral entry and generally have a good 
correlation with neutralisation experiments using live virus (HCVcc) bearing 
similar sequences , experimental results obtained with HCVpp do not always 
give identical results to HCVcc(154).  
Therefore I aimed to test the ability of the CHCV cohort to neutralise 3 
different HCVcc bearing envelope sequences for gt1a (GT1HQL), gt 2a (JFH-
1 sequence) and Gt 4 (Ad4a). These experiments were performed by Dr 
Vanessa Cowton and Mrs Sarah Cole as they are required to be carried out in 
a Category 3 facility, however the analysis of results is my own.  
Experiments were performed as described in Materials and Methods, briefly 
infectious virus was produced in Huh7 cells by electroporation of RNA 
encoding full-length JFH-1 or chimeric JFH-1. The neutralization of cell culture 
infectious HCV (HCVcc) infection was tested in Huh7-J20 cells, and infectivity 
was assessed at 3 days post-infection using a Phospha-Light assay system 
(Thermo Fisher) to measure secretory alkaline phosphatase (SEAP) levels. 
Percentage neutralisation for each of the CHCV individuals is shown in Table 
3.9. Only 13/51 subjects were able to neutralise one or more of the HCVcc at 
the 50% level. Eight of these 13 were broad neutralisers in the XG panel and 
5/6 of those which had been tested in the IG1 panel were broad neutralisers. 
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Cohort demographics were analysed according to whether their IgG could 
neutralise any of the HCVcc panel at the 50% level. There were no significant 
differences in clinical parameters between the groups (Table 3.10). This may 
simply be a reflection of the small number of individuals in the neutralising 
group but it again suggests that cross genotypic neutralising ability is perhaps 
less important in chronically infected individuals than a broad intragenotypic 
neutralising response. 
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Table 3.10 Clinical characteristics of individuals by HCVcc neutralising group 
Individuals were classified as HCVcc neutralising if their IgG neutralised any of the HCVcc at the 50% 
level. P values were calculated using Fisher’s exact test for categorical variables and Wilcoxon Rank 
Sum for ordinal variables 
 
HCVcc Non-
Neutralising 
(n=38) 
HCVcc 
Neutralising 
(n=13) 
P value 
Age Median 
(range) 
46 
(28-68) 
47 
(37-66) 0.43 
Gender 
No. male (%) 
28 
(73) 
7 
(54) 0.30 
Ethnicity 
Caucasian (%) 
35 
(92) 
12                       
(92) 1.00 
Source of infection 
No. IVDU (%) 
25 
(66) 
7 
(54) 0.51 
Estimated duration 
of infection (years) 
Median (range) 
22                        
(2-51) 
28                         
(5-55) 0.76 
IL28B CC 
genotype 
(%) 
11                      
(29) 
6                           
(46) 0.31 
Anti-HBc positive 
(%) 7 4 0.74 
BMI kg/m2 
Mean (range) 
25.7                      
(19.4-31.0) 
25                   
(21.0-31.0) 0.58 
Diabetes 
Present (%) 
2                          
(5) 
0                           
(0) 1.0 
 
Previously treated 
(%) 
14                      
(37) 
7                         
(54) 0.34 
HCV RNA load pre-
treatment  IU/ml 
Median (Range) 
1884564 (8670-
11300000) 
892486 (2272-
3010000) 0.13 
Cirrhosis 
Present (%) 
15                      
(39) 
4                           
(31) 0.50 
Transient 
elastography (kPa) 
Median (Range) 
9.5                       
(4-69.1) 
9.0                           
(4-28) 0.70 
Genotype 1 
(%) 
18                         
(47) 
9                        
(69) 0.31 
Genotype 3 
(%) 
20                        
(53) 
4                        
(31) 0.31 
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Table 3.9 CHCV individuals purified IgG ability to neutralise HCVcc virus 
 
Patient sera GT1 HQL GT2a JFH1 Gt4 Ad4a Number of cc neutralised
1001 32.5 28.7 2.6 0
1002 9.8 6.6 -11.7 0
1003 54.7 51.7 48.8 2
1006 26.5 16.8 30.2 0
1008 29.9 21.4 4.3 0
1009 24.5 28.6 18.4 0
1010 36.5 20.9 17.0 0
1012 44.0 40.0 6.1 0
1013 51.6 24.4 12.7 1
1015 37.9 47.5 7.4 0
1016 42.1 46.0 36.1 0
1018 31.3 37.7 20.2 0
1020 26.6 37.2 -42.7 0
1021 44.5 64.2 6.9 1
1022 35.6 40.5 10.5 0
1023 38.6 37.3 16.1 0
1024 35.2 42.1 2.5 0
1029 40.9 36.1 -4.4 0
1030 24.5 36.6 -17.7 0
1031 40.1 19.3 19.8 0
1032 41.8 54.2 15.2 1
1033 25.7 28.6 18.0 0
1034 30.8 27.1 12.2 0
1035 35.1 25.5 19.0 0
1036 36.0 17.0 -12.5 0
1037 34.0 19.7 9.6 0
1038 38.7 53.4 -9.8 1
1040 30.8 39.8 4.8 0
1041 33.3 39.9 -8.8 0
1042 67.0 65.2 20.0 2
1043 48.6 35.0 21.6 0
1045 51.5 47.5 -2.6 1
1046 39.9 61.8 25.1 1
1047 46.3 57.0 14.4 1
1049 42.0 48.8 26.1 0
1050 59.6 60.3 6.8 2
1052 34.5 35.8 -52.6 0
1054 41.6 38.8 -1.8 0
1055 33.8 43.0 -0.8 0
1056 45.4 54.2 -3.9 1
1057 36.4 44.4 -20.0 0
1060 43.1 39.6 3.0 0
1061 52.1 50.5 -15.2 2
1062 39.4 21.4 -21.7 0
1063 22.1 38.1 -8.7 0
1064 16.6 30.8 3.1 0
1072 37.2 34.1 23.9 0
1074 42.5 38.0 7.7 0
1089 38.4 30.9 15.6 0
1112 50.0 36.4 19.9 1
1128 32.6 39.2 -1.1 0
 169 
 
Percentage reduction in infectivity of HCVcc is shown when incubated with sample IgG as detailed in 
Materials and Methods compared to HCVcc infectivity without sample IgG. Red shading indicates low 
or no neutralisation. Blue shading indicates higher levels of neutralisation. The number of cc 
neutralised column indicates how many of the 3 HCVcc strains had infectivity reduced by 50% or 
greater by sample IgG. 
 
3.8 Correlation between ELISA binding profiles and 
neutralisation 
 
To determine the level of agreement between individual ELISA binding profiles and 
breadth of neutralisation activity, non-parametric correlation co-efficients 
(Spearman’s rho) between the assays were calculated. For strength of ELISA 
binding to individual genotypes and ability to neutralise the same E1E2 sequences in 
the HCVpp system, there was a modest correlation for 4 of the subgenotypes but not 
for either of the gt 2 E1E2 sequences (Fig. 3.7 a-f). Outliers are also visible in all 
genotypes which have similar levels of HCV glycoprotein binding to neutralising 
samples, but do not neutralise in the HCVpp system. 
The correlation between ELISA binding rank and the number of strains neutralised in 
the various panels was also calculated (Fig. 3.8). In those 20 gt 1-infected individuals 
who were tested against both XG and IG1HCVpp panels, there was a significant 
correlation between the number of strains neutralised in the two panels (Spearman’s 
Rho correlation co-efficient =0.56 P=0.008, Fig. 3.8a). Overall for the full cohort there 
was a modest correlation of cross-genotypic ELISA binding rank with number of 
genotypes neutralised in Panel XG and a stronger correlation with Panel IG1 
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(Spearman’s Rho correlation co-efficient -0.31, P=0.03 and -0.56, P=0.008, 
respectively) (Figs. 3.8b, 3.8c).  The modest correlation between ELISA binding and 
neutralisation highlights that while an individual with strong HCV-binding antibodies 
tends to have potent neutralising antibodies this is not always the case. I also 
compared the number of HCVpps neutralised in the XG panel with the number of 
HCVcc neutralised, this again revealed a modest correlation (Fig. 3.8d Spearman’s 
Rho correlation co-efficient 0.35, P=0.012) which goes some way to confirm that the 
HCVpp assay has relevance to live virus.  
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Figure 3.7 Non-parametric correlation of individual samples’ absorbance on E1E2 by ELISA 
and percentage neutralisation of HCVpp for each subgenotype tested. 
ELISA assays and HCVpp neutralisation assays were carried out with purified patient IgG out as 
previously described. For each subgenotype (A-1a,B -1b, C -2a, D-2b, E- 3 and F-4) individual 
samples’ percentage neutralisation of HCVpp was plotted against relative absorbance compared to 
1µg/ml AP33 calculated using a standard concentration curve. Spearman’s r co-efficient and 
corresponding P value were calculated using GraphPad Prism 6.0. 
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Figure 3.8 Non parametric correlations between neutralisation in the different panels and 
ELISA binding rank.  
Nonparametric correlation between E1E2 ELISA binding and neutralization. (A, B). The number of 
HCVpp neutralized was plotted against the ELISA binding rank (calculated as described previously) 
for panel XG (A) and panel Gt1 (B). (C) For those gt1-infected individuals whose antibodies were 
tested for reactivity against HCVpp in both panels, the number of HCVpp isolates in panel XG 
neutralized was plotted against the number of HCVpp isolates in panel Gt1 neutralized at the 50% 
level. (D) The neutralization activity of antibodies from the full CHCV cohort against HCVpp in panel 
XG and the HCVcc viruses (1A-HQL, JFH-1, 2B1.1/JFH1) was analysed, and the number of strains 
neutralised to the 50% level plotted for each individual. Spearman's rho correlation coefficient and 
corresponding P value was calculated for all graphs. 
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3.9 Role of HLA-DQB1 polymorphisms in predicting 
antibody neutralisation breadth   
  
Two SNPs (designated rs9275224 and rs2395522) in an MHC Class II gene, HLA 
DQ have recently been shown to have an association with breadth of antibody 
response in acute HCV infection and acute viral clearance. This region is involved in 
antigen presentation (133). Therefore I analysed our cohort for any association 
between this and the number of HCVpp neutralised in both panels.  
There was no significant association between presence of these alleles and the 
number of HCVpp neutralised in Panel XG (P=0.41; Fig. 3.9a). However, the 
presence of the rs9275224 GG or AG allele was significantly associated with a 
greater number of HCVpp neutralised in Panel IG1 (P=0.038; Fig. 3.9b). There was 
no association between SNP rs9275224 and liver fibrosis P=0.46; Figs. 3.10). In 
addition, I tested another genetically linked HLA-DQ SNP rs2395522. The SNP 
typing in the CHCV cohort showed 100% linkage of subtype with the rs9275224 
allele (i.e. all rs9275224 GG individuals had the rs2395522 AA type, AG had AT and 
AA had TT respectively). As expected the AA or AT allele was also significantly 
associated with increased neutralisation breadth in panel IG1 (P=0.038, data not 
shown as the graphs are identical due to the genetic linkage between the SNPs). 
These SNPs are present in the intergenic region of HLA-DQ; their functional 
consequences are unknown, however, they are associated with autoimmune 
diseases including systemic lupus erythematosus, systemic sclerosis and 
rheumatoid arthritis (268, 269). They have also been identified as being associated 
with spontaneous HCV clearance in GWAS studies (87). Interestingly, while only 
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20% of the European population carry the unfavourable alleles (NCBI Genbank data 
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_viewTable.cgi?pop=1409 , accessed 
11/04/2017), 40% of our CHCV population had the rs9275224 AA genotype adding 
further weight to the hypothesis that these genes are involved in acute viral 
clearance or resistance. 
GG/AG AA
0
2
4
6
8 P=0.41
GG/AG AA
0
5
10
15 P=0.038
 
Legend for Figure 3.9 on following page 
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Figure 3.9 Association between HLA DQ SNP rs9275224 and number of genotypes neutralised 
in the (A) XG panel and (B) IG1 panel.  
Number of genotypes neutralised in the XG and IG1 panels were determined as described previously. 
SNP typing for each individual in the CHCV cohort was conducted using the TaqMan ® SNP 
Genotyping Assay (Life Technologies) assay as described in Materials and methods. For individuals 
in the favourable (GG/AG) and unfavourable (AA) genotypes number of HCVpps neutralised at the 
50%  level in each panel was plotted. P values were calculated using the Wilcoxon Rank Sum test. 
Median and interquartile range are shown. 
 
Figure 3.10 Comparison of and levels of fibrosis as measured by transient elastography by 
Fibroscan ® across the two groups HLA DQ SNP rs9275224 genotypes. 
Number of genotypes neutralised in the XG and IG1 panels were determined as described previously. 
SNP typing for each individual in the CHCV cohort was conducted using the TaqMan ® SNP 
Genotyping Assay (Life Technologies) assay as described in Materials and Methods. For individuals 
in the favourable (GG/AG) and unfavourable (AA) genotype groups, liver stiffness by transient 
elastography measured using a Fibroscan ® machine (Echosens) was plotted. P values were 
calculated using the Wilcoxon Rank Sum test. Mean and SD are shown. 
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3.10 Chapter 3 Discussion 
3.10.1 Cross genotypic glycoprotein binding by ELISA and viral 
load 
This analysis of a clinical cohort chronically infected with HCV has yielded several 
new insights into host factors associated with functional breadth of the antibody 
response. A broad cross-genotype HCV-binding antibody response as measured by 
ELISA was significantly associated with reduced viral load while no association was 
evident between viral load and breadth of neutralisation activity. This suggests 
distinct biological roles for non-neutralising and neutralising anti-HCV antibodies. 
The link seen between broader  ELISA binding and lower viral loads could reflect the 
presence of antibodies binding to conserved non-neutralising regions which may 
promote opsonisation and phagocytosis, thus  helping clear bound virus from serum 
but not effectively preventing  hepatocyte infection. Conversely, viral loads may be 
lowered artefactually in some individuals with cryoglobulinaemia which may 
confound this association. 
 
3.10.2 Association of neutralisation breadth with clinical 
features 
Although no clinical features were significantly associated with cross-genotype 
neutralisation of HCVpp or HCVcc, significant associations were observed using a 
larger intra-genotype 1 panel. Most importantly, it has shown that individuals infected 
with HCV gt 1 who are better able to neutralise an HCVpp panel incorporating 
different gt 1 E1E2 sequences are less likely to have cirrhosis or significant liver 
fibrosis. As this panel encompasses the majority of variable aa positions observed 
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within gt 1 envelope sequences it is likely to represent common aa substitutions that 
may occur within host virus in attempting to escape the adaptive immune response. 
 
This association is not sufficient evidence to conclude that a bNAb profile protects 
from liver fibrosis. However, it corresponds with case studies documenting more 
rapid progression of liver injury and fibrosis in individuals with genetic or iatrogenic 
antibody suppression (270, 271). It is biologically plausible that those individuals with 
a diverse array of antibodies are better able to prevent spread of new HCV variants 
within the liver, and therefore could have slower progression of disease. Of note, the 
‘broadly neutralising’ group was also significantly younger with lower BMIs. There is 
already evidence that those infected with HCV in older age have more rapid disease 
progression (212) and the cellular aging process is linked to progression of liver 
disease with biomarkers of ageing shown to have an association with liver disease 
progression in HCV infection(272, 273). From an immune perspective  the  breadth 
of the B cell repertoire narrows with age (274). In addition, those with a higher BMI 
have been found to have shorter telomere length (a marker of ageing) within immune 
cells(275). Therefore a narrower breadth of neutralisation may reflect an ageing 
immune system in this population.  
It is also important to consider other possible confounding factors. If older patients 
were infected with an earlier strain of HCV virus, their antibody response may be 
more adapted to this older virus, whereas the viral sequences used in the IG1 panel 
were mainly derived from samples collected in the past decade. As HCV is 
constantly evolving in response to immune pressures placed on it by different hosts, 
these sequences may contain escape mutations from common responses to older 
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version of virus. This process of immune evasion has been documented within 
individuals by Dowd et al. (137). 
It is not clear why these associations were not observed from testing for antibody 
breadth against panel XG. It may be these associations are gt 1-specific or simply 
caused by limitations due to smaller numbers of genotypes used to determine 
‘breadth’ in the cross-genotypic panel. It is also important to remember that genotype 
is not a good predictor of ease or difficulty of neutralisation (276). Some individuals 
who had narrow XG neutralisation profiles showed broad neutralisation activity 
against the IG1 panel. As the XG panel was selected solely based on genotype it 
may not have provided an adequate array of variation at key epitopes (e.g. aa 412 to 
445, which contains key binding regions for monoclonal bNAbs such as HC-11, see 
Fig. 3.11) to identify individuals with a broad antibody response. Conversely, it could 
be that some bNAbs may be gt1 specific.  
No association between levels of E1E2 binding and fibrosis was found. An earlier 
study showed an association between absorbance values against gt 1 envelope and 
fibrosis levels in chronically infected individuals, (277). I did not find any relationship 
between antibody binding to the autologous genotype and clinical outcomes 
although there was a trend towards cirrhosis in gt 1-infected individuals with poor 
binding to gt 1a E1E2 (P=0.10, Fig. 3.12). In light of the significant association 
between breadth of neutralisation and lower levels of fibrosis, this suggests that if 
anti-envelope antibodies do have a protective effect, this is most marked where the 
antibodies target regions necessary for virus entry.  
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Legend for Figure 3.11 on following page 
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Figure 3.11 Alignment of E1E2 protein sequences from the XG panel HCVpps 
Alignments of protein sequences for the E1E2 glycoproteins expressed on the HCVpps used in the 
XG panel were generated in Genomics Workbench 7.0. Sequences are labelled by genotype except 
H77 (gt 1a) and JFH-1 (gt 2a). Percentage conservation at each aa is indicated below the consensus 
sequence. Amino acid numbering relates to the H77 sequence. 
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Figure 3.12 Absorbance of IgG from gt 1 infected CHCV patients and presence of cirrhosis. 
Absorbance of purified IgG from individuals infected with gt 1 CHCV on gt 1a E1E2 was determined 
by ELISA as previously described. A standard curve of AP33 was used and the ratio of sample 
absorbance to absorbance of 1µg AP33 calculated. Individuals were categorised as having cirrhosis 
or not and the absorbance values between the groups compared using a Wilcoxon Rank Sum test. 
Mean and SD is shown. 
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3.10.3 HLA genotype and bNAb responses 
While there are many possible explanations why individuals may mount a bNAb 
response, the SNP typing assays confirmed that SNP rs9275224 in the HLA-DQ 
gene is associated with the development of bNAbs in gt 1-infected patients (133).  
Genes in this region have already been identified in genome wide association 
studies as one gene which seems to influence the outcome of HCV infection (278). 
Given that such genes are involved in antigen presentation it is plausible this may 
reflect restriction in CD4 presentation of epitopes to B cells. In contrast, no 
association with this SNP was observed in  the ability of IgG from gt 3-infected 
individuals to neutralise the standard gt 3a HCVpp (P=0.85, Fig. 3.13). This may be 
due to the limitations of small sample size and testing against one gt 3, alternatively 
it is possible that other HLA genes could be more important in humoral responses to 
infections of different genotypes. In support of this, recent research by the STOP 
HCV consortium, examining associations between amino acid polymorphisms and 
HLA type in gt 3 infected individuals, identified an association between 4 amino acid 
changes in E1E2 and HLA subtypes (aa 348I with B*13:02, 372I with C*08:02, 444Y 
with A*29:02 and 561L with C*15:02)(279). Similar research into viral characteristics 
and host HLA and neutralisation profiles would be useful in further determining the 
extent to which infecting viral strain and host genotype influence the development of 
bNAbs. 
As gt 3 developed predominantly in the Asian subcontinent it is interesting to note 
that the unfavourable alleles explored in my study are less common in non-
European, non-African populations (39% vs 47% in European populations(87)). 
Therefore gt 3 virus may have evolved to overcome the advantage that the 
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favourable alleles confer. Further studies will be required to distinguish between 
these possibilities. 
 
 
 
 
Figure 3.13 Percentage neutralisation of gt 3a HCVpps in individuals infected with gt 3 HCV 
analysed by rs9275224 genotype. 
Neutralisation assays of gt 3a HCVpps were conducted as described previously as was rs9275224 
genotyping. Percentage neutralisation of gt 3a HCVpp in individuals infected with gt 3 HCV was 
plotted against their rs9275224 genotype. The P value was calculated using a Wilcoxon Rank Sum 
test. Mean and SD is shown. 
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3.11 Chapter 3 Summary  
 Breadth of antibody binding to the whole E1E2 protein is associated with 
lower HCV viral load 
 Broad anti-HCV neutralising responses are associated with lower levels of 
liver fibrosis, raising the possibility for a protective role in chronic infection. 
 Older and more obese patients are less likely to display bNAb responses, the 
reasons for this are unclear. 
 Host HLA DQ genotype appears to play a factor in ability to produce bNAbs 
against gt1 HCV. Different host polymorphisms may be involved in producing 
antibodies targeted against different genotypes. 
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4 Investigation of neutralising antibody epitope 
targets and neutralisation-resistance mutations 
in chronically infected individuals 
[Some of the work described in this chapter has been published in Swann et al., J. 
Virol, 2016(251)  - the American Society of Microbiology copyright licence allows 
authors to reproduce their work as part of academic theses] 
4.1 Introduction 
Due to the error prone HCV NS5B RNA-dependent RNA polymerase, mutations in 
HCV sequences occur commonly with a large percentage of sequence variation 
between, and even within, genotypes(15). Selection of the variants produced 
within a host depends upon the fitness of the virus to infect and replicate and also 
on immune pressure from the host’s innate and adaptive immune systems(280). 
Only a small number of chronically infected individuals with bNAbs have been 
studied in detail with little information on the regions of the E1E2 glycoproteins that 
are preferentially targeted by the in vivo humoral response. A recent study 
demonstrated that some HCV infected individuals largely target one immunogenic 
domain whereas others produce antibody responses to multiple domains (118). 
The impact of antibodies binding different epitopes on neutralisation breadth has 
not been fully explored, although there are conflicting reports of simultaneous 
binding of antibodies targeting more than one region conferring additive or 
interfering effects on virus neutralisation (84, 281) . In addition, the underlying 
mechanisms by which some host and viral characteristics result in an effective 
neutralising immune response whereas others do not has not been fully defined. 
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Many examples of envelope amino acid substitutions  which alter the entry 
characteristics of HCV and susceptibility to neutralisation by various monoclonal 
antibodies have been identified (see Table 4.1). Mutational escape from 
neutralising antibody responses, observed both in vitro and in vivo, are well-
documented, with chronically infected individuals often possessing antibodies able 
to neutralise an earlier isolate of virus but not their current dominant strain (137). 
Viral diversification after acute infection has been associated with the likelihood of 
progression to chronic viral infection, perhaps because this gives the virus the best 
chance of escaping initial adaptive immune responses (282). Interestingly, several 
mutations that confer escape from broadly neutralising antibodies also appear to 
affect infectivity or use of certain entry proteins in functional testing (see Table 
4.1),  presumably because effective neutralising antibodies tend to target areas of 
the virus that are critical for cell entry. The mutations documented in Table 4.1 are 
in addition to information from alanine scanning data of antibody binding sites 
detailed in Table 1.2. 
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Table 4.1: Mutations detected in vivo or generated in vitro affecting cell entry or promoting 
escape from monoclonal antibodies 
Glycoprotein 
interactions 
affected by 
mutation 
Amino acid (aa) position 
change 
Effect Ref 
SRBI/CD81 I347L Rescues infectivity in Δ HVR-1 virus (283) 
SRBI L399R Key for interaction with SRBI (284) 
SRBI/CD81 Y507L,V514A,V515A Modulate dependence on SRBI (285) 
SRBI I262L, N415D Restore infectivity in Δ HVR-1 virus (286) 
SRBI/CD81 
G451R Reduces dependency on SRBI/ 
enhances neutralisation sensitivity (29) 
E1/E2 
interaction 
M308I, T330A, L345M 
Mutations restore infectivity and 
interact with aa 580-651 of E2 to 
enable Claudin-1 binding. (41) 
CD81 L438F Reduces CD81 binding (121) 
Cell entry F447 S458G, R478C Enhanced infectivity (287) 
CD81 
529-535 
Core CD81 binding region – does not 
tolerate escape mutations (121) 
CBH-2 D431G, A439E Escape from neutralisation (121) 
HC-11 
N434D, T435A and L438F 
Escape from neutralisation (NB 
reduction in infectivity) (121) 
AP33 
L413A, N415A, G418A, 
W420A Reduces binding of AP33 to E2 (146) 
AP33, HC-1 
N417S Allows escape from neutralisation by 
AP33 and HC1 due to alteration in 
the glycan shield (145) 
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AP33, CBH7, 
HC-1, HC-11 
Y611A, R614, C652A 
Reduces binding of AP33 and 
multiple conformational antibodies 
to E2. Probably changes structure (146) 
CBH-4B, CBH-
4D, CBH-4G, 
CBH-5 and 
CBH-7 
aa 611-631 
Reduces binding of multiple 
conformational antibodies to E2. 
Probably changes structure (288) 
HC-84, HC-
111, HC-33, 
AR3 
R424S 
Reduces neutralisation by polyclonal 
sera and monoclonal antibodies in 
an ancestral isolate “Bole” gt 1a but 
not in H77 (289) 
HC33, 
L403F, L408M 
Reduces neutralisation sensitivity to 
HC33  (290) 
AR4A 
L403F, L438V,S686T, V720I 
Reduces neutralisation sensitivity to 
AR4A (290) 
AR5A 
L665W Escape from neutralisation, requires 
compensatory mutations to maintain 
infectivity (291) 
HC84.22, 
CBH2, AR3A, 
CBH5, CBH2 
D431E, F560Y, I538V, 
Q546L, T563V Additive effect on neutralisation 
escape (292) 
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In order to identify which epitopes would be the optimum targets for vaccine 
design and which may be susceptible to viral resistance, it is important to detail the 
regions of the envelope protein targeted by those with a bNAb response and 
identify naturally occurring escape mutations. I aimed to determine common E2 
epitope targets for bNAb responses in gt 1 patients in the CHCV cohort and 
determine the impact of specific amino acid variations on virus functionality and 
susceptibility to antibody neutralisation. Several approaches were used to achieve 
these aims: 
 Performing competition assays with selected antibodies to known epitopes 
to determine sites targeted by the polyclonal IgG response of individual 
patients.  
 Analysing the sequence characteristics of HCVpps from the HCVpp panel 
less sensitive to neutralisation by individuals with bNAbs and by monoclonal 
bNAbs (251) (Chapter 3). By identifying common sequences in those 
resistant to neutralisation, I aimed to infer regions where escape from 
neutralising responses may occur. 
 Studying the proportion of synonymous to non-synonymous nucleotide 
substitutions in viral sequences derived from the same patient in order to 
identify regions of the virus where mutations are advantageous to survival 
and regions where conservation of sequences is necessary. For those 
regions where mutation is advantageous, immune selection pressure can 
be inferred(292).  
 Characterising the infectivity and susceptibility to neutralisation of HCVpp 
bearing closely related E1E2 sequences isolated from a single patient. By 
aligning sequences and grouping them by functional state I hoped to 
identify any single aa changes associated with change in functional status. 
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 In addition, I also aimed to determine if sensitivity to neutralisation was 
related to dependence on the cell entry protein SR-BI as previous groups 
have identified single aa mutations which can alter dependency on this 
molecule. 
4.2 Common epitope targets of the broadly neutralising 
polyclonal IgG response 
4.2.1  Competition ELISA for the identification of E2 epitopes 
targeted by patient IgG 
In an effort to gain an understanding of the epitopes targeted by the IgGs from 
individuals with bNAb, I performed competition ELISAs using IgG from the 20 gt 1-
infected patients that were tested for their ability to neutralise the IG1 panel 
(Chapter 3 Section 6, Table 3.7). These individuals had been categorized as 
broadly neutralising or narrow neutralising depending on the number of HCVpp 
strains in the IG1 panel they could neutralise.  
Competition ELISA assays were designed to determine if patient derived IgG 
competed for binding to gt 1a sE2 with a panel of 6 well-characterized neutralising 
and non-neutralising anti-E2 monoclonal antibodies (HmAbs: CBH-4B, HC-1, HC-
11, CBH-7, HC-84.1 and  mAb AP33). Several of these antibodies bind to non-
competing regions of the E2 protein and therefore have been described as 
targeting different immunodomains. Non-neutralising HmAb CBH-4B binds to a 
region designated immunodomain A, the neutralising HC-1and HC-11 bind to 
immunodomain B, which contains the CD81 receptor binding sites. CBH-7 and 
HC-84   also neutralise and bind to immunodomains C and D respectively  (120). 
Lastly, the neutralising mAb AP33 binds to the linear epitope aa412-423 (also 
referred to as immunodomain E). Further details of the competition ELISA assay 
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are given in Materials and Methods and more information on binding sites of these 
antibodies is presented in Tables 1.2 and 2.5.  
 Six of the ten patient samples identified as broadly neutralising in the intra-
genotypic analysis (see individuals neutralising >7/11 HCVpp strains in the IG1 
panel, Table 3.7) competed with at least 3 of the HmAbs tested at the 50% level, 
and 9/10 reduced binding of 3 of the HmAbs by 45% or more. Conversely, in the 
narrow neutralising samples only one competed with more than 2 HmAbs at this 
level (sample 1010, Table 4.2). Furthermore, while 15/20 samples tested 
competed with HmAb HC-11 at the >50% level, the majority of those with broad 
neutralising activity inhibited HmAbs CBH-7 and HC-11 binding by >50% (6/10) 
compared to (1/10) of narrow neutralising samples. There was also a significant 
association of percentage inhibition of these antibodies with inter-genotypic 
neutralisation breadth (P=0.02) (Fig.4.1). Together these data suggest that those 
with a broadly neutralising phenotype tended to compete with antibodies at 
multiple sites on E2 within more than one immunodomain whereas those with a 
narrow neutralising profile target limited numbers of neutralising epitopes. 
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Table 4.2 Competition of purified patient IgG with mAbs to specific epitopes on E2 
Patient 
IgG 
  
Neutralisation 
Breadth in 
panel IG1   
  
Immunodomain No. 
domain
s bound 
 aa412-
423 A C         B                          B/D 
AP33 CBH-4B CBH-7 HC-1 HC11 HC-84 
1001/00 Narrow 18.3 19.9 22.9 51.9 58.7 11.2 1 
1002/00 Narrow 7.2 1.0 1.1 0.0 4.7 -2.1 0 
1010/00 Narrow 33.2 48.5 76.4 55.2 82.7 9.5 2 
1022/00 Narrow 0.4 20.3 22.9 57.6 73.4 9.1 1 
1030/00 Narrow 13.4 16.7 15.2 0.6 36.3 6.5 0 
1034/00 Narrow 10.0 5.4 26.3 3.6 43.5 20.6 0 
1036/00 Narrow -0.1 -13.7 1.9 35.3 65.3 14.9 1 
1037/00 Narrow 6.4 6.4 9.0 7.8 32.2 14.5 0 
1045/00 Narrow 7.9 20.7 20.9 39.6 26.4 0.7 0 
1047/00 Narrow 12.3 16.5 29.1 62.5 71.9 12.6 1 
1072/00 Narrow 8.2 16.6 14.3 53.2 56.1 12.6 1 
1003/00 Broad 5.7 26.1 71.7 80.4 77.9 37.5 2 
1012/00 Broad 43.8 58.3 76.0 46.8 75.3 15.8 3 
1013/00 Broad 33.9 9.9 6.1 14.1 57.0 13.1 1 
1016/00 Broad 3.4 10.2 47.0 75.8 75.0 30.6 2 
1023/00 Broad 19.5 37.3 82.8 68.9 77.5 -1.8 2 
1031/00 Broad 10.9 49.4 50.2 51.5 83.4 13.9 2 
1032/00 Broad 28.2 44.7 85.7 70.0 92.4 26.6 2 
1035/00 Broad 8.6 18.0 53.9 63.2 77.4 20.1 2 
1112/00 Broad 14.5 24.4 48.2 69.3 74.0 18.0 2 
         
 
Competition ELISA of gt1 patient IgG with E2 monoclonal antibodies CBH-4B, HC-84, AP33, CBH-
7, HC-1 and HC-11 was performed as described in Materials and Methods. The mean percentage 
of competition (i.e. reduction in binding of the monoclonal antibody) from 3 independent 
experiments is shown with higher percentages being highlighted in green whereas lower 
percentages are shown in red. Samples categorisation as broad or narrow neutralisation breadth is 
based on the number of strains of HCVpps neutralised in the IG1 panel as shown in Table 3.7.  
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Figure 4.1 Association of competition of patient IgG against CBH-7 and HC-11 with breadth 
of neutralisation status 
A competition ELISA of gt1 patient IgG with E2 monoclonal antibodies including CBH-7and HC-11 
was performed as described in materials and methods. Briefly Immulon II plates (Nunc) were 
coated with sE2 and incubated with purified patient IgG at 200 µg/ml in PBSTM for 1h. 
Subsequently, monoclonal antibodies (mAbs) (listed in Table 2.5) to discrete E2 immunodomains 
(119, 120, 145) were added at a concentration close to their EC50. The mean reduction in relative 
binding of each HmAb (calculated as percentage reduction in absorbance) on addition of patient 
IgG compared to PBSTM control was determined for each IgG sample. Competition for binding at 
these sites was compared between IgG samples classed as broad neutralisers and narrow 
neutralisers against the IG1 panel. P values were calculated using the Wilcoxon Rank Sum test. 
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4.2.2 Bioinformatic analysis of potential linear epitopes targeted 
by broadly neutralising polyclonal IgG responses 
As sequence data were available for all of the 11 E1E2 proteins used in the intra-
genotype 1 panel I aimed to determine if further bioinformatics analysis could 
identify linear antibody targets of the polyclonal responses of patient IgGs tested 
against this panel. 
Dr Sreenu Vattipally from the Bioinformatics department at our Centre developed a 
program to cluster the HCVpp sequences in the panel using 10 and 20 amino acid 
(aa) sliding window. This program also compared the similarity of the clustering of 
HCVpp E1E2 sequences in each window to the pattern of clustering by the ability 
of each individual patient’s IgGto neutralise the different HCVpp strains in the 
panel. As a control, the HCVpp neutralisation data for HmAbs HC-11 and HC-84.1, 
which have well characterised binding sites, was also included in the panel. For 
some of the windows an association was noted between HCVpp sequence 
differences at particular windows and the ability of patient derived IgGs to 
neutralise these HCVpps. These sequence windows were then flagged up as 
potential antibody binding sites for the patient derived IgG. 
From this, predicted antibody binding sites were generated for some of the patient 
derived IgGs. Identified targets are listed in Table 4.3 below. For the HmAb HC-11, 
a region containing one of its previously identified binding sites (aa429-449) was 
located by the program. Some of our patient samples were also found to target 
similar regions to the shared HC-11/HC-1 binding site which complements the 
findings of patient IgG competition with HC-11 in the competition ELISA (see Table 
4.2).  
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This analysis works on the basis that amino acid mutations in regions targeted by 
patient antibodies will reduce neutralisation overall. Of the five patients identified 
as targeting the shared HC-11 binding sites on bioinformatics analysis, two did not 
display significant cross-competition with any other broadly neutralising HmAb in 
the competition ELISA. This suggests that the majority of their neutralising 
antibody response may be directed against this region and that mutations here 
may confer resistance to their neutralising antibody response. For individuals with 
a polyclonal response targeting multiple epitopes, this program may have difficulty 
determining which regions are targeted as they may still be able to neutralise in 
the presence of mutations conferring resistance at one epitope.  In addition, this 
bioinformatics analysis only looks for linear clustering of amino acids which limits 
its sensitivity as many bNAbs target discontinuous epitopes.  This is supported by 
the fact that the majority of patients tested appeared to have antibodies competing 
with HC-1 and HC-11 but only 5 were detected by the program. 
Other sites identified in some of the broadest neutralising individuals were not 
tested for in the competition ELISA, such as aa 632-642. It may be that mutations 
in this region confer a conformational change in other areas targeted by their 
antibody response. Using  alanine scanning mutagenesis, Pierce et al 
(2016)(145),  showed that mutation of single amino acids in the region 638-644 
reduced binding of  E2 to CD81 and multiple conformational antibodies (HC-1, HC-
11,CBH-7 and HC-84). However, alanine scanning is not reliable in predicting the 
effect of substitutions with other amino acids more commonly seen in vivo. The 
effect of mutations in this region on bNAb efficacy requires further investigation.  
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Table 4.3 Predicted E2 antibody binding sites from bioinformatics analysis of neutralisation 
patterns.  
Predicted E2-antibody 
binding sites based on 
subsequence clustering 
 
Start Site 1 
 (aa) 
End Site 1 
(aa) 
Start Site 2 
(aa) 
End Site 2 
(aa) 
C1001 613 623 
  C1003 427 449 
  C1010 427 449 
  C1022 437 453 
  C1023 563 573 632 642 
C1031 401 411 428 449 
C1032 415 425 
  C1035 400 410 
  C1036 437 453 
  C1037 393 408 
  C1072 400 411 
  C1112 563 573 632 642 
HC11 429 449 
  HC84-1 437 453 
   
Sequence and neutralisation data were entered into a bespoke bioinformatics programme created 
by Dr Sreenu Vatiipally. This identified similarities short windows of HCVpp amino acid sequences 
with their sensitivity to neutralisation by patient derived IgGs or HmAbs. Only those samples where 
a probable site of antibody binding was identified are included in the table below. No probable sites 
of binding were found for patient samples 1012, 1013, 1016, 1022, 1030, 1034, 1045 and 1047. 
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4.3 Within patient amino acid variation and escape from 
autologous antibody responses 
4.3.1 Amino acid selection within individual patients (dN/dS data) 
In order to gain more information about the viral sequences targeted by 
individual’s neutralising responses, I selected samples from a number of gt 1 virus-
infected individuals from the CHCV cohort for clonal sequence analysis. This is 
described in more detail in Methods and Chapter 3 Section 3. Briefly, viral RNA 
was extracted from serum, cDNA libraries generated using random hexamers and 
E1E2 sequences were amplified using a gt 1-specific degenerate primer set (see 
Table 2.3, Methods). Resulting products of the expected size (1.8 kbp) were 
excised from agarose gel and extracted using a Qiagen Gel Extraction kit before 
inserting into the pENTR/DTOPO entry vector and transforming competent E. coli 
to enable clonal sequencing. 
E1E2 amplification and subcloning of product in the pENTR D-TOPO vector 
proved challenging, therefore while sequencing was attempted for 15 patients, 
only 6 samples yielded more than 5 clones containing full length E1E2 (sample 
IDs 1012, 1013, 1034,1037,1047,1112). For one of these individuals (1047) 19/20 
clones isolated were identical. For the other 5 patients, sequences from all clones 
generated were aligned and dN/dS plots were generated using MEGA 6 software. 
These plots compare the proportion of nucleotide substitutions at each codon 
which result in no amino acid changes (synonymous or dS) compared to those 
which result in an amino acid change (non-synonymous or dN). A negative value 
indicates amino acids which are relatively conserved with positive values 
indicating a tendency towards mutation (Fig. 4.2 a-f). The HVR-1 region (aa384-
411) was the most mutated in all individuals with the exception of some conserved 
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amino acids (402 and 403) within this region as previously reported (39). When 
overall dN/dS scores were compiled for the 5 individuals studied, some commonly 
conserved and mutated regions were identified. These are listed along with any 
previously defined function in Table 4.4a and 4.4b and shown relative to key E2 
regions in Fig. 4.3. It should be noted that while some of the individual dN/dS 
scores were positive or negative across patients tested, none of the values 
reached a p value of <0.05 at any of the amino acid positions, likely due to the 
small number of sequences included. Therefore, no firm conclusions can be drawn 
from this data.  
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 Figure 4.2 dN/dS plots of sequences from individual patients.  
The sequence for E1E2 was amplified as described in Materials and Methods and the subsequent 
PCR product cloned and sequenced using Sanger sequencing. Nucleotide sequences were 
aligned and analysed using the MEGA6 Hy-Phy programme to give a value for the ratio of 
nucleotide changes with alteration of an amino acid compared to the number of nucleotide changes 
associated with conservation of the amino acid. A positive ratio reflects relative positive selection of 
aa mutations whereas a negative ratio suggests relative conservation of the region. dN/dS ratio 
values are plotted for each amino acid with E1 starting at 192 and E2 terminating at aa746. None 
of the ratios reached statistical significance therefore P values have not been shown.  An average 
dN/dS ratio for each position from all of the sequences was calculated and plotted in (A). The 
individual dN/dS plots are also shown from B-F from samples 1012 (B), 1013 (C), 1034(D), 1037 
(E) and 1112 (F).  
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Table 4.4a Most conserved regions according to dN/dS ratio.  
Conserved 
Regions 
dN/dS 
(Sum) 
Description Ref 
Amino Acid  
Position 
 
 
644 
-12.12 
Cysteine 
(293) 
(44) 
 
291 -9.16 Potential fusogenic region of E1 (294) 
304 -9.16 Cysteine (293) 
273 -9.00 Just before fusogenic region (294) 
560 -6.01 
Ectodomain - Mutation confers resistance to bNAbs - 
possible CD81 binding role or structural role. 
(292) 
 
419 -6.00 Conserved CD81 binding region targeted by AP33 antibody (129) 
465 -6.00 Unknown  
429 -6.00 End of HmAb HC-11 epitope (121) 
508 -5.96 Cysteine (44) 
226 -5.91 E1   
201 -5.85 
HmAb H-111 epitope (antibody to this region blocks viral 
attachment to cells and infectivity) 
 (122) 
452 -4.95 Cysteine (44) 
340 -4.94 E1 – unknown Function (294) 
289 -4.79 Fusogenic region of E1 (294) 
250 -4.43 E1  
281 -4.26 Fusogenic region of E1 (294) 
330 -4.00 E1 interaction with E2 (41) 
383 -4.00 E1/E2 junction  
290 -3.89 Fusogenic region of E1 (294) 
403 -3.42 A Conserved amino acid in HVR-1 (39) 
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Table 4.4b Most mutated regions according to dN/dS ratio. 
Variable 
regions:  
 
dNdS 
(Sum) 
Description Ref 
Amino Acid 
Position  
  
397 2 HVR-1  
400 1.88 HVR-1  
394 1.82 HVR-1  
398 1.61 HVR-1  
405 1.6 HVR-1  
396 1.52 HVR-1  
501 1.5    
241 1.5 E1  
515 1.47 Region determining SRBI dependence (285) 
404 1.37 HVR-1  
388 1.33 HVR-1  
646 1    
395 0.96 HVR-1  
359 0.92 E1  
466 0.92 Non-neutralising linear antibody domain before HVR-2 (295) 
399 0.92 HVR-1  
532 0.88 Near HmAb HC-11/HC-84 binding region (124) 
733 0.86 E2 transmembrane domain  
446 0.84 Target for multiple monoclonal antibodies  
253 0.84 E1 (124) 
586 0.81 E1 interaction site (41) 
MEGA 6 software was used to calculate the dN/dS ratio for each codon position for the 5 patients 
studied. The sum of the ratio for all samples at a single codon position was calculated to determine 
if there were any commonly conserved or mutated positions. The literature was then examined to 
determine if these had previously been documented. The table shows aa position and function of 
the 20 most conserved and 20 most variable aa positions with references given where available. 
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4.4 Interaction of autologous virus with host IgG in broad 
and narrow neutralising profile patients 
In individuals with more than 5 E1E2 sequences obtained on clonal analysis, these 
sequences were inserted into a phCMV expression vector as described in 
Materials and Methods. The resulting expression vectors were tested for their 
ability to generate functional HCVpp. In 3 individuals, more than one E1E2 
sequence produced functional HCVpps. Infectivity data for the sequences from 
patient 1012 is shown in Chapter 3, Fig. 3.3b. Infectivity data for patient 1047, 
1013 and 1034 are shown below (Fig. 4.4a,b and c respectively). For patient 1047, 
sequence 1047-16 was approximately tenfold less infective than 1047-10. These 
were the only clones tested for patient 1047 as all of the other sequences obtained 
were identical to 1047-10. For the sequences tested from patient 1013, two out of 
4 HCVpps showed infectivity at comparable levels. While other sequences were 
identified from this patient, several of these were not in frame in the directional 
cloning vector could not be transferred to the expression vector for analysis of 
functionality.  From all the sequences tested in the HCVpp system for patient 
1034, only one sequence (1034-11) showed significant infectivity to allow 
neutralisation assay testing although 1034-14 shows probable infectivity (Fig 4.4c). 
Only one sequence from patient 1037 was functional in the HCVpp system (1037-
04).  
 I subsequently tested the ability of serial dilutions of autologous IgGs from 
patients 1012, 1013, 1047 and 1037 to neutralise these sequences in vitro (Fig. 
4.5) as described in Materials and Methods. Results of these assays were 
analysed alongside sequence data available for the clones from each patient and 
previous information about antibody targets and neutralisation ability of the patient 
derived IgG from the assays described in Chapter 3. The key findings from the 
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sequence analysis and dN/dS plots of sequences derived from individual patients 
in addition to autologous neutralisation assays (where it was possible to perform 
these) are detailed below.  
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Figure 4.4 Infectivity of HCVpp bearing E1E2 derived from patients 1047, 1013 and 1034 
Huh7 cells were infected with HCVpp bearing different E1E2 sequences from patients (A) 1047, (B) 
1013, and (C) 1034. At 72 h post-infection, cells were lysed and the level of infectivity determined 
by measuring the luciferase activity as relative light units (RLU). HCVpp carrying E1E2 from the gt 
1a isolate H77c or no envelope were used as positive and negative control, respectively. Values 
shown are the mean result from three independent assays. Error bars show the SEM.   
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Patient Sequence Autologous IgG IC 50 ( µg/ml)
1012-01 12
1012-02 26.1
1012-06 22.6
1012-10 22.8
1012-22 23.2
Patient Sequence Autologous IgG IC50 ( µg/ml)
1013-01 101
1013-05 97
Patient Sequence Autologous IGg IC 50 (µg/ml)
1047-10 (478S) 25
1047-16 (478N) 75
Patient Sequence Autologous IgG IC50 ( µg/ml)
1037-04 9.8
 
 
 
 
 Legend for Figure 4.5 on following page 
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Figure 4.5 Relative neutralisation of patient-derived HCVpp by IgGs of autologous sera. 
IgG was purified as described in Materials and Methods. HCVpp bearing E1E2 from different 
strains of envelope sequence derived from subject A) 1012, B) 1047, C) 1013 and D) 1037 were 
generated as described in Materials and Methods. 40µl of HCVpp containing media was incubated 
with decreasing dilutions of IgGs for 1 hour prior to adding to Huh7 cells. Percentage neutralisation 
of HCVpps was determined by calculating the relative percentage reduction in light units in wells 
with IgG compared to a PBS control. % Neutralisation is plotted against log concentration of IgG 
with error bars representing SEM. Relative IC50 values, as calculated using Graphpad Prism 6 
software, are shown below each figure.  
 
4.4.1 Analyses of the viral E1E2 sequences derived from patient 
1012 
For patient 1012, 20 diverse E1E2 sequences were identified by clonal 
sequencing. After constructing a phylogenetic tree (see Fig. 3.3a Chapter 3), 9 
sequences representing the main clades had been selected for testing in the 
HCVpp system as described above. Of these 9, 5 were functional. From the 
neutralisation assay with autologous IgG, it became apparent that one of these, 
HCVpp 1012-01, was more sensitive to neutralisation by autologous IgG than the 
others (Fig. 4.5a). Analysis of a protein alignment in using MEGA 6 software was 
performed to determine any unique aa changes in this sequence (Fig. 4.6). 
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 Figure 4.6 Variable amino acid positions from alignment of E1E2 sequences derived from 
patient 1012.  
Sequences from patient 1012 which are functional in the HCVpp system were translated into 
protein and aligned using MEGA 6 software. They were organized according to sensitivity to 
neutralisation by autologous IgG. Non-conserved aa between all sequences are show in the figure 
above. Amino acid changes which are unique to sequence 1012-01 are highlighted. 
 
 Analysis of the alignment revealed sequence 1012-01 had 4 unique aa 
differences compared to the other patient 1012 sequences tested in the HCVpp 
system: A223T L441F, S449F and P471L. The second of these, L441F, lies in a 
region identified as a key CD81 binding site and is targeted by a number of 
broadly neutralising monoclonal antibodies including HC-1 and HC-11and HC-84. 
IgG from this patient was previously shown to competitively inhibit binding of HC-
1and HC-11 to E2 (Table 4.2) suggesting this individual has antibodies which bind 
in this region. S449F is adjacent to the 451 site identified by Grove et al as 
responsible for a SRBI entry-protein usage switch(29). The final aa change is in a 
region recognized by a linear antibody AP320 produced from mouse immunization 
studies within our lab (259) but is not known to be important in viral neutralisation.  
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The dN/dS plot for all twenty sequences isolated from pt 1012 (Fig. 4.2b) reveals 
areas of higher levels of non-synonymous mutations between 385 and 415 (HVR-
1). Other areas of a high (>1) dN/dS ratio include aa 423-429 (CD81 binding 
region, target of HC-11 like antibodies), 443-446 (another CD81 binding region 
and target of HC-11 like antibodies), 460, 495, 509 and 511.  
4.4.2 Analyses of the viral E1E2 sequences derived from patient 
1047 
While 20 clones were isolated from pt 1047, only clone 1047-16 differed from the 
other 19 by a single amino acid change, S478N, which lies within the HVR-2 
region of E2. Therefore HCVpp 1047-16 (N478) was tested along with HCVpp 
1047-10 bearing the majority sequence (S478) for neutralisation by IgGs derived 
from the autologous serum. S478 had an IC50 3 times lower than N478 (Fig. 
4.5c). This serine to asparagine change in 1047-16 creates a potential N-linked 
glycosylation site in HVR-2. Further testing is required to confirm if this site is 
targeted directly by the individual’s Nabs or whether it induces some other 
conformational change allowing escape. Interestingly a study by Falowska et al. 
(2007) showed that adding a glycosylation site at aa 476 increased cell entry and 
decreased sensitivity to neutralisation, therefore it is plausible that the introduction 
of an additional glycosylation site adjacent to this region might amplify this 
effect(296).  
IgGs from this individual compete with antibodies recognizing the E2 CD81 binding 
epitopes (HmAbs HC-1 and HC-11) (Table 4.2). It is possible that additional 
glycosylation of a region around aa 476 impairs binding at these regions.  Escape 
from a neutralising response would usually result in positive selection, however, 
N478 is only a minority variant in our clonal analysis. As the other 19 sequences 
are the same and this mutation occurred distant to primer sites, it is unlikely to be 
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a result of PCR bias, however it is possible that this mutation was introduced as an 
error at the reverse transcription stage. Nevertheless, it is still interesting to study 
the effect of this amino acid change. Infectivity in the N478 HCVpp appears to be 
slightly lower than S478 (Fig. 4.4a) and the site 478 appears well conserved in gt 
1a (>95% S, the next common variant being T) in an alignment of over 300 gt 1a 
E2 sequences from the Los Alamos database (data not shown) and conserved in 
80% of all gt 1 E1E2 sequences held in the Los Alamos database (see Fig 1.12) 
therefore there may be some fitness cost to adding a glycosylation epitope at this 
site. McCaffrey et al showed that HVR-2 is essential for correct envelope formation 
and infectivity of virus suggesting that key mutations in this region may impair viral 
assembly or cell entry (286). 
4.4.3 Analyses of the viral E1E2 sequences derived from patient 
1013 
From the 7 E1E2-encoding sequences generated from this patient, 2 HCVpp 
derived from them were functional on testing in the HCVpp system. While IgG from 
patient 1013 showed strong neutralising activity against other gt 1 HCVpp, e.g. 
being able to neutralise 5 of the HCVpp in the previously described intra-genotype 
1 panel by >80% at 100 µg/ml (Table 3.7 Chapter 3), it has relatively weak 
neutralising ability against its own E1E2 sequences with an IC50 of approximately 
100 µg/ml (Fig. 4.5c).  
Sample 1013 is also intriguing as despite its IgG being a broad neutraliser of the 
IG1 panel, it has relatively poor ability to neutralise other genotypes in the XG 
panel. It also shows competition with HmAb HC-11-like antibodies and displays a 
degree of competition with mAb AP33 but not with HmAbs HC-1 or CBH-7 (Fig. 
4.1). 
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Analysis of dN/dS ratio shows evidence of selection for most variability in the E2 
HVR-1 and also some strongly selected sites in E1 (aa201), E2 aa 491, 502 and 
also the E2 heptad repeat region (Fig 4.2) (a structural motif found in viral fusion 
glycoproteins consisting of a repeating sequence of seven amino acids). This is 
interesting as this region is generally conserved (40). There is very little variability 
seen around the known CD81 binding regions targeted by many bNAbs, although 
some of these will be conserved to preserve infectivity. It is possible that the 
circulating variants sequenced have successfully escaped from antibodies directed 
at these regions and are no longer under immune pressure to mutate further, as 
reflected by low neutralising titre. Indeed the HCVpp derived from patient 1013 
was poorly neutralised by both monoclonal bNAbs and IgG derived from 
chronically infected patients in our panel experiments (Chapter 3, Table 3.7) 
Negative selection of persistent variants in chronic infection is a well described 
phenomenon with resultant narrowing of viral diversity(297, 298). Alternatively,  
host antibodies may be targeting regions/residues outwith these epitopes. 
4.4.4 Analyses of the viral E1E2 sequences derived from patient  
1034  
Clonal analysis for patient 1034 identified 20 diverse sequences. These were 
aligned and a phylogenetic tree constructed (Fig. 4.7). Four sequences from 
separate clades were selected for testing in the HCVpp system, unfortunately only 
one of the HCVpp tested was functional (1034-11, Fig. 4.4c). Although this HCVpp 
is relatively easily neutralised by the individuals with broadly neutralising 
antibodies, IgG from 1034 was unable to neutralise this HCVpp at a concentration 
of 100 ug/ml (data from IG1 panel, Chapter 3, Table 3.7), therefore a 
dose/neutralisation curve was not performed. This is consistent with the 
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classification of IgG from patient 1034 as poorly neutralising when tested against 
the IG1 panel (Chapter 3.6) 
 
Figure 4.7 Phylogenetic tree of sequences isolated from patient 1034. 
Five sequences were excluded from the alignment as they were incomplete. The evolutionary 
history for the remaining 15 sequences was inferred by using the Maximum Likelihood method 
based on the Tamura-Nei model(257). The bootstrap consensus tree inferred from 100 replicates is 
taken to represent the evolutionary history of the taxa analysed. Branches corresponding to 
partitions reproduced in less than 50% bootstrap replicates are collapsed. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test (100 replicates) 
are shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically 
by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using 
the Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior 
log likelihood value. The analysis involved 16 nucleotide sequences. Codon positions included 
were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. 
There were a total of 1726 positions in the final dataset. Evolutionary analyses were conducted in 
MEGA6(16). 
 
dN/dS analysis of the regions of E1E2 which are relatively mutated or conserved 
in the variants available by clonal analysis reveals evidence of selection in the 
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regions aa 443, aa 445 and aa 530-538 which are regions targeted by the HmAb 
HC-11. This would fit with the finding that this individual has evidence of antibodies 
which compete with HC-11 but not with HC-1 (see Figure 4.1a). It is possible that 
mutations in this region to escape antibody pressure have resulted in an infectivity 
cost in the variants sequenced. dN/dS analysis also shows some evidence of 
selection at aa 647-648 and aa 668. The importance of these regions in cell entry 
and neutralisation has not yet been demonstrated.  
4.4.5 Analyses of the viral E1E2 sequences derived from patient 
1037 
Six viral sequences were obtained for pt 1037. Three of these were tested for 
infectivity, however only one of these (1037-04) was found to be sufficiently 
infective in the HCVpp system for use in neutralisation assays. This sequence was 
neutralised by autologous purified IgG with an IC50 of 9.8 µg/ml (Fig.4.5d). 
The IgG derived from patient 1037 was found to have a narrow neutralising 
capability when tested against the Gt1a panel (Chapter 3 Table 3.7). 
Bioinformatics analysis (Section 4.2.2) identified HVR-1 as a potential target for 
antibodies from this patient. Indeed, dN/dS plots revealed the most variable aa 
positions were within the HVR-1 region or E1 (Fig 4.2e). In addition, the amino 
acid sequence was variable in the SRBI dependence region (aa 515) identified by 
Lavie et al.(285). Competition assays with HmAbs to known epitopes revealed no 
evidence of significant binding at these sites apart from weak inhibition of HC-11. It 
is therefore likely that this individual’s humoral response preferentially targeted the 
HVR-1 region with the virus adapting to remove dependence on HVR-1/SRBI 
interaction for cell entry. Immune responses preferentially targeting the HVR-1 
region are well documented in acute HCV and associated with progression to 
chronic infection (282).  
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4.4.6 Analyses of the viral E1E2 sequences derived from patient 
1112:  
While 10 sequences were identified on clonal analysis, unfortunately no functional 
HCVpps could be generated for these sequences. This individual did show 
evidence of broadly neutralising activity against 11 HCVpp strains in the IG1 panel 
however (Chapter 3, Figure 3.7), and so I examined sequence data for any 
evidence of selection pressure in the clones isolated. 
dN/dS ratio analysis showed peak areas of variability in E1 aa232-254, E2 HVR1, 
and separate E2 amino acids between 493 and 533 (Fig. 4.2f). This section 
contains a CD81 binding region targeted by the neutralising HmAbs  HC-1 and 
HC-11and the HmAb e137 which recognisesE2 residues W529, G530, and D535 
that are crucial for E2-CD81 interaction(299).  
4.5 Single amino acid changes associated with infectivity 
and resistance to neutralisation 
4.5.1 Non-infective E2 producing sequences 
As described above, some HCVpp incorporating E1E2-encoding sequences 
derived from patients were non-infectious. To test whether this phenotype was due 
to lack of viral glycoprotein expression or inability of specific E2 glycoprotein 
sequences to form infective HCVpp, the lysates of HEK-293T cells transfected 
with 8 constructs from patient 1012 were analysed for the presence of E2.  
For the purposes of this experiment, non-functional or non-infective sequences 
were designated as those which gave a RLU signal of <5 times the background 
(i.e. lysates of cells not transfected with E1E2-expressing construct) on testing in 
the HCVpp system. Functional sequences were determined as those with a RLU 
 215 
 
signal >10 times the background. One HCVpp (12-08) gave an intermediate signal 
therefore was included separately in the analysis. The lysates of the HEK cells 
used to produce these HCVpps were tested using an ELISA for binding to mAb 
AP33 and HmAb CBH-4B as described in Materials and Methods (Section 2.4.8). 
As a negative control, lysate from HEK cells transfected with a non E1E2 
containing plasmid was used. Presence of E2 was confirmed with an absorbance 
reading of greater than 2 times that of the negative control (see Fig. 4.8).  
For those non-infective clones where E1E2 production was confirmed, MEGA 6 
software was used to align these sequences with infective ones derived from the 
same individual and identify amino acid differences only present in non-infective 
isdolates. Comparison of amino acid changes unique to non-functional sequences 
highlighted several regions of importance (Table 4.5).  
Sequence 1012-11 has a single unique amino acid change (M/L608P) compared 
with infective sequences from the same patient. Mutations in this region have 
already been identified as having a dramatic effect on CD81 and conformational 
antibody binding(145, 288) and it is likely that rather than being a CD81 binding 
epitope per se, this region is critical for the structure of the envelope proteins 
facilitating correct binding. It is interesting to note, that while this sequence has 
clear evidence of AP33 binding, it gave one of the lowest positive values for 
conformational antibody binding, again suggesting disordered structure. 
The data also highlight the critical role of E1 which has been relatively neglected 
compared to E2. Two non-functional sequences showed single aa changes in the 
region 294-296 this is adjacent to Perez-Berna’s proposed fusogenic region of 
E1(294). Therefore, it is possible that these changes modulate the function of this 
region. Finally, the sequence from patient 1012-20 had 2 mutations compared to 
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infective strains, both at uncharacterized regions of E1 (R213H and G350D). 
Interestingly a recent paper described attenuated infectivity in a virus with an 
alanine inserted at aa 213. This strain also used a different class of Claudin to the 
un-mutated strain (Claudin-6 compared to Claudin-1 in un-mutated virus), and 
displayed reduced binding to CD81 which may have had an impact on infectivity in 
Huh7 cells (300). Further exploration of the effect of mutating these regions of E1 
may yield new insights into the E1 structure and role in HCV cell entry. 
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Figure 4.8  ELISA of HEK cell lysate transfected with plasmids containing E1E2 sequences 
from patient 1012 to determine E2 expression. 
 HEK cells were co-transfected with plasmids containing E1E2 sequences derived from patients 
1012 together with Gag-Pol and luciferase-expressing plasmids in order to create HCVpps (as 
described in Materials and Methods). Supernatant media containing HCVpps was filtered and 
tested for infectivity of Huh7 cells.  At 72 h post-infection, the infectivity was determined measuring 
luciferase activity as RLU reading 10 times greater than negative control (see figure 3.3b for 
infectivity data). ELISA of lysates from HEK cells transfected with pHCMV-E1E2 plasmids 
producing non-infective HCVpps was performed to determine synthesis of E2. Lysates were tested 
using A) a linear antibody (AP33) and B) conformation sensitive antibody (CBH-4B). Anti-mouse 
antibody A4416 and streptavidin-HRP respectively were used as a secondary substrate.  Lysates 
from HEK cells transfected with a pHCMV plasmid not containing a E1E2 sequence were used as 
a negative control.  Absorbance readings of two times control were used as a cut off to determine 
presence of E2. The results shown are from a single experiment containing 3 replicates. Error bars 
represent SEM. 
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Table 4.5 Mutations in non-functional E2 producing sequences compared to sequences 
from the same patient producing functional (infective) HCVpps.  
Isolate Amino acid changes*  Comments 
1012-08 S294P, S401N, V515M HVR-1 and SR-BI dependence switching regions(aa 515) 
(285)  NB intermediate signal for infectivity, see Fig 3.3b 
1012-11 M/L608P Possible role in structural integrity 
1012-20 R213H, G350D Possible effect on CD-81 binding and other entry protein usage 
 *Amino acid substitutions only found in non-functional sequences were noted and their 
function documented (where known).  
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4.5.2 Amino acid mutations associated with resistance to 
neutralisation by monoclonal antibodies and polyclonal 
patient-derived IgGs 
The experiments described in Chapter 3 using the IG1 panel of 11 gt 1a HCVpp 
characterized the ability of polyclonal IgG derived from single patients and HmAbs 
to prevent Huh7 infection by HCVpps bearing diverse envelope sequences. 
However, examining the patterns of HCVpp neutralisation across the panel, some 
HCVpp appeared relatively resistant to neutralisation by individual HmAbs and 
patient IgG samples. In particular those bearing UKN1A20.8 (1Av220), 1012-02, 
1013-01 and UKN1B_5.23 glycoproteins were only neutralised by a minority of 
patient IgG and HmAbs. (Chapter 3, Table 3.7 and Table 4.6).   
Table 4.6: Number of patient derived IgG samples and HmAbs able to neutralise each E1E2 
sequence in the HCVpp G1 panel.  
Sequence No. Individual patient 
 IgG samples  neutralising 
to >50%  (n=21)  
No. Neutralising Monoclonal Panel 
antibodies neutralising to >50%  
(n=4) 
1Av220 0 1 
UKN1B_5.23 3 3 
1013-01 9 0 
1012-02 11 0 
1Av93 12 2 
UKN96 13 2 
1034-11 17 2 
1037-04 18 3 
ET10 18 3 
H77 19 4 
UKN181 20 3 
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As sequence information was available for all of the HCVpps in the IG1panel, I 
aimed to analyse the sequences of the HCVpps resistant to neutralisation by the 
antibodies tested to determine if any particular amino acid changes in the 
envelope protein conferred this resistance. Figure 4.9 shows the percentage 
conservation of each amino acid in an alignment of the gt 1 E2 sequences used in 
the IG1 panel (A) in comparison with an alignment of all the E2 sequences stored 
in the  Los Alamos database (B). This gives a picture of the most variable regions 
within the protein and demonstrates that the amino acid variability within the IG1 
panel covers the majority of variable sites in genotype 1 sequences.  
Detailed methods for the testing of neutralisation against the IG1 panel are 
described in Materials and Methods. To identify aa changes which were 
predominantly found in neutralisation-resistant envelope sequences (and therefore 
could possibly be responsible for escape from neutralisation) I used a similar 
technique to that described by Bailey et al(292). Briefly, for each HmAb or 
polyclonal sera, HCVpp E1E2 aa sequences were aligned using MEGA6 software 
and arranged in order of resistance to neutralisation by that antibody. Amino acid 
differences from the sequence most sensitive to neutralisation were highlighted. 
Amino acid changes only present in HCVpp relatively resistant to neutralisation by 
a particular HmAb or polyclonal sera (i.e. infectivity over 50% in the presence of 
the patient IgG or monoclonal antibodies being studied) were identified manually 
from these alignments and recorded in Fig. 4.10a and 4.10b. Mutations present in 
all neutralisation-resistant HCVpp sequences but not sensitive sequences were 
colour coded in red as these are most likely to have an impact on function. These 
sites have also been shown on a linear diagram of E2 (Fig 4.11) alongside 
previously identified  naturally occurring escape mutants(292) and other relevant  
mutations from the literature as detailed in Table 4.2.   
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Figure 4.9 Percentage conservation of each amino acid position and consensus amino acid 
sequence in E2 for alignments of A) Panel of 11 gt 1 HCVpp E1E2 sequences B) All 
complete envelope sequences from Los Alamos HCV database.  
Alignments of all envelope sequences for A) the intra gt 1 HCVpp panel and B) complete E1E2 
sequences uploaded to the Los Alamos HCV database 
(https://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html accessed 23/02/2016) were created 
using MEGA 6 software. These were imported into the CLC Genomics Workbench 7 program 
which calculated percentage conservation at each amino acid position. 
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While no universal amino acid motifs were noted to confer resistance, both HCVpp 
1012-02 and 1Av220 contained the L442 mutation which has previously been 
associated with escape from neutralising monoclonal antibodies. Sequence 1012-
02 also bears the previously identified escape mutation E431 (292).  
Some of the other amino acid differences associated with mAb resistance fell in 
well-characterized binding sites for the broadly neutralising monoclonal antibodies 
used (e.g. 434, 438, 442, 444), however, others were distant to previously 
identified regions of escape (e.g. 500, 528, 570) (Fig. 4.11). Some of these sites 
have been identified as having functional importance in previous work (Table 4.2). 
In particular, Wasilewski et al identified aa570 as one which had mutated relatively 
early on in the evolutionary history of HCV suggesting that this region may play a 
key part in escape from the host  response (289). However, their study did not 
identify any advantage against neutralisation by polyclonal sera. 
 It is likely that some of the amino acid substitutions identified are coincidental or 
compensatory rather than being primarily responsible for resistance to 
neutralisation, while others may confer structural changes. Nevertheless, further 
characterization of these regions may yield helpful insights into the interaction 
between the immune response and HCV. 
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Figure 4.10 Amino acid (aa) position changes in HCVpps in sequences resistant to 
neutralisation by A) monoclonal antibodies and B) polyclonal IgG derived from patients.  
The ability of antibodies (either HmAb or patient IgG) to neutralise the 11 E1E2 HCVpps in the gt1a 
panel was determined as described in Materials and Methods. Subsequently the sensitivity of the 
panel to neutralisation by each individual HmAb / patient IgG was considered in turn. For the 
antibody being tested, the 11 E1E2 sequences from the IG1 HCVpp panel was categorized as 
resistant (<50% neutralisation), intermediate (<60% neutralisation) or sensitive (>60% 
neutralisation). An alignment of these 11 sequences was then analysed to determine if there were 
any aa changes only present in sequences resistant to neutralisation by the antibody being tested. 
Amino acid substitutions present in a majority of resistant +/- intermediate sequences but not in any 
sensitive sequences were identified. These were classified according to number of resistant 
sequences containing the mutation as follows: Weak (shown in green) present in 50% of resistant 
sequences and at least one intermediate sequence, Moderate (shown in orange): present in >50% 
of resistant variants +/- present in intermediate variants.  Strong (shown in red): Present in all 
resistant variants or a majority of resistant variants and a majority of intermediate variants. Aa 
positions are labelled. Those aa positions highlighted in red type were previously identified by 
Bailey et. al (2015)’s study of a intergenotypic panel tested against a number of monoclonal 
antibodies, including HmAb HC-11(292). 
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4.6 Differential use of the cell entry protein SRBI 
4.6.1 Use of the SRBI receptor and resistance to neutralisation 
The SRBI receptor is proposed to play an important role in HCV cell entry by 
binding to the E2 HVR-1 and inducing a conformational change in the envelope 
polyprotein which exposes the CD81 binding regions of E2(283). In vivo SRBI 
primarily functions as a high affinity receptor for HDL incorporating Apolipoprotein 
A-I(114). HCV lipoviral particles also incorporate this apolipoprotein which may 
enhance the use of this receptor to gain cell entry(301). In addition, HCV envelope 
protein mutations have been discovered that increase or decrease usage of SRBI 
and in some cases, alter sensitivity to neutralisation (285, 290).  SRBI 
dependence, unlike CD81 binding, can vary without necessarily compromising 
infectivity, as HCVpp are able to infect hepatocytes in the absence of HVR-1(286). 
In the dN/dS analysis of sequences from the CHCV cohort, HVR-1 was identified 
as the most variable region (Fig. 4.2).  
As discussed above, some HCVpps from the IG1 panel were less sensitive to 
neutralisation by patient IgG compared to others when expressed in the 
pseudoparticle system, namely 1012-02,1013-01, UKN1B_5.23 and 1Av220 (see 
Chapter 3 and Table 4.6). In addition, within patient 1012 sequences, increased 
sensitivity to autologous neutralisation was noted in sequence 1012-01 (Fig. 4.5a). 
Variable SRBI usage could explain some differences in neutralisation sensitivity 
observed in the patient-derived sequences. Therefore the diverse IG1 panel of 11 
HCVpp and four functional HCVpp derived from patient 1012 were tested for their 
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infectivity in the presence of serial dilutions of anti-SRBI antibody (further details in 
Materials and Methods).  
Among the IG1 panel of HCVpps, 2 of the sequences most resistant to 
neutralisation by monoclonal antibodies and polyclonal patient derived IgG also 
had reduced sensitivity to SRBI blockade (1012-02 and UKN1B_5.23) compared 
to the rest of the panel (Fig. 4.12a). However, sequence 1Av220, which was the 
most resistant to neutralisation in the IG1 panel, was sensitive to SRBI blockade 
compared to the other HCVpp tested. In addition, while sequence 1012-01 is more 
sensitive to neutralisation by autologous IgG than the other patient 1012 derived 
sequences, there was no appreciable difference in SRBI sensitivity (Fig. 4.12b: 
note no isolate had infectivity reduced by 50% even at a concentration of 10µg /ml 
of anti-SRB1 antibody).This suggests that even if SRBI dependence is responsible 
for modulating sensitivity to neutralisation in some isolates, this is not a universal 
feature.  
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Sequence IC50
1037-04 3.11
ET10 1
1Av220 0.03
1013-01 1.12
1012-02 >10
UKN1B_3.23 >10
1A H77 2.55
1034-11 3.11
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Figure 4.12: Comparison of sensitivity of HCVpp to SR-BI blockade. 
 A selection of HCV pseudoparticles derived from patient sequences were tested alongside the 
standard laboratory sequences H77 1A for ability to infect Huh7 pre-incubated with increasing 
concentrations of anti-SRBI antibody as described in Materials and Methods. A) Infectivity of 
HCVpp bearing sequences derived from different patients are shown against concentration of anti-
SRBI antibody. IC50s were calculated in GraphPad Prism 6 and displayed in a table below the 
graph. B) Infectivity of HCVpp bearing sequences derived from a single patient (1012) are shown 
against concentration of anti- SR-BI. As no concentration tested inhibited infectivity by 50% IC50 
calculations were unreliable and are not included in this graph. The results presented represent 
three independent experiments with each sample tested in duplicate, due to a shortage of HCVpps 
Av220 was not tested at the lowest concentration of anti-SRB1. Error bars are the SEM. 
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4.7 Chapter 4 Discussion 
4.7.1 Epitope targets of polyclonal bNAbs 
Our data suggests that those gt1-infected individuals who mount a broadly 
neutralising response direct antibodies at more than one neutralising domain on 
E2 i.e. domain B (targeted by HmAb HC-11) and domain C targeted by HmAb 
CBH-7. In contrast, those with a narrower neutralising response appear to target 
only one region, usually that recognized by the HmAb HC-11. Previous studies 
have shown that different regions of E2 interact to prevent neutralisation, with 
some requiring a conformation change to expose CD81 binding epitopes, 
therefore it is likely that an antibody response interfering with multiple regions of 
E2 may be more effective than a IgG targeting a single epitope (286). This is in 
keeping with recent data from Carlsen et al which demonstrated synergy in 
neutralisation when using a combination of two antibodies against differing viral 
glycoprotein domains(126) although a study examining the effect of AP33-like 
antibodies found interfering effects at lower concentrations(135).  
Bioinformatics analysis of E2 sequence and susceptibility to neutralisation by 
polyclonal IgG has confirmed the presence of antibodies to previously 
characterized targets such as the HC-11 binding sites. In addition, it also identified 
a linear epitope, aa 632-642, as having importance in antibody escape. This 
region has not been previously documented as having importance for bNAbs but 
has been shown to impact on CD81 binding in alanine scanning models(145). This 
finding requires further confirmatory testing in vitro. 
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Identification of epitopes targeted by bNAbs was restricted to the range of 
sequences contained in the HCVpp panel and by the monoclonal antibodies used. 
It would be possible to use alternative methods such as peptide and phage display 
capture, which divide E2 into small linear epitope portions to capture antibodies 
directed at these portions, to explore additional regions which may be important in 
bNAb binding. Studies of small cohorts of patients have characterised different 
immunophenotypes of anti-HCV antibody responses using such methods. 
However, these have limited ability to detect antibodies directed at discontinuous 
epitopes (118) therefore our data are a valuable complement to information that 
might be gained from such studies.  
4.7.2 Information gained from dN/dS ratio analyses 
While this analysis of individual amino acid mutations has focused on a small 
number of selected individuals, studying their viral sequences and antibody 
responses in depth yields some interesting findings. Examining dN/dS ratios 
highlights different domains which are likely to be under immune pressure from the 
host. Some of the variable regions identified corroborate information already 
gained from competition ELISAs indicating mutation to escape from immune 
pressure in known CD81 and HmAb binding regions such as aa446 and 532. 
Despite this, a few individuals had evidence of persistence of envelope sequences 
which were more sensitive to neutralisation by autologous IgG. While one might 
expect these variants to be eradicated in favour of more resistant variants, a 
recent paper has suggested that persistence of more antibody reactive variants 
may be beneficial to the persistence of resistant variants by maintaining an 
ineffective antibody response (termed antigenic co-operation)(302).  
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While non-conserved regions (i.e. positive dN/dS) were less consistent between 
individuals, some common areas of positive selection were highlighted. As 
expected, the highest ratios were found in E2 HVR-1 however some sites in E1 
and less well studied regions of E2 were revealed (e.g. aa 241,253,359,501 and 
646) , particularly in individuals with broadly neutralising antibodies. While it has 
not been possible to study these sites during the course of my research due to 
time constraints, future work involving identification and isolation of antibodies 
binding to these regions may help determine if they are contributing to the broadly 
neutralising response.  
4.7.3 Amino acid changes associated with resistance to bNAb 
and mAb neutralisation 
Despite being a marker of immune pressure, the dN/dS ratio data did not highlight 
all of the amino acid mutations associated with antibody resistance in the HCVpp 
panel. This may be because mutations which confer an advantage may already 
have been heavily selected for in the population. Therefore, evidence of this 
selection may be lost by sampling at a single time point. In addition, there are 
many limitations of clonal sequence analysis in analyzing viral population diversity 
and the number of clones we obtained was relatively small. However, studying 
within patient evidence of selection is a powerful tool which can give a more 
accurate picture of the effect of intra-host pressures than a simple comparison of 
all sequences stored in online databases.  Next generation sequence analysis of 
the whole envelope proteins and bioinformatics analysis of neutralisation against 
larger panels of envelope sequences will provide more robust tools for identifying 
areas of selection pressure from neutralising antibodies and escape.  
The analysis of aa mutations in resistant IG1 HCVpp sequences yielded a number 
of possible resistance mutations. Some of these have already been reported as 
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conferring resistance to bNAbs, in particular aa 438 for domain B antibodies(292).  
Despite this, polyclonal IgG from the broadest neutralising individuals tested were 
able to prevent infection by sequences which appeared resistant to neutralisation 
by the ‘broadly neutralising’ monoclonal antibodies in our panel. For example, 
patient 1012, from whom the sequence 1012-02, was derived, was able to 
neutralise this pseudoparticle with an IC-50 of 26.1 µg/ml. This suggests some of 
the antibodies contained within the isolate were capable of preventing cell entry 
despite mutations conferring resistance to anti-HCV IgG responses from other 
hosts. This may be due to production of a more potent bNAb, or may be explained 
by a synergistic effect of multiple bNAbs present in the polyclonal IgG response.  
In addition to the previously known aa substitutions conferring resistance to 
HmAbs, several new mutations which may be associated with escape from 
neutralisation were identified. In particular for the less well characterized HmAb 
CBH-7 aa 570 was identified as a possible site for escape mutations. Interestingly 
this site was one of the few not tested for its effect in Pierce et al’s study using 
alanine scanning to identify key antibody binding sites(145, 303). 
4.7.4 SR-B1 dependance and sensitivity to neutralisation 
It is intriguing to note that two of the most poorly neutralised E1E2 sequences in 
the panel tested (1012-02 and UKN1B_5.23) are relatively insensitive to SRBI 
blockade. This may be due to escape from the effect of anti-HVR-1 antibodies, 
produced in the majority of patients who progress to chronic infection. However, 
this would not explain its insensitivity to neutralisation by monoclonal antibodies 
targeting the CD81 binding regions. E2 HVR-1 has been proposed to have an 
important effect in shielding CD81 binding sites from the immune response, 
therefore structural changes which alter dependence on SRBI may also impact on 
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the ‘shielding’ effect of the hypervariable regions(286). However, a recent paper by 
Zuiani et al identified 9 mutations in the Gt 2a JFH-1 envelope sequence which 
increased sensitivity to bNAbs HC84.28 and H77.39 (which binds a similar region 
to AP33) and reduced dependence on SRBI for cell entry (304). This suggests that 
from the relationship between bNAbs sensitivity and SRB1 is complex. 
Our data has identified several regions on E2 which may be responsible for 
escape from bNAbs, some of which have not previously been described. The 
impact of single aa mutations on neutralisation sensitivity is difficult to define, as 
mutations conferring resistance in one viral strain may not have the same effect in 
another, presumably due to compensatory changes elsewhere in the envelope 
sequence(292). Further investigation of patients with bNAbs and in vivo escape of 
envelope proteins from recognition by these antibodies will help inform vaccine 
design. In addition, further work could include directional mutation of sensitive 
sequences to introduce amino acid changes at these sites to evaluate their impact 
on infectivity and resistance to neutralisation. 
4.7.5 Limitations of the findings 
While much previous work on neutralisation has focused on experiments using the 
HCVpp system (123, 276) as I have done in this set of experiments, this system 
does have some limitations. As mentioned previously, the structure of HCVpps is 
not identical to the envelope of live virus, especially as it does not incorporate lipid 
which can mask important epitopes(161). In addition, the assumption through 
studying neutralisation in vitro is that antibodies eliciting a strong neutralising 
response would likely be effective in preventing infection in vivo. However, in 
humans, many sub-viral particles are produced which do not contain viral 
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RNA(141). As these particles have no infectious potential but bind neutralising 
antibodies, these may reduce the impact of the antibody response in vivo. 
 
4.8 Chapter 4 Summary 
 Hepatitis C virus entry characteristics, the viral epitopes targeted by the 
host IgG response and the neutralising efficacy of this polyclonal response 
vary widely between individuals and viral quasispecies. 
 Individuals with broadly neutralising polyclonal IgG tend to compete with the 
non-overlapping monoclonal antibodies HC-11 and CBH-7 suggesting they 
target multiple CD81 binding epitopes. 
 Bioinformatic study of the ability of patient derived envelope sequences to 
form functional HCVpp, their sensitivity to neutralisation and cell entry 
protein usage can yield useful information on single aa sites which may play 
a crucial role in these processes. 
 While the CBH-7 epitope has not been fully mapped, amino acid 
substitutions at E2 positions 416 and 570 may impair its ability to neutralise. 
 Mutations in the region surrounding aa 608 are likely to have a role in 
maintaining the structure of the E1E2 heterodimer to allow it to retain 
function, and mutations around the putative fusogenic region of E1 (aa 274 
to 291) may also have a significant effect on cell entry. 
 Insertion of an extra glycosylation site at position 476 in the HVR2 region of 
E2 may have an effect on sensitivity to neutralisation. 
 Dependence on SRBI for cell entry varies widely between gt 1 sequences. 
Lower levels of dependence on SRBI may protect against neutralisation 
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from antibodies raised in vivo, however this is not a universal feature of 
‘hard to neutralise’ gt 1 E1E2 sequences. 
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5 Association of anti-HCV envelope antibody 
reactivity and neutralisation with long-term liver 
outcomes in a historically recruited cohort 
5.1 Introduction 
In Chapter 3, I described an association between bNAb antibody responses and 
lower levels of liver fibrosis in chronically infected individuals. The association 
between anti-HCV antibodies and liver outcomes has also been noted by Hamed 
et al (277), albeit using total IgG binding to E1E2 by ELISA as a predictor. 
Anecdotal reports have also reported HCV-infected individuals with inherited 
hypogammaglobulinaemia and those treated with the anti-B cell monoclonal 
antibody Rituximab have a more aggressive disease course suggesting antibodies 
have a protective effect (270, 271). 
This contrasts with the understanding that hepatic damage induced by HCV is 
largely immunopathic; that is, when the immune response fails to clear viral 
infection, inflammation, necrosis and subsequent fibrosis result in the continuing 
presence of virus in hepatocytes. While much of this damage occurs through direct 
activation of the innate inflammasome by HCV, the adaptive immune component 
may contribute by local release of pro-inflammatory mediators and through 
cytotoxic effects (305). Therefore, induction of immune responses without clearing 
virus may have a deleterious effect. 
Determining any causative effect that antibody responses have on disease 
outcomes is challenging in HCV infections as pathology develops over many years 
and in the present era, guidelines recommend treating all of those infected. Many 
infected individuals also have other risk factors for progression of liver 
disease(218). Here, I aimed to explore the hypothesis that a broad anti-envelope 
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antibody response early in the liver disease process is associated with rate of 
progression of liver disease, using samples and clinical data from a cohort of 
historically recruited individuals with HCV infection. 
5.2 Selecting the Progressor and Non-Progressor 
cohorts 
For this study, ethical approval was granted to use serum samples from a tissue 
bank of HCV infected samples from 198 individuals taken between1999 and 2005. 
These individuals had been recruited by Professor Peter Mills (Gartnavel Hospital, 
Glasgow) as part of a liver biopsy study, and each subject had clinical data 
recorded, liver disease staging with liver biopsies and serum samples taken at the 
point of recruitment. Clinical data was maintained in a database with follow up 
outcome data being available for 98 patients within the database. For simplicity, I 
will refer to this group of individuals as the ‘Historical cohort’. 
I used anonymised clinical and biopsy data to identify two groups of patients of 
interest from this cohort: 
‘Progressor’ group: defined as those with a Metavir fibrosis score of 0, 1 or 2 on 
their initial liver biopsy who went on to develop clinical cirrhosis as evidenced by 
further biopsy, Fibroscan >12.5 kpa, clinical decompensation, development of 
varices on endoscopy or confident radiological evidence of cirrhosis. 
‘Non-Progressor’ group: defined as those with Metavir fibrosis score 0, 1 or 2 at 
the time of sampling who did not show progression to cirrhosis as evidenced by 
subsequent biopsy or Fibroscan. Those achieving an SVR within 5 years of 
sampling were excluded, as were those with other liver disease on biopsy. 
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As age and genotype can have an influence on liver disease outcomes, for each of 
the ‘Progressor’ patients, 2 Non-Progressors infected with the same genotype and 
of a similar age were included. For 2 of the Progressor individuals, only 1 suitable 
Non-Progressor match could be found. Final demographics of the 25 selected 
patients are shown in Table 5.1.  
Table 5.1 Demographics of Progressors and Non-Progressors from Historical Cohort 
Progressors (n=9) Non-Progressors 
(n=16) 
P-
value 
Age at sampling (years) 
(range) 
35 (r 24 - 44) 37.5 (31-47) 0.71 
Median year of sampling 
(range) 
1999 (1999-2002) 2001 (1999-2004) 0.22 
Gender – Male (%) 6 (67%) 7 (44%) 0.41 
IVDU (%) 8 (89%) 8 (50%) 0.09 
Duration of infection at 
cirrhosis or censor  
(years) (range) 
23 (8-31) 18 (8-33) 0.07 
Alcohol excess (%) 4 (44%) 6 (38%) 1.0 
Ever treated (%) 0 (0%) 2 (13%) 0.52 
Genotype 1 (%) 5 (55%) 7 (44%) 0.69 
 
P-values calculated in SPSS v.22 using the Chi squared test for categorical data and t-test for 
continuous data. Alcohol excess was recorded in the clinical database if hospital or GP records 
included a diagnosis of alcoholic liver disease, alcoholism, alcohol withdrawal or regular 
consumption of >50 units of alcohol per week. 
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5.3 Cross genotypic-HCVpp-neutralising IgG shows a 
trend to association with non-progression 
For each of the selected individuals, serum IgG was purified according to the 
protocol described in Materials and Methods. This IgG was then tested for its 
ability to prevent Huh7 infection by HCVpp bearing envelope sequences from the 
cross-genotypic (XG) panel (gt 1a,1b, 2a, 2b, 3a and 4) as described in Chapter 3 
and Materials and Methods. Briefly, subject IgG was incubated with HCVpp at a 
final concentration of 100µg/ml and the mixture added to Huh7 cells. The 
Luciferase signal from HCVpp incubated with IgG was compared with control wells 
where only PBS had been added. Healthy control IgG was also used as a negative 
control. Individuals reducing infectivity by a mean of >50 % were recorded as 
having neutralising activity.  
The number of genotypes neutralised by the Progressor and Non-Progressor 
groups are compared in Fig. 5.1, where no association was seen between number 
of genotypes neutralised and progression status. Interestingly, the number of 
genotypes neutralised by the historical cohort as a whole was fewer compared to 
the CHCV cohort (P=0.006, Fig. 5.2). Only 5 individuals in the historical cohort 
neutralised >4/6 subgenotypes. Therefore to allow sufficient numbers to compare 
samples better at neutralising with those poor at neutralising, all subjects able to 
neutralise 3 or more subgenotypes were categorised as “broadly neutralising” and 
the remainder as “narrowly neutralising”. A Kaplan Meier plot was generated to 
determine time to progression or censor in the broadly and narrowly neutralising 
groups, this showed separation of the survival curves with narrow neutralisers 
tending to have a shorter time to cirrhosis, however this difference was not 
significant (Fig. 5.3 P=0.18). Finally the demographics of those with broadly 
neutralising and narrowly neutralising phenotypes were compared. No significant 
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differences were observed but those with a broader binding profile tended to be 
older at time of sampling (Table 5.1). 
  
 
Figure 5.1 Number of XG HCVpp neutralised by purified IgG from Progressor and Non-
Progressor individuals. 
Purified IgG from each sample was tested for its ability to neutralise HCVpp bearing E1E2 from 6 
different subgenotypes in the XG panel as described previously. The number of HCVpp 
subgenotypes neutralised by >50% is shown for individuals in the Progressor (P) and Non 
Progressor (NP) groups. The P -value was calculated using the Wilcoxon Rank Sum test. Median 
and interquartile range are shown. 
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Figure 5.2 Number of XG HCVpp neutralised by purified IgG from Historical Cohort and 
CHCV cohort 
Purified IgG from each sample was tested for its ability to neutralise HCVpp bearing E1E2 from 6 
different subgenotypes in the XG panel as described previously. The number of HCVpp 
subgenotypes neutralised by >50% is shown for individuals in the Historical cohort described in this 
chapter and the CHCV cohort described in Chapter 3. The P-value was calculated using the 
Wilcoxon Rank Sum test. Median and interquartile range are shown. 
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Figure 5.3 Kaplan-Meier plot of cirrhosis free survival in individuals from the Historical 
cohort stratified by breadth of neutralisation in the XG HCVpp panel 
Individuals from the historical cohort (Progressors and Non Progressors) were divided into two 
groups  - those who neutralised 3 or more of the HCVpp in the XG panel (HistBroad) and those 
who neutralised fewer than 3 (HistNarrow). The time from initial sample to development of cirrhosis 
(or censor where cirrhosis had not developed) was plotted. Censor was taken as date of death or 
last clinic appointment. Graph and statistical analysis was carried out using GraphPad Prism v.6. 
Censored data points are indicated by a small bar in the survival plot. 
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Table 5.2 Characteristics of broadly and narrowly neutralising historical cohort patients.  
 Broadly  
Neutralising 
Narrowly 
Neutralising 
p 
(n=10) (n=15) 
Age at sampling (years) 
(range) 
38 (31-47) 34 (24-46) 0.16 
Year of sampling 
(median) 
2001  (1999-2002) 2001 (1999-2002) 0.71 
Gender – Male (%) 4 (40) 9 (60) 0.42 
IVDU (%) 7 (70) 9 (60) 0.69 
Date of presumed 
infection (median) 
(range) 
1988 (1978-2001) 1988 (1980-2000) 0.82 
Time from infection 
until cirrhosis or censor 
(median years) (range) 
23 (8-33) 22 (8-31) 0.75 
Alcohol excess (%) 3 (30) 5 (33) 1 
Treated before initial 
sample (%) 
1 (10) 1 (7) 1 
SVR post sample (%) 2 (20) 4 (27) 1 
Genotype 1 (%) 3 (30) 9 (60) 0.22 
Progressor (%) 2 (20) 7 (47) 0.23 
 
P values calculated using SPSS v.22 using Chi squared test for categorical data, Wilcoxon rank 
sum for ordinal data and t-test for continuous data.  
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5.4 IgG binding to diverse E1E2 glycoproteins shows a 
trend to association with progression 
IgG from individuals in the cohort was tested for strength of binding to E1E2 
proteins of the subgenotypes from the XG panel expressed in HEK-293T cells as 
detailed in Chapter 3 and Materials and Methods. Briefly, lysate from HEK-293T 
cells transfected with plasmids containing E1E2 sequences from the selected 
subgenotypes was used in a GNA capture ELISA. A standard curve of humanised 
mAb AP33 (hAP33) (249) was used as a positive control.  
As detailed in Chapter 4 Section 4, there is no accepted cut –off for a ‘positive’ 
value in this assay. Moreover, I was interested in comparing those with stronger 
and weaker signals in the cohort rather than ascertaining the presence of anti-
envelope antibodies, which would be expected to be present in a majority of those 
with chronic infection. Therefore, to allow comparisons to be made within the 
cohort, individuals were ranked according to their relative absorbance to each 
genotype (with rank 1 being highest level of binding). The sum of ranks for the 
individual for each genotype was obtained and this final number used to rank the 
cohort for breadth of cross-genotype binding. 
Time to progression was compared between the highest ranked (1-13) and lowest 
ranked (14-25) individuals using a Kaplan Meier survival plot. This showed a 
shorter time to cirrhosis in those with a broader glycoprotein binding profile (i.e. 
higher ELISA rank Fig. 5.4 P=0.049). A comparison between the capacity of IgG-
mediated virus neutralisation and the IgG HCV E1E2 binding rank revealed a lack 
of correlation between two parameters (Fig. 5.5, Spearman’s correlation coefficient 
r=0.05). This diagram also highlights the association of glycoprotein binding and 
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progressor status with progressors tending to cluster in the higher ELISA ranks, 
while non-progressors cluster in the lower ones.  
 
Figure 5.4 Kaplan-Meier plot of cirrhosis free survival in individuals from the Historical 
cohort stratified by breadth of binding to E1E2 from the cross genotype HCVpp panel 
Purified IgG from individuals from the historical cohort was tested by ELISA for ability to bind E1E2 
containing lysate from 6 different subgenotypes of HCV as described in Materials and Methods. 
Each individual sample was ranked for ability to bind each genotype with1 assigned to the highest 
absorbance reading and 25 the lowest. Each individual’s ranks across the genotypes were 
summed and the individual given an overall rank. The cohort was then divided in half into the 
broadest binders (numerical ranking closest to 1, termed ‘Broad binding’) and the weakest binders 
(‘Narrow binding”). The time from initial sample to development of cirrhosis (or censor where 
cirrhosis had not developed) was plotted for each group. Censor was taken as date of death or last 
clinic appointment. Graph and statistical analysis was carried out using GraphPad Prism v.6, 
censored data points are indicated by a small bar in the survival plot. 
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Figure 5.5 Scatter plot of historical cohort samples according to rank for breadth of 
neutralisation and ELISA binding. 
Purified IgG from individuals from the historical cohort was tested for breadth of neutralisation of 
HCVpp and ELISA binding to a cross-genotype panel of 6 subgenotypes as described in Materials 
and Methods. Each individual sample was ranked for ability to bind each with1 assigned to the 
highest absorbance reading and 25 the weakest. Each individuals ranks across the genotypes 
were summed and the individual given an overall rank. The individual samples were also ranked 
based on the number of HCVpps they could neutralise (1 being able to neutralise the most HCVpp 
types).  The Spearman’s correlation coefficient (r) was calculated and is shown on the graph. 
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5.5 Intra-genotypic neutralisation of gt 1 HCVpp by gt 1-
infected historical cohort IgG shows no association 
with progression 
To determine if breadth of neutralisation within genotype 1 was associated with 
progression, IgG from the 12 gt 1-infected individuals in the historical cohort were 
tested for their ability to prevent the IG1 panel of HCVpps infecting Huh7 cells. 
This panel was developed as described in Materials and Methods and represents 
a wide variation of sequences at key CD81 binding regions within the E2 
glycoprotein of gt 1 HCV. It should be noted that only 3/9 of the broadly cross-
genotype neutralising samples were from gt 1-infected individuals. 
There was no significant difference in number of HCVpp neutralised between 
Progressor and Non-Progressor individuals (Fig. 5.6a) although there was a 
possible, non-significant trend to greater numbers of HCVpp neutralised in the 
progressor group (P=0.16). Again, the overall number of HCVpp neutralised by the 
individuals in the gt 1-infected historical cohort was significantly lower than in the 
more recently recruited CHCV cohort (Fig. 5.6b). 
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Legend for Figure 5.6 on following page 
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Figure 5.6 Number of HCVpp strains in the IG1 panel neutralised by IgG from the Historical 
cohort. 
A) IgG from gt 1-infected patients in the historical cohort were tested for neutralisation ability 
against the panel of 11 gt 1 pseudoparticles as previously described. A) The historical cohort 
results were split according to progression status (Progressors (P) and Non Progressors (NP)) and 
the median number of HCVpp neutralised was compared between the two groups using the Mann 
Whitney U test. B) Comparison of the number of IG1 panel HCVpps neutralised by the gt 1 infected 
subjects in the Historical cohort with the gt 1-infected subjects in the CHCV cohort. Number of 
pseudoparticle strains neutralised by both groups were plotted on the graph and a statistical 
comparison made using the Mann Whitney U test. Median and interquartile range are shown. 
 
5.6 Breadth of intra-genotypic neutralisation of gt 1 
HCVpp by gt 1-infected historical cohort IgG and 
association with SNP rs9275224 
The SNP rs9275224 in the HLA-DQB gene has previously been associated with 
breadth of neutralisation within genotype 1 and in Chapter 3 an association with gt 
1 neutralisation breadth was demonstrated in the CHCV cohort. Here, I aimed to 
determine if there was any association between presence of the favourable alleles 
AG/GG and neutralisation breadth in the historical gt 1-infected individuals. 
As no whole blood was available, DNA was extracted from serum of individuals in 
the historical cohort using the Qiagen Viral RNA kit without a DNAse step. 1µl of 
the eluted DNA solution was used as described in Materials and Methods with a 
custom Applied Biosystems qPCR probe for SNP typing. I was able to type 11 of 
the cohort using this method. Four of the cohort had the unfavourable SNP (AA), 
none of which neutralised more than 4/11 genotypes. However there were too few 
samples to demonstrate a clear relationship between SNP and neutralisation 
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breadth (Fig. 5.7a P=0.37). There was no relationship between cross-genotypic 
neutralisation and SNP type (P=0.78 Fig. 5.7b). In addition only one of the SNP 
AA individuals was in the Progressor group suggesting no strong relationship 
between the SNP and progression. Again, the numbers are too small to draw any 
firm conclusions. 
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Figure 5.7 Association of rs9275224 SNP genotype with breadth of intra-genotype 1 and 
cross-genotype neutralisation  
A) 10/12 historical cohort individuals tested in the intra-genotype 1 panel were typed for the HLA 
DQ-B1 SNP rs9275224 as described in Materials and Methods. The number of HCVpp strains 
neutralised in those bearing the AA SNP compared to the more favourable AG/GG SNPs were 
compared. B) The number of HCVpp genotypes neutralised in the cross-genotypic panel was 
compared by SNP rs9275224 genotype for the 11 individuals in the historical cohort who had been 
typed. Statistical comparisons were made using the Wilcoxon Rank Sum test.  Median with 
interquartile range is indicated. 
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5.7 Genotype specific responses and progression status 
As half of the progressor  cohort were infected with genotype 3, I also analysed 
the ELISA and neutralisation data to explore whether genotype-specific responses 
were associated with progression status in this cohort.  
When the strength of ELISA binding to gt 3 E1E2 in those infected with gt 3 virus 
was examined, those in the Progressor group displayed significantly stronger 
binding compared to the Non-Progressors (Fig. 5.8a P=0.02). However, no 
significant difference in glycoprotein binding to gt1a or gt1b was observed between 
P and NP groups in those who were infected with gt 1 (Fig 5.8b and c). 
In those infected with gt 3, there was no association between ability to neutralise 
the laboratory prototype gt 3 HCVpp and progression status (Fig. 5.8d). Similarly, 
there was no difference between gt 1-infected individuals in the Progressor and 
Non-Progressor groups in their ability to neutralise HCVpps bearing  gt 1a or gt 1b 
glycoproteins (Figs. 5.8e and f).  
I further analysed the absorbance readings on ELISA against different genotypes, 
separating the samples by infecting genotype. Interestingly while those infected 
with gt 1 showed no difference in absorbance to gt 3 lysate between Progressor 
and Non-Progressor groups (Fig. 5.9a), those infected with gt 3 in the Progressor 
group had significantly higher binding to gt 1a (P=0.03) and 1b (P=0.02) by ELISA 
compared with gt 3-infected Non-Pogressor patients (Fig. 5.9b). 
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 Legend for Figure 5.8 on following page 
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  Figure 5.8 Analysis of the association of progressor status with strength of patient IgG 
binding to HCV glycoproteins (A,B,C) and neutralisation of HCVpp bearing HCV 
glycoproteins (D,E,F)  derived from the same genotype as the subject’s HCV infection.  
Data from ELISA (A,B,C) and HCVpp neutralisation assays (D,E,F) conducted as described in 
Materials and Methods and as detailed in Sections 5.3 and 5.4 were further analysed to examine 
whether there was any association between progression status and individuals’ ability to bind or 
neutralise envelope glycoproteins  from the same HCV genotype that they were originally infected 
with. Bars shown are mean and standard deviation. Statistical comparisons were made using the 
Wilcoxon Rank Sum test. 
 
  Figure 5.9 Analysis of progressor group and binding strength of patient IgG to HCV 
glycoprotein by ELISA from A) gt 3 in gt 1 infected individuals and B)  gt 1 in gt 3 infected 
individuals 
Data from ELISA assays conducted as previously described were analysed to examine whether 
there was any association between progression status and individuals ability to bind HCVpp 
bearing an envelope glycoprotein of a different genotype to that they were infected with. For gt 1-
infected individuals, their ability to bind to gt 3 E1E2 lysate was plotted by progression status (A). 
For gt 3-infected individuals, their ability to bind to gt 1a and gt 1b E1E2 lysate was plotted by 
progression status (B). Bars shown are mean and standard deviation. Statistical comparisons were 
made using the Wilcoxon Rank Sum test. Mean and SD are indicated. 
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5.8 Chapter 5 Discussion 
The findings from this historical cohort are limited by a number of factors including 
small sample size, variability of the cohort with multiple confounders and scarcity 
of samples. Nonetheless, the historical sample bank represents a valuable 
resource as it provides a rare snapshot of antibody status early in the disease 
course for those who are known to go on and develop significant liver disease.  
Such cohorts are challenging to obtain for many liver diseases, as typically liver 
pathology develops over decades with many individuals presenting to medical 
attention at a late stage in their disease process. It is unlikely that we could 
expand this HCV-infected cohort with prospective recruitment in the UK at the 
present time as advances in therapy should ensure that the majority of individuals 
presenting without significant liver fibrosis are treated before they progress to 
cirrhosis. 
I attempted to determine if neutralising antibody status at baseline could predict 
development of significant liver disease. While no statistically significant 
association was observed, there was a possible trend towards faster disease 
progression in those without broadly cross-genotype neutralising antibodies. De 
Jong et al. have shown that neutralising antibodies have the potential to clear 
established HCV infection in vivo (144). A broadly neutralising response should be 
better able to cope with envelope sequence variation making viral escape more 
difficult. Reducing the number of hepatocytes infected with virus would be a 
plausible mechanism by which such antibodies could delay disease progression. 
However, it is possible that viral characteristics, such as slower evolution of virus, 
may be linked to both slower progression and a narrower antibody response. 
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The small sample size of this historically collected cohort makes it difficult to draw 
any firm conclusions as any effect would have to be very large to be detected in 
the presence of other potentially confounding factors. .  
While broader neutralising antibodies may have a protective effect, there was a 
significant association between broader binding to viral glycoproteins by ELISA 
assay and progression status. This was particularly evident in the 4 individuals 
infected with gt 3 HCV who had progression of their liver disease. With such a 
small cohort, it is possible that there are confounding factors resulting in both a 
strong ELISA response and progression of their liver disease. However, from the 
clinical data available for these individuals, none had a history of alcohol excess 
and their other demographics (Table 5.1) were comparable to the cohort as a 
whole.  
It is possible that high titres of non-neutralising anti-envelope antibodies may have 
a cytopathic effect. The degree of histological inflammation at baseline has been 
linked to progression in HCV (306). On reviewing the necroinflammatory scores on 
biopsies from the cohort there was a non-significant trend towards higher levels of 
inflammation in the progressor group (P=0.065 Figure 5.10a), however there was 
no association between levels of inflammation and glycoprotein binding as 
measured by ELISA (P=0.43 Fig. 5.10b)  
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Figure 5.10 Liver biopsy necroinflammatory score at baseline with A) progression status 
and B) breadth of IgG binding to envelope glycoproteins of different genotypes by ELISA.  
Histological Activity Index necroinflammatory scores for the historical cohort liver biopsies were 
taken from clinical pathology reports issued. Where none had been given but the description of 
inflammation levels was sufficient to allocate a score, one was assigned to that sample. There was 
insufficient information to assign an inflammation score to one of the biopsy samples which was 
excluded in this analysis. Scores were then plotted against A) Progressor status as defined 
previously (with median and interquartile range shown,) and B) ELISA binding rank determined as 
described previously from ELISAs using purified patient IgG binding to E1E2 from 6 sub-genotypes 
of HCV. In this case a rank of 1 indicates the strongest binding response across all sub-genotypes. 
The Wilcoxon Rank Sum test was used to calculate the P value in A. In B the value given as r is 
the Spearman’s correlation co-efficient, a non-parametric measure of correlation with its 
corresponding P value. 
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Work from one group has suggested that a significant interfering effect from non-
neutralising antibodies may exist (307). In those of the Historical cohort with the 
broadest ELISA binding, 6 were broad neutralisers and 7 narrow neutralisers. 
Within the broad ELISA/broad neutraliser group 2/6 progressed to significant liver 
disease whereas in the broad ELISA/narrow neutraliser group 6/7 progressed 
(P=0.10 Fishers exact test). While there are many possible confounders, this could 
indicate that those who have a broad binding but not neutralising response may 
have a tendency to more aggressive liver disease. The identification of individuals 
who had broad ELISA binding but narrow neutralisation also reinforces the 
findings in Chapter 3 that a neutralization response is not simply a function of 
overall levels of anti-‘whole E1E2’ antibodies. 
Another interesting observation from this cohort was the difference in 
neutralisation breadth between this cohort and a more recently recruited cohort. 
There are several possible explanations for this: 
1) These individuals were sampled earlier in their disease course than the 
CHCV cohort. The Historical cohort were sampled a median of 13 years 
following probable exposure to HCV wheras the CHCV cohort were 
sampled at a median of 23 years following probable infection. Neutralising 
antibodies usually take up to a year to first appear in chronic HCV infection 
(308). In addition, HCV envelope proteins tend to evolve over time to 
escape neutralising antibodies, with the humoral response lagging behind 
(309). It is likely that, in chronic infection, a polyclonal antibody response 
with neutralising properties develops in reaction to viral evolution and 
exposure to a variety of viral epitopes over time.  
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2) Degradation or denaturation of antibody samples over time. Serum from the 
historical cohort was stored at -70 for 10-15 years before use whereas the 
CHCV cohort antibodies were used within 1-2 years of sampling. While it 
appeared that none of the serum vials had been used prior to this study, it 
is possible that they were exposed to previous freeze-thaw cycles during 
their long period of storage. However, the anti-gt 1a and -gt 3 glycoprotein 
absorbance readings obtained by ELISA for these antibodies were 
comparable to those obtained for the CHCV cohort suggesting that similar 
quantities of antibodies with functional E1E2 binding ability remained in 
these samples although quality of these antibodies is harder to measure.  
3) The sequences tested against are genetically distant to the virus that the 
Historical cohort was exposed to. While both the CHCV cohort and the 
Historical cohort were recruited from the same geographical region 
(Glasgow), HCV envelope sequences can evolve rapidly even within hosts. 
Therefore, it is possible that the circulating gt 1 and gt 3 viruses in Glasgow 
at the time these individuals were infected differ in important ways from the 
strains from which the gt 1 panel were derived (in samples recruited from 
2006-2013). This alone would not explain the reduced level of neutralisation 
against the cross genotype panel. However, the viral population over time is 
shaped by adaptation to host responses, which balance viral fitness to 
infect and replicate against the need to escape adaptive and innate 
immunity (310, 311). If those infected with more ‘modern’ HCV sequences 
raise antibodies to a virus containing common ‘escape’ mutations their 
antibody response may target more conserved regions of the virus and be 
effective against a wider range of strains.  
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In an effort to explore this, we attempted to extract viral RNA from the stored 
serum and amplify E1E2 sequences using methods previously described. 
However no PCR product was generated for any of the samples suggesting RNA 
may have degraded. Further attempts to compare viral envelope sequences from 
these time points, perhaps using next generation sequencing methods, would help 
explore this theory.  
5.9 Chapter 5 Summary  
 Historically collected biological samples from individuals at an early stage of 
a chronic liver disease are a valuable resource to identify features which 
predict progression, albeit the small number in this cohort limits the 
conclusions which can be drawn from this data. 
 A cross-genotypic bNAb response shows a non-significant trend to 
association with slower progression of liver fibrosis, however the numbers 
studied in this cohort are too small to draw any firm conclusions on 
influence on progression or host predictors of bNAb responses. 
 Broad ELISA binding appears to predict more rapid progression of disease, 
particularly in gt 3-infected individuals and those who do not have a 
corresponding bNAb response. The mechanism which links these two 
features is not clear but interfering antibodies or immunopathic effects may 
play a role. 
 The IgG samples in these historical samples have significantly narrower 
neutralising profiles than those collected from a contemporaneous cohort of 
chronically infected individuals. This may be due to i) duration of infection ii) 
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differences in infecting viral sequences or iii) deterioration of sample during 
storage.  
 
 262 
 
6 Spontaneous clearance of HCV following viral 
relapse in the presence of potent, broadly 
neutralising anti-envelope antibodies 
6.1 Introduction 
Studying those who are able to control and clear HCV infection can yield valuable 
insights for vaccine design. While broad T cell responses were originally thought to 
be the most crucial for HCV clearance in the acute phase, a growing body of 
evidence has shown that early production of broadly neutralising antibodies 
(bNAbs) are also important (113, 131, 133, 137).  
 Previous work by Dr Emma Thomson had identified a cohort of HIV-positive 
individuals acutely infected with HCV (the St Mary’s cohort – see Materials and 
Methods for further details). From this cohort of 99 individuals, six had 
undetectable viral levels on IFN-based therapy but relapsed following cessation of 
treatment. Next generation sequencing conducted by Dr Tamer Abdelrahman  
confirmed the relapsing strain was present prior to therapy indicating that these 
were cases of true relapse rather than reinfection (312). On clinical follow up of 
individuals with viral relapse, two were found to have spontaneously cleared their 
virus without further therapy. This is a newly described phenomenon which I have 
termed “secondary spontaneous clearance”.As it follows a pattern of initial antigen 
exposure with subsequent re-exposure to the same virus followed by viral 
clearance similar to the principles of protection by vaccination, it may have 
particular significance for vaccine development. 
Therefore, with permission from and in collaboration with Dr Emma Thomson, I 
planned to study the humoral anti-HCV response for one of these individuals 
infected with gt 1a HCV.  I aimed to characterise this individual’s antibody 
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response in detail during initial infection, relapse and subsequent HCV clearance 
to determine if neutralising antibodies could have played a significant part in this 
“secondary spontaneous clearance”.  
 
6.2 Clinical characteristics of the individual studied 
(patient ET) 
For ease of reference I have termed the individual whose samples were used in 
this study ET. This individual was receiving antiretroviral therapy (HAART) for HIV 
infection at the time of developing acute HCV. Diagnostic laboratory testing of 
stored samples confirmed a HCV gt 1a infection with a duration of less than 3 
months. As there was no drop in viral load after 12 weeks of presumed infection, 
24 weeks of pegylated interferon and ribavirin therapy was commenced as was 
accepted standard therapy at the time (2009). Despite apparent viral clearance 
during therapy, 12 weeks later the individual was found to have detectable HCV 
RNA (Fig. 6.1) suggesting relapse. Illumina sequencing of the HCV E2 HVR-1  
region at this point  confirmed re-emergence of a minority strain (conducted by 
Tamer Abdelrahman, Abdelrahman et al, 2015, Hepatology) (312). However, on 
subsequent samples up to 5 years following relapse, the virus was not detected. 
Serum samples were available for viral sequencing and IgG purification from 
Timepoint A (at time of initial infection, TPA), Timepoint C (at time of relapse 
following treatment, TPC) and Timepoint D (taken less than 1 month following 
spontaneous clearance of infection, TPD). The sample from Timepoint B (mid 
therapy, TPB) was at a time during interferon exposure therefore while clinical 
laboratory results were available from this sample, serum from this TP was not 
suitable for testing for neutralisation ability and not used further in this study. 
 264 
 
Vi
ra
l l
oa
d 
(iU
/m
l)
A
ST IU/L/ C
D
4 per m
m
3
 
Figure 6.1 Clinical events and diagnostic laboratory tests during primary infection, 
treatment, relapse and secondary spontaneous clearance in patient ET. 
Graph showing clinical events and laboratory parameters at these times (Liver enzyme ALT, HCV 
viral load and CD4 count reflecting the control of HIV infection). These samples were taken as part 
of the St Mary’s cohort study and laboratory parameters measured using standard methods by the 
diagnostic laboratory at St Mary’s hospital. Times of sampling for TPA, TPB, TPC and TPD are 
indicated on the graph as A, B, C and D. 
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6.3 Sequence analysis of whole E1E2 from TPA (pre-
treatment) and TPC (relapse) 
Viral RNA was extracted from serum from TPA and TPC using the QIAamp Viral 
RNA Kit (Qiagen) as per protocol. The E1E2-encoding sequence was amplified 
using degenerate primers for gt 1a with a directional tag to enable subcloning 
using the pENTR/D-TOPO directional cloning kit (ThermoFisher Scientific) (see 
Materials and Methods for protocol and Chapter 3 for further detail on PCR 
optimisation). Initial amplification was performed using this protocol by Ms Eva 
McGregor, all subsequent steps were performed by me).  
The amplification products were gel-purified and subcloned using the pENTR/D-
TOPO vector kit. For the sample from TPA, few clones were obtained using the 
pENTR kit. Therefore further subcloning was conducted using the TA cloning 
vector CloneJet PCR cloning kit (ThermoFisher Scientific) system. 20 colonies 
were selected for each TP, grown in selective media, plasmid DNA extracted using 
the Qiagen Miniprep kit and purified DNA sequenced by the Sanger method 
(GATC Biotech). 
Only 6 complete unique sequences were returned for both time points. These 
sequences were aligned and consensus sequences generated using CLC 
Genomics Workbench 7 software. The translated consensus sequences for each 
time point were compared using a MEGA6 software package. This clonal analysis 
of the HCV envelope protein sequences demonstrated the majority variant of virus 
isolated before therapy (Timepoint A) and at relapse (Timepoint C) differed by 6 
amino acids, mainly in the HVR1 region (T223A, V386F, T396A, G401S, K408R) 
and N574D  (Figs. 6.2 and 6.3 ). The evolution of the HVR-1 region suggests this 
is likely to have been the target of an early, ineffective, adaptive humoral 
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response, similar to previously shown sequence evolution within hosts progressing 
from acute to chronic infection (140).  
 
 
Figure 6.2 Molecular Phylogenetic analysis of sequences from TPA and TPC by Maximum 
Likelihood method  
Sequences from both time points obtained by clonal analysis were aligned. From this alignment, 
the evolutionary history was inferred by using the Maximum Likelihood method based on the 
Tamura-Nei model (257). The tree with the highest log likelihood (-2542.6456) is shown. The 
bootstrap value (i.e. the percentage of trees from 1000 generated using this data in which the 
associated taxa clustered together) is shown next to the branches. Initial tree(s) for the heuristic 
search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of 
pairwise distances estimated using the Maximum Composite Likelihood (MCL) approach, and then 
selecting the topology with superior log likelihood value. The tree is drawn to scale, with branch 
lengths measured in the number of substitutions per site. Alignment and evolutionary analyses 
were conducted in MEGA6 (16). 
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6.4 1Infectivity and receptor usage of HCVpp bearing 
sequences from TPA and TPC is equivalent 
The consensus E1E2 sequences from TPA and TPC were transferred into a 
phCMV gateway expression vector and used to manufacture HCV pseudoparticles 
(HCVpp) as described in previously in Materials and Methods. Media containing 
these HCVpp was harvested and their ability to infect HUH7 cells confirmed. 
HCVpps bearing TPA and TPC sequences were comparably infective on all 
assays (less than 0.5log difference in luciferase signal in relative light units, Fig. 
6.4).  
 
 
Figure 6.4. Relative infectivity of HCVpp bearing consensus envelope sequences isolated 
from TPA and TPC. 
Sequences were isolated and HCVpp generated as described above and in Materials and 
Methods. 40 µl of HCVpp were used to infect Huh7 cells and relative infectivity determined using 
the BrightGlo Luciferase Assay (Promega). Results shown are from three independent 
experiments. Error bars show the SEM.  
                                         
1 NB the E1E2 sequence from TPC has been used in the IG1 panel under the name ET10 
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As HVR-1 mutations have been associated with adaptations in entry receptor 
usage, I aimed to determine if altered use of entry proteins was a factor in the 
differential ability of the host to control the primary and relapsed infection. 
Therefore I set out to assess the sensitivity of pseudoparticles bearing sequences 
from TPA and TPC to anti-SRBI and anti-CD81 antibody blockade.  
Briefly, HCVpp were generated as described previously. Prior to adding these to 
Huh7 cells, the cells were incubated with 40 µl modified DMEM containing anti-
CD81 antibody (clone JS-81, BD Biosciences) at decreasing concentrations from 3 
µg/ml to 0.04 µg/ml or anti-SRBI mAb151-NP1 (252, 260) at decreasing 
concentrations from 10 µg/ml to 0.03 µg/ml. After 1 hour, the DMEM was removed 
and 40 µl of test pseudoparticles were added or DMEM added to control wells. 
These were incubated for 4 hours and then medium changed. Infectivity of 
pseudoparticles in the presence of cell receptor blockade was determined using a 
BrightGlo Luciferase Assay (Promega), as described previously, at 72 hours post-
infection. 
The above assays revealed both HCVpp were equally sensitive to anti-SRBI and -
CD81 blockade. There was no appreciable difference between the receptor 
dependence of the two sequences (Fig. 6.5). 
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Figure 6.5 Sensitivity of pseudoparticles bearing E1E2 glycoprotein sequences derived from 
TPA and TPC samples to blockade of entry proteins A) SRBI and B) CD81.  
As described in Materials and Methods, pseudoparticles were added to Huh7 cells which had been 
pre-incubated with serial dilutions of either A) anti-SR-BI antibody or B) anti-CD81 antibody in 
DMEM. Relative infectivity was determined by measuring luciferase levels as described in 
Materials and Methods. Results shown are from three independent experiments. Error bars 
represent the SEM. 
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6.5 Secondary spontaneous clearance is associated with 
neutralizing antibodies targeting E1E2 proteins 
IgG from TPA, C and D were tested in GNA ELISA assays and HCVpp 
neutralisation assays for their ability to bind to and neutralise both previously 
generated HCV E1E2 sequences from different genotypes (the XG panel 
described in Materials and Methods and Chapter 3) and to neutralise HCVpp 
bearing autologous E1E2 glycoprotein sequences from TPA and TPC. 
Briefly, ELISA analysis to detect antibodies against E1 and E2 glycoproteins was 
performed as described previously (313). ELISA plates coated with GNA were 
used to capture E1E2 glycoproteins from HEK-293T cell lysates for gt 1a, gt 1b 
and gt 3a. These are the same HCVpp from these genotypes used in the XG 
panel described in Materials and Methods.  IgG purified from each time point  was 
subsequently added at a concentration of 200 µg/ml and bound human IgGs were 
detected using HRP-anti-human IgG antibody (Sigma A0170) and TMB (3,3’, 5, 5’-
tetramethylbenzidine, Sigma) substrate. IgG from healthy controls (recruited at the 
same time as the CHCV cohort – see Chapter 3) were used as a negative control. 
A dilution curve of the humanised anti-HCV E2 mouse monoclonal antibody AP33 
(129) was included as a control. Absorbance values were measured at 450 nm 
and normalised according to the AP33 curve to enable comparison of results 
obtained from separate ELISA plates. Purified IgG was also tested for its ability to 
prevent infection in vitro by HCVpp from the 6 subgenotypes of the XG panel (gt 
1a, 1b, 2a, 2b, 3a and 4). These assays were conducted as described in Materials 
and Methods at a concentration of 100 µg/ml.  Neutralisation assays were also 
conducted against the autologous HCVpp generated from TPA and TPC 
sequences. Due to the small volume of sample available for TPA, there was 
insufficient purified IgG available for use in this assay. Therefore serum from TPA, 
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TPC and TPD was heat-treated to deactivate virus and their ability to prevent 
infection from the HCVpp bearing autologous E1E2 sequences tested at serial 
dilutions of serum from 1:50 to 1:40000 in PBS.  
While there was evidence of a weak anti-envelope antibody response from IgG 
purified from TPA (Fig. 6.6), this had no significant ability to prevent infection of 
Huh7 against the XG panel of HCVpp from differing genotypes (Fig. 6.7a). Serum 
from this timepoint was also unable to prevent infection by HCVpps bearing 
autologous viral sequences from both TPA and TPC, even at a 1:50 dilution (Fig 
6.7b and c). In contrast, IgG and serum from TPC andTPD showed robust binding 
to and neutralising activity against a number of HCV genotypes (Fig. 6.6 and 6.7a) 
with potent protection against autologous viral sequences (Fig. 6.7b and c). The 
IC50 for serum from TPC was 1:3300 against the TPA HCVpp and 1:10000 
against the TPC HCVpp with overlapping confidence intervals suggesting no 
significant difference in neutralisation sensitivity between the sequences. Serum 
following resolution of infection (TPD) displayed persistent neutralising activity with 
an IC50 in the region of 1:500 for autologous HCVpp from both time points (Figs. 
6.7b and c).  
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Figure 6.6 Relative binding of purified IgG to E1E2 lysate from gt 1a,  gt 1b and gt 3a. 
Graph show absorbance of purified IgG tested at 200 µg/ml to HEK-293T cell lysate containing 
E1E2 proteins from differing standard genotypes as described in Materials and Methods. AP33, a 
broadly reactive antibody recognising a conserved linear epitope in  HCV envelope glycoprotein E2 
was used as a positive control at the concentrations shown in the graph. HC samples were used as 
a negative control and absorbances plotted as a ratio of mean sample absorbance to mean HC 
sample absorbance. Statistical differences in absorbance between TPA and TPC and D were 
determined using the Wilcoxon rank sum test. Results shown are from a single experiment due to 
paucity of serum, each sample was tested in duplicate. Error bars represent the SEM. 
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Timepoint IC-50
A N/A
C 1/3300
D 1/500
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Timepoint IC 50
A N/A
C 1/10 000
D 1/500
 
Figure 6.7 Neutralisation of HCVpp by IgG and serum from TPA, C and D.  
A) Pseudoparticles bearing E1E2 proteins from the XG panel were generated as described in 
Materials and Methods. Purified IgG from TPA, C and D was tested for their ability to prevent 
infection from these pseudoparticles at a concentration of 100 µg/ml. * indicates that there was 
insufficient IgG from TPA to test for neutralisation against gt 1b, 2a and 2b and 4 pseudoparticles. 
The criterion for positive neutralisation is 50% reduction in relative light units. B+C) Neutralisation 
of HCVpp bearing envelope proteins of autologous viral sequences from B) TPA and C) TPC by 
serum diluted in PBS . The results shown are mean % reduction in HCVpp infection compared to 
no serum control i.e. percentage reduction in relative light unit signal on luciferase assay. Serum 
from TPA, C and D (post clearance) were heat-treated to inactivate any live virus, then tested in 
serial dilutions in PBS for the ability to neutralise the HCVpp as described in the IgG neutralisation 
assay in Materials and Methods. Results shown are from three independent experiments. Error 
bars represent the SEM. 
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6.6 Competition of neutralising antibodies with mAbs to 
known neutralising epitopes on E2 
In an effort to gain an understanding of the epitopes targeted by the neutralising 
IgGs from TPC and TPD, a competition ELISA assay was performed to determine 
if they competed for binding to E2 with some well-characterized neutralising and 
non-neutralising antibodies to discrete immunodomains. The antibody panel and 
competition ELISA are described in Materials and Methods and Chapter 4 Section 
2. It included  non-neutralising HmAb CBH-4B, neutralising HmAbs HC-1, HC-11, 
CBH-7 and HC-84.1 and mAb AP33 (120) (119) (124) (129). 
To determine whether purified IgG contained antibodies targeting similar domains, 
we incubated test IgG on purified sE2 coated plates at a concentration of 200 
µg/ml in PBSTM in addition to control wells containing PBSTM only. Subsequently 
biotinylated antibodies from the above panel were added to these wells at a 
concentration close to their EC50 (119, 121, 255, 314) (Fig. 2.4). HP conjugated 
secondary substrates were added and binding measured as previously described 
(see Materials and Methods and Chapter 4). The reduction in relative binding of 
each biotinylated antibody (calculated as percentage reduction in absorbance) in 
the presence of IgG compared to control was determined for TPC and D.  
This revealed the IgG antibody response at Timepoints C and D competed for 
multiple binding sites on E2, in particular they demonstrated competition with 
monoclonal antibodies known to target CD81 binding sites with broad neutralising 
activity (Fig. 6.8).  
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Figure 6.8 Ability of neutralising IgG from Timepoints C and D to compete with antibodies to 
known epitopes on E2.  
The ability of purified IgG at 200 µg/ml to competitively inhibit binding by biotinylated monoclonal 
antibodies with known epitopes to E2 was determined as described in Materials and Methods. 
Percentage reduction in binding signal from the test monoclonal antibody in wells where IgG had 
been added compared to those where only PBSTM had been added is plotted on the graph above. 
The results shown are from three independent experiments. Error bars represent SEM. 
 
6.7 Chapter 6 Discussion 
Viral infection and resolution resulting in protection on re-exposure to a similar 
virus forms the basic principle of immunisation, being used in several primate 
models of HCV immunity (148, 315). Deliberate human re-exposure to HCV is 
unethical but this case provides a rare example of a natural version of such an 
experiment.  
This report is the first detailed molecular study of viral populations and humoral 
immune responses in secondary spontaneous hepatitis C viral clearance after 
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post-therapy relapse.  As another patient with a similar clinical pattern was also 
identified in the St Mary’s cohort, this suggests that secondary spontaneous 
clearance may be a more common phenomenon than previously understood. 
Many clinics do not conduct routine viral load testing following confirmed relapse 
after therapy and such individuals may not be tested again until being considered 
for further treatment. Following presentation of this data, I have been informed of 
several anecdotal reports of individuals who relapsed after interferon based 
therapy but were found to be HCV PCR-negative on assessment for further 
therapy [personal communications from Barclay S, Thomson E and data from the 
Scottish HCV clinical database (265)]. The individual described in these 
experiments was HIV-positive as was the other patient in this cohort with a similar 
clinical picture. It may be that this phenomenon is more common in those with HIV 
where fluctuations in CD4 count may affect the efficacy of the adaptive immune 
response. 
Cases of re-infection following therapy with spontaneous clearance of the 
reinfection have been previously reported (316, 317) and population data suggests 
that treated individuals who remain at high risk for re-infection have lower incident 
infection rates than naïve individuals (318). These results suggest that adaptive 
immunity may play a protective role following successful anti-viral treatment with 
IFN. I cannot exclude the possibility that the patient here was re-infected with the 
same strain of virus during follow-up although he did not report high risk activity 
during this time. 
These findings provide new evidence of the importance of the anti-envelope 
antibody response in clearance of HCV infection after treatment. Those who are 
able to resolve HCV infection acutely tend to have a favourable immunogenetic  
profile which will also influence their likelihood of clearing further infections. A 
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meta-analysis of acutely-clearing individuals who spontaneously cleared on re-
infection showed association with the IFNL4 CC genotype(77) while the HLA-
DQB1 locus has been linked to the ability to raise an early, broad neutralising 
antibody response leading to resolution of acute infection (113). In the majority of 
HCV-infected individuals production of neutralizing humoral responses is delayed, 
which may explain the initial lack of functional antibodies in our patient (276, 280) . 
Patients co-infected with HIV have a particularly delayed response, often resulting 
in later diagnosis of infection (117). Therefore, it is encouraging to demonstrate 
that, even in an individual who did not have a favourable acute response (and who 
was co-infected with HIV), it is possible to generate sterilising antibody-mediated 
immunity.    
The majority of HCV-infected individuals with relapse post-therapy develop chronic 
viraemia. Viral escape from both the T cell and antibody response has been 
described in detail in chronic infection (137, 319, 320). One key feature of our 
subject’s antibody response at TPC was targeting of multiple CD81 binding 
epitopes. A multispecific T cell response is associated with HCV clearance and in 
Chapter 3, I described how individuals possessing antibodies targeting multiple 
CD81 binding epitopes of E2 (competing with monoclonal antibodies HC11 and 
CBH7) have the ability to neutralise the majority of a panel of gt 1a E1E2 variants 
(251). Other researchers have also identified a synergistic effect of monoclonal 
antibodies targeting separate epitopes when used together (126). This may have 
been an important factor in preventing viral escape from neutralising antibody 
response, leading to eventual clearance.   
A further factor which may have favoured resolution of infection here was the short 
duration of the initial infection. In chronic HCV and HIV infections with persistent 
antigen stimulation, T cells may display an exhausted phenotype (106, 107). While 
 280 
 
no direct effect on B cells has been demonstrated, they are known to display the 
activation and exhaustion marker molecule PD-1 on chronic exposure to antigen 
(109). In addition, given the co-stimulatory role of CD4+ T cells and complex 
interplay of B and T cell immune responses in viral clearance, it would follow that a 
persistent defect in the T-cell repertoire could have significant implications for B 
cell function.  It has already been shown that such exhaustion is reversible after 
short periods of infection, however once chronic infection is established, an 
exhausted phenotype persists (108). It may be that development of neutralising 
antibodies generated in chronically infected individuals may fail to prevent re-
infection but, in combination with cellular responses, such antibodies may be more 
likely to be effective if generated by brief exposure to antigen as in acute 
resolution of infection or vaccination. Timing of exposure and reappearance of 
virus may have been particularly important in this HIV-infected patient, as the 
substantial reduction in CD4 count on IFN therapy may have resulted in a 
diminished B cell functionality followed by a recovered response after completion 
of therapy. 
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6.8 Chapter 6 Summary 
 This is the first sequencing confirmed case of spontaneous clearance of 
viral relapse after interferon-based therapy where the presence of broadly 
neutralising antibodies has been demonstrated. 
 Despite differences in the E2 HVR-1 sequence between initial infection and 
relapse, there was no effect on infectivity or dependence on SR-BI for Huh7 
entry when tested in the HCVpp system. 
 Broadly neutralising antibodies were identified from samples during and 1 
month following secondary spontaneous clearance which were able to 
neutralise a range of envelope sequences both autologous, and of different 
genotypes. 
 These antibodies appeared to compete with mAbs targeting multiple 
neutralising epitopes on E2. 
 These findings support the importance of neutralising antibody responses in 
clearance of HCV infection and highlight the potential for NAb to contribute 
to viral clearance on second exposure. 
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7 Anti-E1E2 antibody responses in a cohort of 
uninfected individuals at high risk of repeated 
HCV exposure 
[The work described in this chapter has been published in Swann and Mandalou2 
et al., J. Viral Hepatitis, 2016 (321) with permission for reproduction of this work 
under the Creative Commons Attribution License] 
7.1 Introduction 
In the search for a prophylactic vaccine, it is especially relevant to study 
individuals who appear to have natural resistance to HCV infection. Individuals 
who have repeated probable exposure to HCV through regularly injecting drugs 
and sharing injecting paraphernalia are at very high risk of HCV exposure. Up to 
90% of long term users with these risk factors show serological evidence of 
previous or current HCV infection (322) . However, a proportion of individuals in 
this high risk group appear resistant to HCV infection, and this is an increasingly 
well documented phenomenon (323). Conventionally HCV infection status is 
determined using a PCR assay to detect viraemia and an Enzyme Immunoassay 
(EIA) to detect antibodies to core and non-structural HCV proteins. Individuals at 
high risk of exposure who show no serological evidence of past or current infection 
have been termed exposed but uninfected (EU) and a number of such cohorts 
have been defined in previous studies (92-94, 324).  
 
                                         
2 P Mandalou recruited the cohort and provided their samples and clinical data. I designed and 
conducted the experiments described in this chapter with some assistance from P Mandalou. 
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EU cohorts have been shown to be immunologically distinct from both healthy 
controls and those who spontaneously clear HCV infection (see Table 1.1 in 
Introduction) (91-93)  with raised levels of natural killer cell activity, IL6/IL8 and 
TNF- activity compared to IDUs infected with HCV (94, 95). There are also 
substantial differences in the immunogenetics of individuals in EU cohorts, those 
who spontaneously resolve acute HCV infection and those with chronic HCV(96). 
HLA-C1 and KIR2DL3 genes are over represented in both EU and spontaneous 
resolver groups, whilst prevalence of  the IL28B (IFNL3) polymorphism is more 
prevalent in spontaneous resolvers but similar in EU and  chronically infected 
cohorts (93, 95, 97, 98). In terms of adaptive immunity, EU cohorts have been 
shown to display HCV-specific T cell responses in up to 60% of individuals (92). 
By definition, EU cohorts do not show detectable antibody responses to core and 
non-structural proteins in a diagnostic assay, suggesting cellular infection and 
replication has not taken place. However, the role played by antibodies directed at 
the envelope protein, which may prevent cellular infection, has not yet been 
explored. As described previously, bNAbs are thought to play a significant role in 
acute clearance of HCV (133). Neutralising antibodies (NAbs, capable of 
preventing infection by one or more strains of HCV,) are also upregulated in those 
who acutely clear HCV infection on multiple exposures. Therefore, it is possible 
that such antibodies may provide a degree of protection from infection in the IDU 
EU population (113). Primate studies using HCV gt 1a envelope proteins as a 
vaccine substrate have shown that NAb were raised in the majority of animals 
immunized on 2 occasions. These were able to prevent de novo infection and had 
some activity against strains of virus from different genotypes (315). If one accepts 
that previous evidence suggests these individuals have indeed been exposed to 
HCV virions or at least some of the proteins contained therein, it would not be 
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surprising to find an adaptive anti-envelope response which could possibly confer 
a protective effect. Therefore, I aimed to determine the presence of functional anti-
HCV envelope antibody responses in an IDU EU cohort of with a high risk of 
repeated exposure to HCV. 
 
7.2 Defining the cohort 
The EU cohort described in this study is detailed in Materials in Methods. Briefly 
IDU were recruited between 2003 and 2014 from a variety of locations in Plymouth, 
UK as previously described (92, 93)  (clinical subjects recruited and clinical data 
collected by Professor M. Cramp and Dr P. Mandalou, South West Liver Unit 
Plymouth). Individuals were screened for evidence of current or past HCV infection 
and they completed a confidential structured questionnaire to collect demographic 
data and a detailed injecting history. For this study only those with no evidence of 
previous HCV infection who were judged to be at substantial risk of HCV exposure 
based on a >1 year history of injecting drug use and regular sharing of injecting 
equipment were included. Serum samples were taken from all individuals and 
where possible, follow up clinical information and clinical samples were obtained. 
As a control group samples from chronically infected individuals in the CHCV 
cohort and their associated healthy controls (HC) were used (see Materials and 
Methods and Chapter 3 for further details) (325).  
A total of 42 EU subjects were included, 5 of which had samples from multiple time 
points. Eight healthy controls and eight CHCV subjects were also included. 
Demographics of these cohorts are shown below (Table 7.1). 
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Table 7.1 Demographics of Exposed Uninfected and control cohorts 
 Exposed 
Uninfected 
(EU)  
n=42 
Chronic 
HCV 
(CHCV) 
n=8 
Healthy 
Controls 
(HC) 
n=8 
Mean age at sampling (years ± 
SD) 
34±8.3 52 ±6.3 47±18.2 
Ethnicity (% Caucasian) 42 (100) 8 (100) 8 (100) 
Sex (% Male ) 37 (89) 5 (63) 4 (50) 
Median estimated year of 
infection 
NA 1981 NA 
Current IDU (%) 42 (100) ND 0 (0) 
Mean age at commencing IDU 
(year) ± (SD) 
21.8 ± 5.2 18.5±6.5 NA 
Mean lifetime injecting episodes 
(range) 
4128(52-
21900) 
ND NA 
Duration of IDU (years ± SD) 7.6 ± 4.3 ND NA 
Sharing needles/syringes (%) 30 (72) ND NA 
Sharing any injection equipment 
(%) 
42 (100) ND NA 
Sharing with IDU known to suffer 
from HCV infection (%) 
12 (28.5) ND NA 
EU data supplied by M Cramp and P Mandalou. ND indicates no data collected on this category in 
this group and NA indicates not applicable to this group. 
 
7.3 Detection of anti-E1E2 IgG responses in exposed 
uninfected subjects 
In order to detect an IgG response to all regions of the envelope protein, a GNA 
capture ELISA was performed as described in Materials and Methods. Purified IgG 
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from serum samples tested against plates coated with lysate from 293T-HEK cells 
transfected with phCMV plasmids containing E1E2 sequences from gt 1a and gt 
3a (see Table 2.2). As there was no way of determining which genotype of HCV 
these individuals may have been exposed to, it was initially planned to test against 
other genotypes including gt 1b, however scarcity of sample from the EU cohort 
combined with a relatively weak binding from CHCV individuals on the gt 1b plate 
used for optimisation rendered this impracticable. For each test subject, 50 µl of 
IgG in PBSTM at a concentration of 200 µg/ml was added to wells in duplicate. 
The ELISA assay was performed as described in Materials and Methods, with 
HRP conjugated mouse-anti human IgG Fc (Sigma A0170) used as the secondary 
antibody at 1:5000 concentration (2µg/ml).  
7.3.1 Reactivity of EU IgG to HCV E1E2 protein lysate  
Median absorbances for the GNA capture ELISAs between the different cohorts 
were compared using a Wilcoxon Rank Sum test. The EU cohort median 
absorbance on gt 1a E1E2 lysate was significantly higher in than the HC group 
(P=0.038) (Fig. 7.1a). While there was a trend towards overall higher absorbance 
readings against gt 3a E1E2 in the EU group than in controls, this did not reach 
significance (P=0.067, Fig. 7.1b). However, three samples showed levels of 
binding to gt 3a lysate comparable to chronically infected controls.  
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Figure 7.1 EU individuals show elevated IgG reactivity to HCV envelope proteins.  
Purified IgGs were tested for their ability to bind HEK-293T-expressed E1E2 in a GNA-capture (A) 
gt 1a and (B) gt 3a ELISAs as described above. To allow comparison between plates, the healthy 
control (HC) panel was tested on each ELISA plate and absorbance values adjusted according to 
the HC mean. For those individuals where serum from multiple time points was available, each 
time point was tested individually but only one value for each individual is plotted. Statistical 
differences between the groups were calculated using the Wilcoxon rank sum test. Bars are 
included to show values corresponding to HC mean plus 2 standard deviations and 2 times the HC 
mean, both accepted arbitrary cut offs for developing a diagnostic assay.  
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7.3.2 HCV exposure risk and E1E2 reactivity 
Logically, individuals more frequently exposed to HCV envelope proteins should 
show stronger antibody reactivity to these. EU IgG absorbance levels to gt 1a and 
gt 3a E1E2 were analysed for association with detailed reported injection 
frequencies for those 37 subjects where data was available. Non parametric 
analysis showed a significant correlation between IgG reactivity against gt 1a 
E1E2 and a higher number of lifetime injecting episodes (Spearman r 0.38, P=0.02, 
Fig. 7.2a), although this association was not seen with gt 3a reactivity (Fig. 7.2b).  
While self-reported behaviours are not always recalled accurately it would appear 
that those who are more frequent risky injectors have higher levels of anti-gt-1a 
HCV envelope IgG. 
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Figure 7.2 Correlation between IgG reactivity to either gt 1a (A) or gt 3a (B) E1E2 and total 
number of lifetime injecting episodes.  
Absorbance values for the binding of EU cohort IgGs to E1E2 proteins from gt 1a- and gt 3a-
transfected HEK-293T cell lysate were determined as described previously. Duration of reported 
injection drug use was multiplied by frequency of reported injection drug use to obtain an estimate 
of total number of lifetime injecting episodes. This was plotted for 37 EU (injection data not 
available for the remaining 5).  
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7.3.3 Reactivity of IgG to purified soluble E2 (sE2) by ELISA 
As it is possible that those with frequent risky injection practices may also develop 
antibodies to human tissues, I aimed to eliminate possible cross-reactivity against 
HEK-293T cell antigens and medium components. To do this, serum samples from 
all individuals were diluted 1:50 in PBSTM and tested for IgG reactivity to 
Immulon® plates (Thermo Fisher Scientific) directly coated with 1 µg/ml  gt 1a sE2 
(produced by Ania Owsianka  from the H77 E2 sequence as detailed in Materials 
and Methods).  There was significantly higher absorbance of IgG from EU to sE2 
than HC (P<0.01, Fig. 7.3).  
.  
Figure 7.3 IgG reactivity to gt 1a sE2 is evident in EU individuals. 
 Diluted serum (1:50 in PBTSM) was added to plates coated with purified gt1a sE2 protein and 
absorbance determined for IgGs from EU, HC and CHCV individuals using a modified ELISA 
protocol described in Materials and Methods. Statistical differences between the groups were 
calculated using the Wilcoxon rank sum test. Mean and standard deviations are shown. 
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7.4 Detection of anti-E1E2 IgM responses in exposed 
uninfected subjects 
In order to establish whether there was evidence of recent exposure to HCV 
envelope proteins, I developed an assay to test for evidence of IgM response to 
E2. While anti-HCV IgM persists in chronic infection, it wanes following viral 
clearance, with levels declining 8 weeks following exposure (326), (327). 
Therefore, elevated levels in the EU cohort would tend to suggest recent contact 
with HCV proteins. IgM is challenging to work with in that it tends to bind non-
specifically and with lower affinity than IgG. In addition, IgMs can be difficult to 
purify as they are soluble under a narrower range of conditions than IgG and are 
more susceptible to becoming denatured (328) . Therefore, I took several steps to 
optimise an ELISA assay for detecting anti-envelope IgM, using the HC and CHCV 
groups prior to testing IgGs from the EU subjects. As I planned to use dilute serum 
(diluted 1:50 in PBSTM) rather than purified IgM in this assay, I also included 
purified IgG as a negative control to ensure there was minimal secondary antibody 
cross-reactivity. 
Firstly, I tested only against purified sE2 (further details in Materials and Methods) 
to reduce the possibility of binding to other cellular proteins. I introduced three 
adsorption steps prior to adding samples to the ELISA plate. This involved 
incubating samples on a GST-coated plate in an attempt to remove non-specific 
binding antibodies. Despite this optimisation, high levels of absorbance from HC 
samples were still observed compared to CHCV samples (Assay 1 see Fig. 7.4). 
By increasing the concentration of Tween-20 in PBST used in dilution and wash 
steps to 0.5% (high Tween PBST) and adjusting the concentration of secondary 
antibody (anti-IgM- HRP conjugate, Abcam) to 1:500 (2µg/ml) from 1:1000 
(1µg/ml), HC absorbance readings were reduced to a level where CHCV and HC 
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IgG binding levels could be easily distinguished (Assay 2 see Fig. 7.4). I then used 
this optimised assay to determine if anti-E2 IgM could be detected in the EU 
subjects. 
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Figure 7.4 Optimisation of IgM ELISA 
Serum samples from the CHCV and HC cohorts were used to optimise an ELISA to detect IgM 
binding to plates coated with gt 1a sE2. CHCV and HC serum samples were diluted to 1:50 in 
PBSTM. Purified IgG samples (at 200 µg/ml) were also used to ensure that there was no cross-
binding with the secondary antibody. In Assay 1 PBSTM with a standard (0.1%) concentration of 
Tween-20 was used and secondary antibody (anti-human IgM HRP conjugate, Abcam) was used 
at 1µg/ml. In the second assay (Assay 2) the same samples were used with high concentration 
Tween-20 (0.5%) PBST in all dilution and wash steps and secondary antibody was used at 2µg/ml. 
Mean and standard deviations are shown.  
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Using this assay to test serum from the EU cohort, EU samples showed 
significantly higher median IgM binding to sE2 than the HC group (P=0.001 
Wilcoxon Rank Sum, Fig. 7.5) with several individuals displaying levels 
comparable to the CHCV group. Overall 30 (71%) of the EU individuals showed 
levels of IgM binding >HC mean+2xSDs, 23 (55%) had absorbances >2x HC 
mean and 22 (42%) displayed absorbance levels at HC mean + 3x SDs. 
 
Figure 7.5 IgM responses to soluble gt 1a E2 are evident in EU individuals.  
IgM binding to purified gt1a sE2 protein was determined for serum from CHCV, EU and HC 
individuals. Serum from each individual was diluted 1:50 in high Tween PBSTM (PBSTM with 0.5% 
Tween) and tested using a modified ELISA protocol developed as described in the text and in 
Materials and Methods. Statistical differences between the groups were calculated using the 
Wilcoxon rank sum test. Mean and standard deviations are shown. 
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7.5 Pseudoparticle neutralisation by IgG from exposed 
uninfected subjects 
In a subset of EU individuals displaying significantly elevated E1E2 binding 
compared to HC on ELISA (higher than 2 standard deviations above the HC mean 
absorbance), HCV pseudoparticle (HCVpp) neutralisation assays were conducted 
as previously described (119) and detailed in Materials and Methods. Briefly, 
purified subject IgG was added to 40 µl of HCVpp-containing medium prepared as 
described in Materials and Methods. Purified IgG was screened for neutralising 
effects at a concentration of 400 µg/ml apart from a small number of individuals for 
whom serum was scarce, where this was reduced to 200 µg/ml.  The mouse 
monoclonal anti-E2 antibody AP33 (258)  and HC IgG were included as positive 
and negative controls, respectively. Virus neutralisation was defined as 50% 
reduction in HCVpp infectivity as measured in relative light units (RLU) using a 
Chameleon II plate reader. Ability to neutralise both gt 1a and gt 3 was tested. For 
those samples with apparent neutralizing activity, further neutralisation assays 
were conducted using serial dilutions of subject IgG where sample volume 
allowed. 
Six of the EU subjects tested (257, 306, 307,315, 331-1 and 458) showed ability to 
neutralise gt 1a HCVpp by 50% or more at a purified IgG concentration of 400 
µg/ml (Fig. 7.6a). IC50 values were between 400 and 200 µg/ml for subjects 315, 
331-1 and 458, whereas subjects 257 and 306 had IC50 values between 100 and 
50 µg/ml (Figure 7.6b). While subject 307 appeared to have significant neutralising 
ability when tested at 200 µg/ml, there was insufficient sample to test serial 
dilutions of IgG in a neutralisation assay.   
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Three EU individuals were able reduce infectivity of gt 3a HCVpp by 50% or 
greater (257,306 and 307) with one further gt 1a neutralising subject reducing gt 
3a infectivity by 40% (EU 458) (Fig. 7.6c). Two further individuals (461, 301) 
showed evidence of a weaker neutralisation effect against both gt 1a and gt 3a 
HCVpp, consistently reducing infectivity by 40%.  
7.6 Duration of antibody detection over time 
For 5 EU individuals, serial samples from time points separated by a period of at 
least 1 year were available. Purified IgG from these individuals was tested on the 
E1E2 GNA capture ELISAs as detailed in section 7.3.1.  Four of these individuals 
displayed absorbance levels equivalent to HC levels and remained at this level on 
subsequent testing (Fig. 7.7a). One individual with significant E1E2 reactivity and 
neutralising responses was studied serially (331), in initial and subsequent 
samples, detectable responses were present over time but with a diminution in 
strength at later time points which may reflect the waning of antibody 
concentration with time following exposure (Fig. 7.6b).  
 
 296 
 
0
10
0
20
0
30
0
40
0
50
0
 297 
 
 
 
 
Figure 7.6 Neutralization of HCVpp by EU purified IgG. 
Virus pseudoparticle neutralization assays were performed using HCVpp bearing E1E2 derived 
from gt 1a strain H77 (A and B) or (C) gt 3 HCV. (A and C) Percentage reduction in HCVpp entry 
after incubation with 400 µg/ml test IgG is plotted as evidenced by luciferase reading at 72 hours 
compared to no IgG control. For those individuals with low sample volume and evidence of strong 
neutralising activity on initial screen were tested at 200 µg/ml (indicated by *). Individuals with low 
sample volume and no evidence of neutralisation on initial screen were not tested further (n.d.). (B) 
Percentage reduction in HCVpp entry after incubation with reducing concentrations of IgG as 
shown. The traditional 50% cut off is shown. The results from at least 3 separate experiments were 
plotted as above. Error bars represent SEM.  
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Figure 7.7 Presence of IgG directed at gt 1a E1E2 over time.  
Samples from the same individuals taken at time points separated by at least 1 year were tested in 
the gt 1a GNA capture ELISA as described previously. Absorbance relative to HC mean is plotted. 
The results of two independent experiments are shown. Error bars represent the SEM. 
 
7.7 Envelope protein binding and neutralisation across 
multiple assays 
While the assays described above have not been externally validated for 
‘diagnosis’ of HCV exposure, an accepted diagnostic ELISA cut-off value of 2 
times the control mean was used as guide to determine a positive result. 
Alternatively HC mean plus 2 or 3 times standard deviation can be used. Using a 
absorbance cut-off of ≥ 2 times the HC mean value as indicating a significantly 
positive result, a total of 20/42 (48%) EU showed evidence of IgG reactivity to 
HCV envelope E1E2 proteins on either the GNA-capture ELISA or IgG gt 1a 
purified soluble E2 (sE2) binding ELISA (Table 7.2). Four of the 7 EUs with the 
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highest level of binding to gt 1a E1E2 lysate (≥ 2 times the HC mean) also had 
significant binding to sE2 displaying absorbance readings ≥ 2 times the HC mean 
with 2 more showing above average binding to sE2 but below this cut off value. 
Seven further individuals with significant responses against sE2 showed elevated 
reactivity against gt 1a lysate but the absorbance attained did not reach the cut-off 
value. Only four samples showed significant binding to sE2 alone. 
As our HC group clustered tightly around the mean, using a less stringent positive 
cut off value of HC mean +2xSD produced even more positive results in the EU 
group. Samples which reached this cut off but did not reach an absorbance value 
of above 2 times the HC mean are indicated in a lighter shade in Table 7.2. In total 
20 (48%) of EUs had an absorbance value of HC + 2x SD on the gt 1a GNA 
ELISA assay, 11 (26%) on the gt 3 GNA ELISA and 25 (65%) on the sE2 assay. In 
the gt 1a GNA-capture ELISA the value of 2x HC mean was equivalent to HC 
mean plus 3x SD (2.0 compared with 2.01). All samples neutralizing at the 50% 
level had binding on at least one ELISA assay at the ≥ 2 times the HC mean level. 
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Table 7.2  EU binding to and neutralisation of E1/E2 across the various assays used. 
EU 
ID 
x HC 
gt1a 
E1E2 
ELISA 
xHC gt3a 
E1E2 
ELISA 
XHC E2 
ELISA 
 
Neutralisation >50% 
        Gt 1                    Gt 
3 
Neutralisation >40% 
Gt 1                      Gt 3 
 
246 1.2 1.3 1.9   
306 2.2 1.5 2.3 Y Y Y Y 
307 1.8 1.2 2.4 Y Y Y Y 
315 1.3 1.1 2.5 Y  Y  
318 1.4 2.5 1.3   
320 1.4 1.2 0.9   
324 1.8 1.4 1.2   
331 2.6 1.7 3.9 Y  Y Y 
333 1.3 1.2 0.8   
352 1.0 1.7 2.6   
353 0.7 1.1 1.5   
354 1.8 1.2 3.5   
447 1.9 1.0 2.2   
461 2.6 1.5 1.7  Y Y 
466 1.0 0.8 1.1   
270 1.3 1.6 1.0   
298 1.2 1.4 0.8   
301 1.8 1.5 2.9  Y Y 
303 1.3 0.9 1.3   
304 0.7 1.1 1.5   
309 1.7 0.9 1.3   
319 0.9 0.9 1.8   
222 2.2 1.1 0.7   
326 1.2 1.2 1.7   
332 0.9 1.0 1.8   
344 0.9 1.1 0.8   
345 1.1 1.2 9.1  Y  
347 1.1 0.8 2.0   
350 0.5 1.7 0.9   
444 1.0 1.3 1.9   
445 1.6 2.4 0.8   
446 2.5 1.2 2.4   
458 2.1 3.9 1.7 Y  Y Y 
459 0.6 0.8 2.0   
469 0.8 0.6 2.9   
257 4.0 1.7 3.2 Y Y Y Y 
290 1.9 1.4 0.7   
294 1.2 1.2 1.0   
346 1.6 1.3 1.3   
348 1.5 1.2 2.2   
349 1.6 1.6 2.1   
456 0.9 0.8 0.9   
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Legend for Table 7.2: Values for ELISA are absorbances as multiples of the HC mean for each 
assay are shown. In neutralization columns, Y indicates HCVpp infectivity was reduced by >50% or 
>40%, respectively, in the presence of 400 µg/ml of purified EU IgG. Values in dark grey reach the 
stringent specified cut off of >2 times HC mean (or 50% neutralisation). Values in light grey are 
between HC mean plus 2 standard deviations and 2 times HC mean absorbance (or 40% 
neutralisation for HCVpp assays). As only selected samples were tested in the neutralization 
assays, a black box indicates the sample was not tested.  
7.8 Epitopes targeted by neutralising IgG from EUs 
In order to determine which epitopes were being targeted by EU sample IgG with 
E1E2 binding and neutralising ability, competition ELISAs were performed. These 
tested the ability of IgG from those neutralising EUs with sufficient sample 
available to compete for E2 binding at the same site as with a panel of well 
characterized monoclonal antibodies (mAbs) targeting known epitopes. Three of 
these (HC-1, HC-11, and CBH-7) recognize amino acid residues critical for the 
interaction of E2 to CD81 (329-332) (see Materials and Methods and Chapter 4). 
Briefly, PBSTM containing no IgG (control) or purified test IgG at 200 µg/ml in 
PBSTM was incubated with a gt 1a sE2 coated plate for 2 h before being washed. 
Subsequently biotinylated mAbs were added to the plate, incubated and washed. 
Presence of biotinylated mAb was detected using Streptavidin-HRP conjugate 
followed by addition of TMB substrate. Percentage reduction in absorbance in the 
test wells compared to the control wells was calculated which gives an indication 
of test IgG competition for similar epitopes or interference with mAb binding. 
Although IgGs from chronically infected samples with neutralizing activity tend to 
compete with antibodies to these regions (see Chapter 4), we did not observe any 
significant competition in the EU samples (Fig. 7.8). While IgG from these 
individuals bound pure E2 in these samples at >2x HC samples (Table 7.2) their 
absorbance values were considerably weaker than CHCV individuals which bound 
 302 
 
to viral glycoproteins at >20 times the strength of HC samples (Fig 7.3). This 
difference in quantity of anti-E1E2 antibody may also have contributed to the lack 
of detectable competition as this assay was developed for use with samples from 
HCV-infected individuals. 
 
 
Figure 7.8 EU IgG fails to compete with conformational antibodies to known epitopes for 
binding to the gt 1a sE2.  
IgG from EU individuals with neutralising ability in the HCVpp system were selected for testing by 
competition ELISA to determine competitive binding with monoclonal antibodies to conformational 
epitopes on E2 (Materials and Methods). Two samples from chronically infected individuals with 
known neutralizing activity were also included as positive controls. Mean percentage reduction in 
absorbance of the monoclonal antibodies was calculated and plotted. Significant competition would 
be expected at a level of 50% inhibition. The results shown are the means and SEM from two 
independent experiments due to limited quantity of serum. 
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7.9 Chapter 7 Discussion 
Individuals who are recurrently and frequently at high risk of HCV exposure 
through sharing injection equipment, but who remain uninfected by conventional 
testing,  represent an ideal cohort to explore mechanisms of natural protection 
from HCV infection. While in other viruses such as HIV, where resistance may be 
conferred by mutations in host entry proteins, no variants in CD81 have been 
identified in HCV exposed uninfected cases (333-335). It is therefore likely that 
such individuals have immune-mediated features which enable them to resist 
infection.  
This study is the first to report evidence of anti-envelope antibodies in an exposed 
uninfected cohort.   Although HCV-specific T cell responses have been 
demonstrated in EU individuals it remains unclear if those have a functional role in 
protecting from infection in these individuals or are merely a marker of viral 
exposure. It has been shown that HCV-specific T cell responses tend to wane 
rapidly on cessation of injection drug use (92, 324). The presence of an anti- 
envelope humoral response provides further confirmation that this EU group has 
indeed been exposed to HCV virions.  
In this cohort, anti-E1E2 IgG responses have been detected at levels significantly 
higher than controls in  almost half of  EU cases with anti-E1E2 IgG binding at 
levels >2 times healthy controls in at least one assay observed in 20 of the 42 EU 
cases. Although such a cut-off is arbitrary and risks false positive (and negative) 
results, all individuals with neutralising activity show binding around this level 
supporting use of this value as a threshold for presence of a significant quantity of 
antibody.  
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Anti-envelope antibodies pose one possible mechanism by which these subjects 
may have resisted infection.  This is further supported by the in vitro evidence for 
viral neutralization with IgGs from a subset of individuals significantly reducing 
cellular entry by HCVpp. IgGs from 6 of the cohort were able to reduce HCV pp 
entry into hepatocytes in vitro by 50% at IC50s ranging from 75-400 µg/ml. In 
order to compare this figure with other studies it is helpful to consider these values 
relative to the concentration of IgG in human serum. As the concentration of IgG in 
human adult serum ranges from 700-1600 mg/dl, the IC50 concentrations from 
these individuals equate to a serum dilutions of approximately 1:25-1:100. This is 
comparable to the strength of neutralising responses observed in in those with 
acute HCV infection during viral clearance (336).  
Individuals who have resolved acute infection show reduction in the strength of 
detectable NAb responses over a period of months to years. However NAb 
responses may be restored in subsequent episodes of infection aiding more rapid 
viral control (113). One individual in the EU cohort, 331, had detectable NAbs 
which persisted responses over a period of at least a year.  In the EU cohort, the 
presence of anti-envelope humoral responses was more pronounced in individuals 
with the greatest likelihood and frequency of HCV exposure suggesting that such 
anti-envelope antibody responses may need ongoing priming by exposure to HCV 
to be sustained.  
IgM is usually a marker of acute exposure to an antigen. The majority of EU 
subjects tested had evidence of significantly higher anti-HCV E2 IgM than healthy 
controls. This would support ongoing intermittent exposure to envelope proteins as 
might be expected through the high risk injecting practices of the cohort. 
Interestingly, the strength of these responses was equivalent to those seen in 
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CHCV individuals with ongoing exposure to HCV antigens and the precise role of 
IgM in resisting infection in the EU cohort and other groups warrants further study.  
Whilst a neutralising effect was demonstrated using EU serum, the regions of the 
viral glycoprotein targeted by their antibodies have yet to be defined.  As there is 
no significant competition of antibodies targeting E2 epitopes known to be involved 
in cell entry, this raises the possibility that novel epitopes, potentially with E1 
binding sites, are involved. However, the lack of competition may simply reflect 
lower avidity of antibodies in the EU cohort. As avidity of binding increases with 
duration of infection (337) it is conceivable that the EU antibody responses are 
directed at the CD81 binding regions tested but are ‘competed off’ by the 
conformational mAbs derived from chronically infected individuals. It is also 
possible that the EUs, in common with most acutely infected individuals, develop 
antibodies predominantly targeting the HVR-1 region of the E2 protein. 
Alternatively, as E2 amino acid sequences are highly diverse, these individuals 
may raise antibodies to a local envelope sequence which has structural 
differences at key CD81 binding regions, resulting in antibodies which have only 
weak cross-reactivity with the H77 sequence at these sites. Future work could 
involve exploring reactivity of the antibodies in EU individuals to locally derived 
envelope sequences and overall breadth of their anti-envelope antibodies. In 
addition, further information about anti-HCV responses could be gained from 
studying the B cell receptor populations in such individuals. 
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7.10 Chapter 7 Summary 
 There is evidence of HCV envelope-specific humoral immune responses in this 
cohort of IDUs who are at high risk of exposure but remain uninfected by 
conventional testing (EU). 
  Levels of anti-HCV envelope IgG appear to correlate with number of lifetime   
injections. 
 Some EU individuals produce neutralising anti-envelope antibodies which may 
contribute to host immunity. It is unclear whether this is at a level sufficient to 
provide protection from subsequent infection. 
 IgGs from EU individuals that are able to neutralise HCVpps do not appear to 
compete with commonly targeted CD81 binding sites on E2 and may therefore 
recognise novel epitopes, alternatively this could simply represent antibodies 
targeting these sites with lower affinity binding. 
 Many of the EU cohort have IgM directed at the HCV E2; in some this is at the 
same level as found in chronically infected individuals.  
 These data complement previous reports of HCV-specific T cell responses (96, 
98), and upregulated innate immune responses in EU populations (97). 
Together, these studies provide robust evidence that such individuals have 
been exposed to HCV, but are resistant to developing established infection.  
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8 Impact of HCV infection and cryoglobulinaemia 
on the B cell repertoire and functional response 
8.1 Introduction 
While the main clinical impact of HCV infection is on the liver, it has various 
extrahepatic effects and is closely associated with clonal B cell pathologies. The 
antibody response to HCV is atypical compared to most other viruses. Although 
neutralising antibodies are produced, their appearance is delayed (308), in 
addition, unlike many chronic infections, anti-HCV IgM remains elevated (327).  
There is growing evidence that HCV can affect B cells in a number of ways: 
infection and replication within B cells can occur (338) altered expression of 
molecules involved in B cell regulation have been described in HCV infection 
(339), finally HCV is the most common cause of the benign clonal B cell disorder, 
mixed cryoglobulinaemia (MC).  
MC is characterised by precipitation of auto-reactive antibody aggregates on 
serum cooling to 4°C which can be redissolved at 37°C. Precipitated antibody 
complexes consist of  auto-reactive antibodies (usually IgM) targeting the fixed 
(Fc) region of host IgG (also known as Rheumatoid factor-like activity) (6). This 
can lead to a clinical syndrome including renal failure and a small proportion of 
affected individuals progress to develop B cell lymphoma (182).  
The prevalence of mixed cryoglobulinaemia in HCV infected populations varies 
widely between geographic regions. While the classical vasculitis syndrome is 
thought to affect 5% of those with chronic HCV infection (340), one meta-analysis 
suggested a cryoglobulin prevalence of 44% in chronically infected patients, with 
the highest prevalence reported in Southern Europe and North America (341, 
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342). There are no published studies reporting the rate in Scottish HCV infected 
populations. 
The exact pathogenesis of cryoglobulinaemia in HCV is incompletely understood. 
As it tends to resolve on viral clearance some have suggested HCV proteins 
induce cryoglobulinaemia by acting as a molecular mimic of the IgG Fc portion 
(142). Similar gene usage in clonal cryoglobulinaemic B cells and B cell Receptor 
(BCR) binding to HCV envelope proteins raises the possibility that envelope 
proteins may induce the autoreactive antibodies seen in cryoglobulinaemia. This is 
also supported by high levels of somatic hypermutation in the BCRs of IgG Fc 
binding B cells, suggesting their affinity for this molecule is antigen driven (343). In 
contrast, some researchers have found HCV infection to be associated with 
expansion of a naïve subtype of B cells (47, 183)  and the IGHV1-69 BCR gene 
commonly expanded in MC is similar to the BCR on immature B1 cells which have 
polyreactivity and do not undergo somatic hypermutation (183).  
In a healthy B cell population there are hundreds of BCR gene classes which are 
expressed at varying levels, giving a potential of >1014 unique BCR 
combinations(344). Conversely in clonal B cell disorders, this expression becomes 
restricted to fewer more dominant gene classes (263). The recent development of 
Next Generation Sequencing (NGS) technology where the sequence of individual 
fragments of DNA within a population can be determined has revolutionised the 
ability to search for patterns in immune cell populations in healthy and diseased 
individuals (263, 345). Previously such detailed analysis would have taken years 
with clonal techniques.  
I aimed to use such techniques in collaboration with the Sanger Centre, 
Cambridge to complement other means of analysing the B cell response to HCV. I 
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hypothesised that chronic HCV infection exerts a pathological effect on the B cell 
population which may be related to the development of cryoglobulinaemia and 
may have an effect on functional antibody responses. I used samples from the 
CHCV cohort in an attempt to answer the following questions: 
 How common are cryoglobulinaemic antibodies in the Scottish CHCV 
cohort and do they have any clinical associations? 
 Does chronic HCV infection or asymptomatic cryoglobulinaemia alter B cell 
population diversity and overall gene usage? 
 Are HCV envelope proteins the targets of cryoglobulinaemic antibodies? 
 Does the presence of asymptomatic cryoglobulinaemia or BCR clonality 
have any association with restricted function of the anti-HCV humoral 
response? 
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8.2 Prevalence of asymptomatic cryoglobulinaemia in a 
British cohort of individuals chronically infected with 
HCV and its association with cirrhosis. 
 
A cohort of individuals chronically infected with HCV (CHCV) were recruited 
alongside healthy controls (HC) from HCV treatment centres in Glasgow. Clinical 
information and samples were collected as described in Materials and Methods. 
Samples for cryoglobulin testing were available for 75 HCV infected patients (36 
Genotype 1, 39 Genotype 3) and 24 healthy controls. Blood from each patient was 
collected, clotted and centrifuged at 37°C before cooling for 7 days at 4°C and 
observed for appearance of a cryoprecipitate. If a cryoprecipitate was observed 
then this was confirmed by dissolution on heating to 37°C and reappearance on 
cooling.  Of the HCV infected individuals, 31% (23/75) had detectable 
cryoprecipitates. No cryoglobulin was detected in the HC samples.  
Samples containing cryoglobulins were washed with an ice-cold saline solution 
and submitted to the diagnostic laboratory at Gartnavel General Hospital for typing 
and detection of rheumatoid factor activity (see Materials and Methods).  
Sufficient cryoprecipitate was available for typing in 10 of the positive samples. Six 
were characterised as Type 2 (monoclonal and polyclonal band) and the 
remainder type 3 (oligo or polyclonal bands). Rheumatoid factor was activity was 
checked in 8 of these patients assay and was positive in 3 (38%) and equivocal in 
1. 
Clinical associations are listed in Table 8.1. A significant association between 
cryoglobulinaemia and liver fibrosis was observed (Fig. 8.1a, P=0.002 by Wilcoxon 
 311 
 
rank sum test). Also, a significantly lower median viral load was seen in the 
cryoglobulin positive group (Fig. 8.1b P=0.026). 
There was no difference in the prevalence of IDU or diabetes in those with 
cryoglobulins. No individual symptom was statistically associated with cryoglobulin 
detection. There was no significant association between IL28B genotype and 
presence of cryoglobulinaemia (P=0.27 by Fisher’s exact test, Table 8.1). 
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Table 8.1 Clinical associations with cryoglobulinaemia.  
 
Clinical Parameter Cryoglobulin 
Positive (n=23) 
Cryoglobulin 
Negative (n=52) 
P value  
Male (%) 14 (60) 41 (79) 0.27 
Age (median yrs and range) 45 (28-65) 44 (28-68)  0.73 
Genotype 1 (%) 12 (52) 28 (54) 0.97 
Genotype 3 (%) 11 (48) 24 (46) 0.97 
Cirrhosis (%) 12 (52) 12 (24) 0.019 
Renal impairment 1(4) 0 (0) 0.28 
Viral load (median IU/ml) 2.3 x105 
(7.6 x103 – 7.1 
x106 ) 
1.1x106 
(5.5 x103 – 1.4 
x107 ) 
0.026 
IDU (%) 15(65) 37(71) 0.25 
Diabetes (%) 1(4) 3(6) 1.00 
IL28B Genotype CC 7 (30) 12 (19) 0.57 
Fatigue (median score/10) 5 5 0.52 
Sensory Symptoms (%) 6 (26) 13 (25) 1.00 
Rash (%) 3 (13) 1 (2) 0.08 
 
Clinical features of the CHCV cohort tested for cryoglobulinaemia were compared between those 
with evidence of cryoglobulins and those without. Renal failure was defined as estimated creatinine 
clearance (<60ml/min). P values were calculated using Fisher’s exact test for categorical variables 
and Wilcoxon rank sum test for ordinal variables.  
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Figure 8.1 Association of liver fibrosis and viral load with cryoglobulin status.  
A) A comparison of liver fibrosis, as determined by Transient Elastography readings (Fibroscan 
kPa), with the cryoglobulin status (positive, pos or negative,neg) of individuals in the CHCV cohort 
using a Mann Whitney U test. Where cirrhosis had been confirmed on prior biopsy but no fibroscan 
was available, a value of 12.5kPa was assumed. Where there was no histological evidence of 
cirrhosis and no fibroscan reading, the sample was excluded. B) Viral load between the two groups 
was compared using a Mann Whitney U test. Median and interquartile range are shown. 
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8.3 HCV infection and asymptomatic cryoglobulinaemia 
does not appear to affect overall BCR diversity but is 
associated with longer CDR3 length and may exert 
small changes on the BCR population 
To investigate any effect that HCV infection and cryoglobulinaemia may have on 
the diversity of the B cell population, 6 HCV gt 1-infected cryoglobulin-positive 
patients, 6 gt 1-infected cryoglobulin-negative patients and 6 healthy controls were 
selected for next generation sequencing (NGS) analysis of the B cell repertoire. 
PBMCs were isolated from these individuals as previously described, RNA 
extracted and cDNA libraries generated using a pool of primers to the BCR region. 
These processes were conducted by me and Dr Mark Robinson with further 
details in Materials and Methods. In addition, for 3 individuals in each group, cDNA 
libraries were generated by Dr Mark Robinson using IgM- and IgG-specific primers 
designed by Dr Rachael Bashford Rogers (RBR) at the Sanger Centre, 
Cambridge. The BCR sequences from the cDNA samples were then amplified 
using RT-PCR and prepared for NGS analysis as described in Materials and 
Methods.  Briefly,  PCR products from the RT-PCR reactions were purified using 
Agencourt® Ampure® XP beads (Beckman Coulter) , then A-tailed and adaptor 
ligated using the Kappa Real-Time Library Amplification kit (KAPA Biosystems) 
and NEBNext® Multiplex Oligos primers for Illumina (NEB). These libraries were 
then sequenced using a MiSeq SystemDesktop sequencer (Illumina). The 
resulting sequence file was transferred to RBR for analysis of BCR gene usage 
using bioinformatics software she had developed as described in Bashford-Rogers 
et al (2015)(263). Quality control information for the samples is shown in Table 8.2 
(prepared by RBR, Sanger Insititute, Cambridge).  
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Table 8.2 Quality of sequencing information for BCR next generation sequencing.  
 
 
Samples were prepared for NGS as described in Materials and Methods. Table prepared by Dr 
Rachael Bashford-Rogers at the Sanger Institute, Cambridge showing quality control data from 
NGS sequencing of the cohorts. 
 
8.4 Diversity of IGHV sequences across clinical groups 
An in-house programme designed by RBR within the Sanger lab was used to 
calculate several different measures of sequence diversity within the BCR 
populations for each of the patients. These measurements were as follows: 
 The vertex Gini index: measurements of overall clonality. 
 The cluster Gini index: measurements of cluster size heterogeneity.  
Clinical 
group Chain 
Mean number of 
 raw reads 
Mean read depth 
after filtering 
Mean read 
length (bp) 
Mean % reads 
retained after 
filtering 
Cryo neg IgG 549822.0 370375.3 240.3 67.4 
Cryo pos IgG 430123.3 294819.7 242.6 70.5 
Healthy IgG 605537.3 397034.0 239.1 65.5 
Cryo neg IGH 251582.3 174317.2 244.6 68.5 
Cryo pos IGH 176042.2 128472.8 247.3 72.8 
Healthy IGH 328644.7 238283.3 245.9 72.4 
Cryo neg IgM 541148.0 354505.0 242.5 65.5 
Cryo pos IgM 445399.3 296493.3 245.4 68.7 
Healthy IgM 628945.0 403285.0 243.8 63.5 
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 The largest cluster size (percentage): to distinguish between samples with 
different maximum cluster sizes. 
 The sum of the largest two cluster sizes (percentage): measurement to 
incorporate the second largest cluster size, which may distinguish between 
samples with secondary rearrangements.  
 The percentage of unique BCRs in the largest cluster: to distinguish 
between samples with different levels of SHM (where present) in the largest 
cluster.  
 The percentage of sequences representing the most frequently observed 
BCR sequence: to distinguish between samples with or without dominant 
BCR sequences. 
 The percentage of sequences representing the first and second most 
frequently observed IGHV-J rearrangement: measurement to distinguish 
between samples with specific rearrangements, irrespective of the largest 
cluster sizes.  
 The ratio of the number of unique CDR3 sequences to unique full length 
BCR sequences: as the CDR3 length is shorter than the full length BCR 
sequence, but B-cells sharing the same CDR3 sequence are likely to 
originate from a single B cell precursor, then lower ratios of unique CDR3 
sequences to unique full length BCR sequences suggests lower B-cell 
clonal complexity. 
 In particular, Gini measures of diversity along with absolute cluster size and 
proportion of reads in clusters compared to total number of reads have previously 
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been used in research of clonal B cell populations in the context of B cell 
malignancies (263). These measurements were further analysed and interpreted 
in collaboration between myself, RBR, and Dr Mark Robinson. 
Linear discriminant analysis (a generalisation of Fisher’s linear discriminant) was 
conducted by RBR and revealed none of these measures were able to 
discriminate between the three clinical groups. Such analysis is increasingly being 
used to analyse features of NGS output (346). There was no evidence of 
abnormally large clusters in the cryoglobulin positive group or of difference in 
overall BCR diversity between chronically infected HCV patients with and without 
cryoglobulinaemia and healthy controls as measured using a number of diversity 
indices (see Fig. 8.2a). In addition, there was no significant evidence of abnormal 
clusters in B cell heavy chain sequence diversity suggesting that significant clonal 
expansion had not yet occurred in these individuals. An example of the distribution 
of BCR gene clusters seen can be visualised as shown in Figure 8.2b. When we 
compared measures of diversity between those with HCV infection (cryoglobulin-
positive and -negative) and healthy control groups there were no significant 
differences. However, there was a trend to lower levels of diversity in the HCV 
infected IgM specific BCR group. This was particularly seen using the Cluster Gini 
Index (Fig. 8.2c, P=0.05) suggesting that the presence of HCV may exert a small 
effect on the IgM BCR population.  
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Figure 8.2 BCR diversity measures across clinical groups. 
 A) Linear discriminant analysis (LDA) performed on repertoire structure measures of the BCR 
sequences generated by NGS sequencing. This technique employs a generalisation of Fisher’s 
linear discriminant. This statistical method determines if a combination of features can be used to 
sort two classes of subjects in a linear fashion. This graph was prepared in SPSS by RBR. Nine 
BCR population diversity and structural features were analysed (the Vertex Gini Index, Cluster Gini 
Index, % of reads in largest cluster, % of reads in largest two clusters, % of unique sequences in 
largest cluster, % of reads  of highest observed sequence, % of sequences with the highest 
observed VJ gene usage, % of sequences with the 2nd highest observed VJ gene usage, ratio of 
unique CDR3s sequences to total reads). The values for each patient group for the first and second 
LDA dimensions (LDA1 and LDA2) are shown on the graph above. There is no clear separation 
between the three clinical groups using B-cell sequencing architecture as shown by the distribution 
of samples projected in the two LDA dimensions. B) Graphical depiction of relative size of clusters 
seen for one patient in each clinical group. Within the circle, each dot is scaled to represent an 
individual cluster of reads. Larger dots indicate larger clusters. C) Scatter plot of Cluster Gini index 
for HCV-positive and -negative individuals for total BCR heavy chain sequences and for IgM 
specific heavy chain BCR sequences. P value was calculated using the Wilcoxon rank sum test. 
Mean and SD are shown. 
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8.5 HCV infection, cryoglobulinaemia and IGHV gene 
usage 
To determine if particular genes were used in increased frequency in either HCV 
infection or cryoglobulinaemia, the proportion of usage of each IGHV gene class 
for individuals in each clinical group were compared. This analysis revealed only 
one significant difference in gene usages between cryoglobulin-positive and -
negative groups (Fig. 8.3a) with IGHV 1-8 appearing at a higher frequency in HCV 
infected cryoglobulin-negative patients than in cryoglobulin positive patients 
(P=0.004), however there was no significant difference between either HCV 
infected group and healthy controls when multiple testing was accounted for using 
the Bonferroni correction.  There also appeared to be a trend to lower IGHV 3-23 
expression in those with HCV infection but this was not statistically significant after 
correcting for multiple testing (Fig. 8.3b). 
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Figure 8.3 Individual BCR gene usage across clinical groups.  
Sequencing data from the BCR libraries were analysed by RBR using an in-house programme to 
identify which genes were represented in each individual sample and what proportion of the total 
number of reads came from each gene. These proportions were compared for different groups as 
follows: A) Percentage of gene frequency across clinical groups for individual genes comprising 
more than 5% of total number of reads. B) Percentage of gene frequency between HCV-infected 
and uninfected individuals where p<0.05. C) Percentage of total reads in IGCH 1-69 class across 
clinical groups – no comparisons reached significance therefore P values not shown. *** denotes 
statistically significant different gene frequencies after accounting for multiple testing using the 
Bonferroni correction. P-values were determined using the Mann–Whitney U test. Figures A and B 
were prepared by RBR and Figure C by me. Mean and SD are indicated on the graphs. 
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As cryoglobulins usually have a monoclonal IgM component and there is evidence 
of abnormal IgM levels in chronically HCV infected individuals (327), the balance 
of IgM and IgG within the different BCR gene types was examined. Analysis of the 
balance of IgM and IgG BCR types within different IGHV genes showed small 
differences in the distribution of IgG and IgM receptors for many gene types in all 
three clinical groups although the majority of these were not statistically significant 
on correction for multiple testing, with only IgH gene 3-30 showing a significantly 
lower proportion of total gene usage in the IgM BCRs compared to the IgG BCRS 
(P=0.0003 Table 8.3). There were no significant differences in the balance of 
IgG/IgM usage in these genes in the healthy control population. 
 When BCR gene usage was compared separately for IgM genes, only IGHV 1-24 
expression showed a significant difference, being higher in individuals infected 
with HCV compared to healthy controls (Fig. 8.4; P=0.0083).  
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Figure 8.4 Proportion of reads for IgM class IGHV 1-24 between clinical groups. 
Reads for individual BCR libraries specific for IgM type receptors were determined as described 
previously. The proportion of reads for each gene in cryoglobulin-positive individuals, cryoglobulin-
negative individuals and all HCV-positive individuals were compared to the proportion of reads in 
the healthy control (HC) group using a student’s t test (unpaired). The bars shown indicate mean 
and range for all individuals within each clinical group for the sequencing output obtained from a 
single experiment as described in Section 8.3 and Materials and Methods.   
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Table 8.3 Proportion of IGHV gene type by IgG and IgM BCRs in different clinical groups  
 
 
Mean frequencies of genes in each clinical group 
(ordered by highest frequency) (%) 
P-value between 
IgG and IgM (two 
sided, paired) 
Gene Cryo neg Cryo neg Cryo pos Cryo pos Healthy Healthy Cryo neg Cryo pos 
  IgG IgM IgG IgM IgG IgM  IgG IgM 
IGHV1-18 6.5791 16.7677 7.0391 23.6382 5.5814 15.4829 0.0418 0.0103 
IGHV3-23 25.4340 16.8431 20.9423 12.4331 25.5579 19.1862 0.0251 0.0280 
IGHV3-7 13.4253 5.1138 12.3611 4.1190 11.1481 5.1333 0.0304 0.0903 
IGHV1-2 7.5508 12.8671 3.4079 12.0451 4.8649 10.0243 0.1369 0.0164 
IGHV3-21 4.7625 5.2171 8.6644 6.0331 8.9115 6.3601 0.7030 0.1521 
IGHV3-30 5.9533 4.0918 6.6180 3.4523 4.5371 2.9144 0.4151 0.0003 
IGHV3-48 4.8587 3.7700 6.2254 3.7283 5.0967 4.1026 0.2320 0.1351 
IGHV3-74 6.6098 4.0614 6.0082 2.8530 8.5867 3.5911 0.3619 0.1220 
IGHV1-8 2.4874 7.3155 1.4449 4.8679 1.9298 6.0558 0.1093 0.1805 
IGHV3-53 3.8098 2.8275 4.2079 3.0231 3.9657 2.7048 0.0241 0.0323 
IGHV3-15 2.2556 1.6997 3.1321 1.9126 2.4207 2.0282 0.4738 0.0982 
IGHV3-30-3 1.4754 1.6835 2.9581 2.3057 1.3927 1.2400 0.5859 0.1321 
IGHV3-33 1.9659 2.3968 2.5384 2.1008 1.7850 2.0045 0.5303 0.3987 
IGHV3-11 1.5914 1.3449 1.8829 1.1532 2.0525 1.1283 0.1458 0.2552 
IGHV1-69 0.3967 1.1288 0.4935 1.7143 0.8017 3.1642 0.2152 0.0886 
IGHV6-1 0.5997 1.1781 0.4123 1.5071 0.4050 0.8599 0.0638 0.0474 
IGHV1-24 1.5406 1.7088 0.7125 1.3803 0.3085 0.4549 0.8780 0.1157 
IGHV3-64 0.6838 0.7611 1.3314 1.0639 1.1183 1.0106 0.2382 0.6536 
IGHV3-66 1.5025 1.2830 1.2832 0.7705 1.6925 1.7046 0.4418 0.4326 
IGHV4-59 0.2653 0.9979 0.2391 1.2642 0.2034 1.0689 0.0575 0.0210 
IGHV3-43 1.6174 0.9557 1.2319 0.5719 1.9204 0.7432 0.4568 0.1014 
IGHV4-34 0.1557 0.5249 0.2430 1.0922 0.1395 0.9459 0.0381 0.0197 
IGHV1-58 0.2572 0.7300 0.4797 1.0813 0.2134 0.9922 0.0316 0.0603 
IGHV3-20 0.2991 0.3760 0.9562 0.4119 0.1598 0.0804 0.4752 0.3994 
IGHV3-72 0.2199 0.1141 0.8924 0.1501 0.5230 0.2326 0.1910 0.1686 
3 cryoglobulin-positive, cryoglobulin-negative and HC individuals underwent NGS sequencing of 
IgM- and IgG-specific BCR libraries (as detailed in Materials and Methods). For the 25 most 
frequent genes the percentage representation of each gene in the IgG and IgM populations were 
compared using a student’s t test. Those with a P value <0.05 highlighted with those where IgG 
higher than IgM coloured in orange, IgM higher than IgG coloured in yellow. 
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8.6 Cryoglobulinaemia and CDR3 length 
The sequencing data also allowed us to measure the length of the CDR3 regions. 
These are the variable region of antibodies and BCRs which enable binding to 
specific antigens. Variations in CDR3 length have been demonstrated with both 
chronic viral infections such as HIV and also autoimmune conditions such as 
Sjorgen’s syndrome (345, 347) 
Within our cohorts, the cryoglobulinaemia-positive group had a significantly longer 
CDR3 length than in healthy controls (p=0.028 Fig. 8.5a). A trend to increase in 
length was seen in IgM and IgG type BCRs (Figs. 8.5 b and c). HCV-positive 
cryoglobulin-negative patients also showed slightly longer CDR3 regions than 
healthy controls but this did not reach statistical significance (0.26) (Fig. 8.5a). 
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Figure 8.5 Comparison of CDR3 lengths between clinical groups.  
CDR3 sequence lengths were calculated for each of the clinical groups using the programme 
developed by RBR and compared using the Mann Whitney U test. A) All BCR sequences or B) IgG 
sequences or C) IgM sequences were analysed. ** denotes statistically significant difference after 
correcting for multiple comparisons. Median and range are shown. 
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8.7 Asymptomatic cryoglobulinaemia is not associated 
with restriction of the functional IgG anti-HCV 
envelope response  
As  51 individuals of the CHCV cohort (from which the cryoglobulin-positive and -
negative patients were derived) had already been tested for functional IgG 
responses in vitro, I aimed to determine if cryoglobulin status was associated with 
any difference in antibody function. As described in Materials and Methods and in 
Chapter 3, serum samples from the CHCV cohort were purified to obtain IgG 
which was subsequently tested for their ability to neutralise viral particles 
containing E1/E2 from different HCV strains and ability to bind to the E1/E2 
proteins. 
8.7.1 ELISA assay for binding to whole E1E2 across different 
genotypes 
As described in Chapter 3, purified IgG was tested in a GNA-capture ELISA for 
binding to E1E2 glycoproteins from differing sub-genotypes of HCV(the XG panel). 
Absorbance levels for each individual in the cohort was ranked for each 
subgenotype tested against. These ranks were added and an overall ‘breadth of 
binding’ rank calculated. The ranks in the cryoglobulin-positive and -negative 
groups were compared (Fig. 8.6a) showing no significant difference between the 
two groups (P=0.48). 
8.7.2 Neutralisation ability across the XG and GT1 panels 
A total of 51 HCV positive patient sera were tested for neutralisation activity 
against 6 different subgenotypes of HCV (the XG panel, see Chapter 3). No 
significant difference in the number of HCVpp types was seen between MC-
positive and MC-negative patients with 4/16 MC-positive patients displaying a 
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broadly neutralising phenotype (neutralising >3 HCVpp) compared with 13/36 in 
the MC negative group (P= 0.37 by Wilcoxon Rank Sum test, Fig. 8.6b). 
Twenty HCV gt 1-infected individuals (5 cryoglobulin-positive and 15 cryoglobulin-
negative) were also tested for their ability to neutralise a wide range of gt 1 
sequences in the HCVpp system (the intra-gentoype 1 (IG1) panel as described in 
chapter 3). No difference was seen in the ability to neutralise a panel of 11 G1 
pseudoparticles (P=0.50 by Wilcoxon Rank Sum,Fig.8.6c).  
8.8 Cryoglobulinaemicprecipitate IgM does not bind to E2 
Due to previous reports of similar gene usage between BCRs targeting the E2 
molecule and those present in HCV associated clonal B cell disorders, I attempted 
to determine if IgM within cryoprecipitates would bind E2. Serum and 
cryoglobulinaemic precipitates from 4 gt 1-infected patients and serum from 2 HC 
samples were tested as described in Materials and Methods. Cryoglobulinaemia 
precipitates were washed in ice-cold saline and redissolved in PBS at 37°C for 30 
minutes. IgM concentration was measured using an IgM quantification ELISA 
alongside serum (see Materials and Methods). Samples were diluted in warm 
PBST to obtain a similar concentration of IgM in precipitate solution and dilute 
serum. These samples were then added to an ELISA plate coated with purified 
soluble gt 1a E2 (sE2). All ELISA steps up to adding the secondary antibody were 
performed with pre-warmed reagents in a 37°C room. Relative binding of serum 
and cryoprecipitate IgM to sE2 was determined. There was no evidence of binding 
of cryoglobulin IgM to E2 when compared with healthy control IgM, while serum 
from patients with cryoglobulinaemia demonstrated significant IgM binding to sE2 
(Fig. 8.7). To determine if lack of binding was simply due to sequence variability, I 
also attempted to assess cryoglobulinaemia precipitate binding to lysate 
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expressing the E1E2 sequence isolated from one of the cryoglobulinaemia positive 
individuals. However, high levels of background in this assay prevented any 
meaningful conclusions being drawn (data not shown). 
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Figure 8.6  IgG responses to a variety of HCV envelope sequences by cryoglobulin status  
A) Overall rank of ELISA binding by cryoglobulinaemia status. Individual patient IgG was tested for 
its ability to bind E1E2 proteins from of 6 differing subgenotypes (the “XG panel”) and ranked 
according to strength of binding across the panel as described in Materials and Methods. The 
scatter plot shows the distribution of these ranks between cryoglobulin positive and negative 
individuals. B+C) Assessment of neutralisation breadth by cryoglobulinaemia status. IgG from 
patients in the cryoglobulinaemia-positive and -negative cohorts were tested for their ability to 
neutralise HCVpp bearing (B) E1E2 of 6 differing subgenotypes, from the XG panel and (C) E1E2 
of 11 diverse gt 1 envelope sequences, the IG1 panel, as described in Materials and Methods. A 
reduction in infectivity by 50% was taken as positive neutralisation.  The scatter plots show the 
number of HCVpp strains neutralised to this level by cryoglobulin-=positive and -negative patients. 
Differences between the groups were analysed using a Wilcoxon Rank Sum test. Median and 
interquartile range is indicated on the graphs. 
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Figure 8.7  IgM binding to gt 1a sE2 by cryoglobulins in solution and dilute serum.  
Serum and cryoglobulin samples from the same 4 gt 1 infected individuals were tested as 
described in Materials and Methods. Briefly, IgM concentrations in the redissolved cryoprecipitate 
and serum were ascertained using an IgM ELISA. Serum from each patient was normalised to the 
same IgM concentration as in cryoprecipitate in PBST. These solutions were tested for ability to 
bind to purified gt 1a sE2 at 37°C in a modified IgM ELISA protocol as described in Materials and 
Methods. Differences in relative absorbance were compared using the Wilcoxon Rank Sum test.  
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8.9 Chapter 8 Discussion 
8.9.1 Prevalence of cryoglobulinaemia and association with 
clinical features 
Subclinical cryoglobulinaemia has a surprisingly high prevalence of 31% within our 
UK based cohort of HCV infected patients. Estimated rates of HCV-associated B 
cell pathologies vary widely depending on geographic region, with the highest 
prevalences of 40-50% being reported in Southern Europe and some North 
American series (341, 348). There are no published studies from a Scottish 
population, with only one London-based study from the UK suggesting a 
prevalence of 19% in the 1990s (349). A genetic predisposition to MC has been 
proposed with the HLA types DR5 and DQ3 identified as more likely to develop 
cryoglobulinaemia in one study, which may go some way to explaining 
geographical variation (350). Best practice guidelines were followed in collecting 
cryoglobulinaemia samples in the CHCV cohort, therefore it is likely that the 
prevalence obtained is a good estimate of the true population prevalence of 
cryoprecipitates in HCV-infected subjects (262) and asymptomatic 
cryoglobulinaemia is common in Scottish patients with chronic HCV gt 1 or 3 
infection. 
In this cohort MC was positively associated with cirrhosis. While many of the 
patients in this cohort were unsure of their date of infection, a previous prospective 
study found an association of cryoglobulinaemia with cirrhosis to be independent 
of estimated duration of infection (351). No positive association with IL28B 
genotype or HCV genotype was found, however this sample was relatively small 
and only patients with genotype 1 and 3 were included. There was also a 
significant trend to lower viral load in cryoglobulinaemia-positive patients, this 
would fit with previous studies which have suggested that precipitation of virus in 
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the presence of cryoglobulinaemia may lead to underestimation of the viral load by 
conventional laboratory methods therefore the presence of cryoglobulins is likely 
to lead to underestimation of viral load (348).  
 
8.9.2 Clonality, CDR3 length Rheumatoid factor activity and 
Cryoprecipitation 
The finding of no clonal expansion of IGHV genes are in contrast with the 
observations of other groups. It is possible that, as this cohort is made up of 
asymptomatic individuals, they represent an earlier stage of disease than those 
traditionally included in studies of MC. Possible suppression of IGHV 3-23 in HCV-
infected individuals is an interesting finding as this antibody class is involved in the 
response to Streptococcus pneumoniae, known to have a more severe course in 
those with advanced liver disease (352). This would be worth confirming in a 
larger cohort of cirrhotic individuals. 
The significantly different length of the CDR3 region in the cryoglobulinaemic 
cohort compared to healthy controls is a new finding and contrasts with other 
autoimmune diseases where pathogenic autoantibodies tend to have a shorter 
CDR3 (353). However, increased length of CDR3 region has been reported in 
chronic HIV infection in addition to other chronic viral infections (354).  BCRs with 
longer CDR3 region are often found on B1 cells and derive more closely from the 
germline sequence. These tend to have a polyreactive phenotype which could 
explain the presence of autoreactivity seen. This could reflect production of 
polyreactive, non-specific antibodies by naïve B cells as found by Rosa et al (47). 
Indeed, while significant somatic hypermutation has been demonstrated in some 
MC studies (343, 355), Charles et al (2013), also identified only low to moderate 
levels of somatic hypermutation in a cohort of MC patients with some clonal B cell 
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populations being unmutated (183, 343). Other researchers have reported the 
ability of HCV to activate naïve B cells through CD81-binding (47) and also by 
stimulating B cell activating factor molecules (184).  
One explanation for these findings could be that HCV infection stimulates B cells 
to produce polyreactive antibodies, over time, as some of these B cells bind 
antigens – perhaps HCV specific proteins – they undergo somatic hypermutation 
and the B cells transition from a naïve type to CD27+ memory B cells. Other 
groups have noted that while naïve and memory B cell populations are expanded 
in MC, the naïve type is more prone to apoptosis (356, 357). This may result in the 
clonally expanded memory B cell population observed in more advanced MC by 
several groups (183, 358).   
Traditionally presence of vasculitic cryoglobulinaemia is synonymous with a 
positive Rheumatoid factor (RhF). In our population RhF positivity was only 
discovered in a third of patients tested, despite finding a typical pattern of 
cryoprecipitation made up of polyclonal and monoclonal immunoglobulins. To 
report a positive RhF a minimum concentration of Fc reactive antibodies must be 
present in the sample (>15IU/ml for the Seimens assay). If the CHCV cohort 
represents an early stage of the cryoglobulinaemia process their concentration of 
RhF may be lower than in textbook cases of cryoglobulinaemic vasculitis. 
Alternatively, there is evidence that B cells with RhF activity lose this property 
when reverted back to the germline sequence (343) and that some monoclonal 
antibodies expressing the typical VH 1-69/Vk3-20 BCR genes did not have RhF 
activity. It is possible that earlier stages of MC may consist of autoreactive 
antibodies prior to extensive somatic hypermutations which results in lower avidity 
binding and a negative RhF assay. Indeed, a recent study of asymptomatic MC 
found cases with very low levels of RhF activity (359). 
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8.9.3 The effect of HCV infection on B cell receptor IGHV gene 
repertoire 
The overall diversity of B cell populations is preserved in the presence of HCV 
infection, even within the cohort of patients with subclinical cryoglobulinaemia 
there were no detectable abnormally expanded clonal clusters. This suggests that 
the presence of cryoglobulinaemic precipitate alone does not necessarily equate 
to the presence of a sizable clonal B cell population.  
However, the data from the CHCV cohort suggest that HCV infection may have 
subtle effects on gene usage within the BCR repertoire. In particular, expansion of 
some IGHV 1 genes and restriction of some IGHV 3 genes were seen (Fig. 8.3). 
This would fit with patterns of gene usage previously reported for anti-HCV 
antibodies, which tend to be in the IGHV 1 class. This  is also the predominant 
IGHV class found in HCV associated B- Cell lymphoma and splenic marginal zone 
lymphoma (185). Interestingly, expansion of IGHV 1 and restriction of IGHV 3 has 
been reported previously in HIV associated B cell lymphoma (360). The shift 
towards IgM usage in some of the genes within this class is also of note as HCV 
associated MC usually is characterised by monoclonal or oligoclonal IgM (361).  
8.9.4 Functional responses 
There was no significant difference in breadth of functional antibody responses 
between MC positive and negative groups. This implies that even if HCV uses 
molecular mimicry as a decoy mechanism, it does not prevent a broad neutralising 
response from developing in a proportion of patients, albeit too late to clear 
infection.  Other researchers have also confirmed that HCV infection does not 
prevent activation of B cells (362). 
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While all of our cryoglobulinaemic patients tested had raised an anti-envelope 
protein antibody response, our data suggested the IgM fraction of the cryoglobulin 
does not easily bind the E2 protein. Until recently, other research groups had also 
struggled to confirm cryoglobulin IgM binding to the E2 protein. However, the E2 
protein has the ability to change conformation, with some flexible regions 
concealing immunogenic epitopes(363) therefore it is possible that E2 as 
expressed in HEK lysates is in a different conformation to that which binds 
cryoglobulinaemic IgM. Since my research was conducted, Dustin et al have 
presented their findings that cryoglobulinaemic antibodies target a conformational 
epitope on the HCV protein [Antibody specificities in HCV-associated mixed 
cryoglobulinaemia, Dustin LB, presented at the Fifteenth UK Hepacivirus meeting, 
May 2017]. This data has not yet been published. . Further exploration of the 
natural antigenic targets of typically expanded BCR populations in 
cryoglobulinaemia may help determine why HCV infected individuals do not 
usually produce a functional antibody response in early infection. Further NGS 
aided study into the impact of early HCV infection on the BCR repertoire would 
also provide useful information and warrants further investigation to determine any 
functional implications. 
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8.10 Chapter 8 Summary 
 
 Asymptomatic cryoglobulinaemia is common in this chronically HCV 
infected cohort with a prevalence of 31%. 
 Asymptomatic cryoglobulinaemia is associated with higher levels of liver 
fibrosis. It is also associated with lower measured viral load which is likely 
to reflect artefactual lower readings due to precipitation of virus.  
 Overall BCR diversity does not appear to be affected by chronic HCV 
infection. 
 HCV infection and asymptomatic cryoglobulinaemia is associated with 
several changes to the B Cell Receptor repertoire, in particular: 
 Lower overall usage of IGHV 3-23 
 Expansion of IgM usage in IGHV 1-24 
 Longer CDR3 regions in cryoglobulinaemia. 
 Functional IgG responses are not different between HCV infected 
cryoglobulinaemia positive and cryoglobulinaemia negative individuals. 
 I could not demonstrate any evidence of cryoglobulinaemic IgM binding to 
HCV E2.  
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9 Discussion and Conclusions 
The field of HCV immunology has made significant progress since initial studies of 
the anti-envelope antibody response 25 years ago (364), with recent work on the 
structure of the HCV envelope proteins and targets of broadly neutralising 
antibodies providing further useful insights (37, 145, 365). The work contained in 
this thesis contributes to our understanding in a number of ways. 
9.1 Defining the breadth of antibody response and its 
clinical impact 
I have demonstrated the presence of broadly neutralising antibodies (bNAbs) in a 
substantial proportion of chronically infected individuals. As demonstrated in this 
thesis and elsewhere, detecting bNAbs depends largely on which panel of 
sequences is used to test for them and the criteria used to define a ‘broad’ 
response (276). While some individuals in the CHCV cohort described in my work 
did produce antibodies capable of neutralising a pan-genotypic panel, this ability 
did not appear to confer any clinical advantage. A ‘within genotype 1’ model of 
defining breadth did discriminate between groups with clinical features which 
would logically be associated with a more robust antibody response – younger, 
non-obese non-cirrhotic individuals.  Similar experiments using a historically 
collected cohort of samples described in Chapter 5 failed to demonstrate a 
significant association between neutralisation breadth and subsequent 
development of cirrhosis, therefore it is probable that such an observation may 
reflect a robust immune response associated with an immune system in generally 
healthier individuals. Nevertheless, a protective effect of bNAbs against cirrhosis is 
biologically plausible and cannot be entirely discounted on the findings from this 
small, heterogeneous cohort. 
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Exploring the impact of HCV infection on the composition of receptors in 
circulating B cells is a novel way to explore “breadth” of response. Next 
generations sequencing is increasingly being used to examine the evolution of 
BCR populations in different disease states. While the study detailed in Chapter 8 
did not focus on determining which BCR combinations were involved in antibody 
profiles with a broad functional response, it is clear that HCV infection has some 
impact on the balance of BCR gene usage and antibody types. NGS BCR 
sequencing is now being used in other disease to gain new insights into the 
immune response and would be a powerful tool to explore in depth the evolution of 
the B cell response to acute infection and vaccination in addition to discovery of 
novel bNAbs (344, 366).  
9.2 Why do some individuals develop a bNAb response 
and others do not? 
In addition to the association with clinical features associated with a bNAb within 
genotype response described in Chapter 3, I have also identified several 
molecular characteristics of such responses. ELISA-based antibody competition 
assays described in Chapter 4 have confirmed that a broad “within genotype” 
response is associated with ability to target two distinct immunodomains on the 
envelope protein, immunodomain B targeted by mAb HC-11 and immunodomain C 
targeted by mAb CHB-7. The ability to compete with these two mAbs was also 
displayed by patient ET who spontaneously cleared a relapse of HCV infection 
following IFN based treatment. While several sequences within the IG1 HCVpp 
panel were resistant to both antibodies, this combination, in addition to other 
antibodies, may have a synergistic effect to overcome escape mutations and 
better control levels of hepatocyte infection. It is likely that any successful vaccine 
with an antibody component would need to elicit a response to these epitopes. 
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Host genetics, in particular, rs9275224 SNP typing has also demonstrated a 
strong association between favourable gt 1 neutralisation profiles which will be an 
important consideration in developing and testing future vaccines. However, there 
is no association between presence of a favourable SNP and ability to target the 
HC-11 or the CBH-7 epitope (Fig. 9.1). Additionally, one of the broadest IG1 
neutralising CHCV samples (1003) had an unfavourable (AA) SNP type. Another 
study has identified other HLA types which are associated with specific envelope 
protein polymorphisms in gt 3 infected subjects(279) .This suggests that while 
many factors can influence developing a bNAb response to gt 1 envelope 
sequences, the underlying mechanisms behind such a response are complex. 
From a vaccine perspective it is also encouraging in that I have not identified any 
absolute barriers to mounting a bNAb response. 
The viral sequences individuals are exposed to may also play a part in determining 
the breadth of response. The findings described in Chapter 4 have confirmed 
some previously described escape mutations from antibodies to the 
immunodomains involved in neutralisation and also identified some potentially 
novel amino acid mutations conferring resistance to neutralisation. It is possible 
that exposing individuals to key epitopes containing common escape mutations 
may elicit antibody responses capable of neutralisation even when these escape 
mutations are present. Indeed, the work to identify the anti-immunodomain D HC-
84 antibodies was based on identifying broadly neutralising antibodies in the 
presence of a domain B escape mutation (124). Some escape mutations require a 
number of amino acid substitutions to maintain viral fitness (291).  Generating 
antibodies which target epitopes where escape has a fitness cost may contribute 
to a successful vaccination strategy, further study of the fitness cost of the escape 
mutations identified in Chapter 4 would help clarify any such regions. 
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Figure 9.1 Ability of individual IgG from the CHCV cohort to inhibit binding of mAbs CBH-7 
(A) and HC-11 (B) by rs9275224 SNP type 
Inhibition of mAb binding to sE2 coated plates by IgG from gt 1 infected individuals in the CHCV 
cohort was determined as described in Chapter 4 and Materials and Methods. SNP typing was 
conducted as described in Chapter 3 and Materials and Methods. The inhibition of mAb binding 
between SNP types was compared using the Wilcoxon Rank Sum test. Mean and SD are shown. 
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9.3 Cross-genotypic versus genotype-specific broad 
responses 
If it was desirable to generate a vaccine only effective against gt 1 HCV then 
further study of the envelope epitopes which raised the broadest antibody 
responses against the IG1 or similar panels would be critical in its development to 
optimise the initial breadth of antibody response. However, in the era of DAAs, the 
geographical regions most in need of a vaccine are not predominantly infected 
with gt 1. Therefore, developing a pan-genotypic vaccine would be ideal. Some 
individuals in the CHCV cohort were able to raise an antibody response which 
reduced infectivity of HCVpps by greater than 50% for all genotypes tested. In 
general, those CHCV individuals with a broad IG1 neutralising response also had 
broad XG neutralising activity (Chapter 3, Fig. 3.7). It is also accepted that 
genotype is a poor predictor of neutralisation profile. From re-analysis of the 
CHCV data presented in Chapter 3 it is evident that those infected with gt 1 HCV 
(therefore exposed to gt 1 envelope proteins) were generally better at neutralising 
HCVpp of all genotypes and not inferior to individuals infected with gt 3  at 
neutralising the gt 3 HCVpp (P=0.83, Fig. 9.2). Previous work studying differences 
between innate immune responses in gt 1 and gt 3 infected individuals in the 
CHCV cohort showed marked differences in the pathways upregulated between 
the genotypes (367). It is possible that gt 3 infection may not induce as robust an 
immune response as gt 1. This provides some hope that an effective gt 1 vaccine 
may provide adequate protection against other genotypes. However, it is likely that 
in non-genotype 1 envelope sequences, there may be additional variations in key 
epitopes which may confer resistance to neutralisation by cross-reactive 
antibodies. Adapting the techniques and tools used in this work to explore anti-
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envelope responses in other genotype infections will be crucial to optimising a 
pan-genotypic vaccine. 
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Figure 9.2 Ability of CHCV individuals infected with gt 1 and gt 3 HCV to neutralise HCVpp 
bearing envelope proteins of different genotypes. 
IgG from the CHCV cohort was tested for its ability to neutralise HCVpps bearing envelope proteins 
of different genotypes in the XG panel as described in Materials and Methods. Here the mean 
percentage neutralisation of each HCVpp by individuals infected with gt 1 HCV and those infected 
with gt 3 HCV is plotted. Error bars represent SEM. Statistical comparisons were conducted using 
the Wilcoxon Rank Sum test, * indicates a P value of <0.05. Values shown are the results of 3 
independent experiments. 
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9.4 Early and durable antibody responses 
Some researchers have suggested that once individuals have been exposed to a 
viral antigen, this antigen and the early responses to it determine the nature of 
subsequent immune responses to similar antigens. This is because antigenic 
exposure results in the development of memory B cells. There is a tendency for 
these to be reactivated in the event of exposure to a similar but not identical 
antigen, rather than activation and affinity maturation of a different set of B cells. 
This is known as repertoire freeze and has been documented in influenza and 
dengue viruses (368-370). This may be advantageous to a virus such as HCV 
which is able to rapidly evolve, in that the host response may consist of 
persistently activated B cells with a low affinity for the mutated antigen and 
therefore ineffective at neutralisation. In light of this, an effective vaccine may have 
to elicit bNAb from the first dose. 
If early antibody responses are key to viral control, then exploring the IgM anti-
HCV response may give helpful insights into why only a minority of individuals 
resist or clear infection acutely. IgM is more difficult to work with than IgG due to 
its less specific binding properties. However, in HCV it remains elevated for longer 
than would be expected for a chronic infection (326) in addition to being involved 
in the pathological condition cryoglobulinaemia (183). Conversely, the onset of 
anti-envelope IgG responses is often delayed (371). In the experiments conducted 
using the Exposed Uninfected cohort samples (Chapter 7) IgM anti-E2 responses 
were detected at similar levels to in chronically infected individuals (Fig. 7.5). 
Further characterising the IgM response in acute HCV infection would be useful in 
determining if it is beneficial for viral clearance or whether a prolonged IgM phase 
is a reflection of pathological effects of HCV. 
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The duration of responses is also key in designing an effective vaccine. In general 
antibody levels to HCV are known to reduce after clearance, indeed this is 
demonstrated in Chapter 6 as the potency of neutralising antibodies reduces 10-
fold in 1 month following viral clearance (Fig. 6.7).  The EU cohort described in 
Chapter 7, show persistence of antibody responses despite absence of infection, 
although higher risk of regular exposure to HCV is linked to concentration of anti-
E1E2 IgG. Therefore optimisation is likely to be necessary to ensure an ongoing 
neutralising response which does not require a ‘booster’ vaccine following the 
initial vaccination period. Encouragingly, patient ET showed a typical ‘boost’ 
response following relapse with a recognised strain of HCV (Chapter 6) which 
suggests that a rapid reactivation of the anti-envelope antibody response is 
possible in the event of re-exposure. 
9.5 Conclusions 
Through examining the breadth of antibody binding and neutralisation of differing 
strains of envelope proteins in the HCVpp system in clinical cohorts, it is clear that 
some individuals when exposed to or infected with HCV produce a polyclonal 
bNAb response. The data presented has identified that host genetics and the 
ability to target multiple neutralising epitopes on the envelope protein are 
associated with such responses, although resistance mutations to bNAbs do exist 
in vivo. In addition, the presence of bNAbs is associated with lower levels of liver 
fibrosis. I have also identified a potentially novel role for NAbs in resisting infection 
in a highly exposed cohort and in spontaneous resolution of viral relapse post-
treatment. Finally, the use of next generation sequencing technology in the study 
of B cell receptors in HCV infection has been demonstrated with the possibility of 
yielding many future insights into the generation of bNAb responses. 
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9.6 Further work 
I would like to expand this work further in future. Particular questions raised during 
my research which I would like to explore, given more time, would be: 
 Do bNAbs have a role to play in progression of liver disease beyond 
cirrhosis to liver decompensation or development of hepatocellular 
carcinoma? 
 What is the relationship between infecting viral strain, development of 
bNAbs and clearance of infection? Are there specific sequences associated 
with bNAb production, in particular, do certain sequences induce antibodies 
targeting the key epitope regions in immunodomain B and C? 
 Further analysis of the impact of the polyclonal nature of bNAb responses, 
which combination of antibodies provides the broadest antibody response? 
 Can an antibody response raised against gt 1 also provide protection 
against a wide range of sequences from other genotypes, particularly gt 3 
and gt 4? If not, which parts of the envelope protein needs to be targeted 
for a bNAb against these genotypes.  
 What is the relationship between host genetics and a bNAb response in gt 3 
and other genotype infections 
 Which BCR sequences are involved in antibodies targeting various 
immunodomains of the E2 protein and how does the BCR repertoire evolve 
in acute HCV infection and exposure. 
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